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Diffuse gliomas are a group of central nervous system (CNS) tumors with a poor patient prognosis. 
Within these diffuse gliomas, isocitrate dehydrogenase (IDH) mutation defines the different tumor 
subtypes and is considered to be an initiating event in gliomagenesis. IDH is a metabolic enzyme that 
in normal conditions mediates the conversion of isocitrate into α-ketoglutarate (α-KG), producing the 
reducing equivalent NADPH. IDH mutation (IDHm) leads to a neomorphic reaction where α-KG is 
consumed to generate the oncometabolite D-2-hydroxyglutarate (D-2HG), using NADPH as reducing 
agent. It has been reported that IDHm-dependent D-2HG synthesis has a direct impact on DNA and 
histone methylation, however the metabolic repercussions are not yet well defined. Due to the 
consumption of NADPH by IDHm reaction, some groups including us have hypothesized that IDHm 
cells may bear an imbalance of reducing equivalents, that may trigger a defective antioxidant defense. 
In the present study we made use of patient-derived cell lines and xenografts thereof as well as clinical 
samples in order to study the metabolic vulnerabilities of IDHm gliomas. 
In the first part of the thesis experimental data, we generated an integrative liquid chromatography-mass 
spectrometry (LCMS)-based proteomic-metabolomic characterization of IDHm metabolism. We made 
use of patients, cell lines and xenografts to address the direct effect of the mutation. We observed that 
IDHm gliomas have altered regulation of key processes in central carbon metabolism through glucose 
and glutamate processing as well as glutathione (GSH) metabolism and fatty acid production.  
In the second part of experimental data, we investigated the redox vulnerabilities of IDHm gliomas. 
Here we discovered that IDHm astrocytomas specifically upregulate cystathionine-γ-lyase (CSE) 
enabling them to synthesize GSH independently of NADPH. CSE is the only known enzyme capable of 
synthesizing cysteine. We found that genetic and chemical inhibition of CSE led to a decrease in cell 
viability upon cysteine restriction. Finally inhibition of CSE in vivo led to a delay in tumor growth rate. 
In conclusion, in the present PhD dissertation we expose a comprehensive study of the metabolic 
behavior of IDHm human gliomas, and we propose a novel therapeutic strategy that might improve 
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Gliomas are commonly defined as malignant primary tumors of the glial tissue of the nervous 
system. Gliomas together with all the tumors of the central nervous system (CNS) correspond 
to a highly heterogeneous type of cancer. The Central Brain Tumor Registry of the United 
States (CBTRUS) is the largest population-based registry of tumors of the brain and CNS 
worldwide, and recently published a report containing age-adjusted data from 2012-2016 and 
presented per 100.000 population (Ostrom et al., 2019). According to CBTRUS, brain and 
other CNS tumors (both malignant and non-malignant) are the cancer type with highest 
incidence rate in 0-14 year old children population, being leukemia in second place. The 
incidence of CNS tumors decreases at older ages, been the third most common cancer type 
after breast and thyroid in 15-39 years old population. Finally in older adults, at age >40 years, 
these tumors are the eighth cancer type in incidence, being prostate and breast the two most 
common (Figure 1). It is important to clarify that overall cancer occurrence increases with age. 
Therefore, although the incidence of CNS tumors over total cancer is higher in younger 
patients, the absolute incidence of this cancer type is yet higher in eldest patients. With regard 
to mortality rate, CNS tumors contribute as the top reason for cancer mortality in children of 
age 0-14 years at death. Among persons age 15-39 years CNS tumors were the second most 
common cause of cancer death and for older population of age >40 years this cancer type 
rises up to thirteenth in death rate position. Similarly as before, although CNS tumors are the 



















Figure 1. Annual average age-adjusted incidence rates of all CNS tumors in comparison to other 
common cancers in the US.  
A. Children at age 0-14 years. B. Adolescents and young adults at age 15-39 years, and C. older adults 
at age 40+ years, CBTRUS statistical report: US Cancer Statistics - NPCR and SEER 2012–2016 
(Ostrom et al., 2019). 
 
 
When considering all the CNS tumors, CBTRUS accounts malignant ones to 30.2% of the 
cases, however gliomas correspond to the majority of all these cases, been only 1.1% of the 
total CNS tumors non-malignant gliomas (Figure 2). The most common tumor type of all the 
ones of the CNS is the non-malignant meningioma (37.2%) and the most common of the 
malignant cases is glioblastoma (14.6%), the most aggressive subtype of all gliomas and CNS 
tumors (Figure 2). 
Indeed, glioblastomas together with astrocytomas (5.1%) and oligodendrogliomas (1.3%) 
correspond to the so-called diffuse glioma group, the deadliest group of gliomas and CNS 
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gliomas according to the up-to-date regulation of the World Health Organization (WHO) (Louis 
et al., 2016b) is forthcoming discussed in section 1.3. Other important malignant non-glioma 
CNS tumors, which account to 5.4% over the total (Figure 2), include choroid plexus tumors, 
neuronal and mixed neuronal-glial tumors, tumors of the pineal region, embryonal tumors, 

















Figure 2. Distribution of CNS tumors by behavior and histology.  
Rates for selected sub-types (where there is a sufficient number of cases to calculate rates). CBTRUS 
statistical report: US Cancer Statistics - NPCR and SEER 2012–2016 (Ostrom et al., 2019). 
 
 
Time trends are important to understand the progression of cancer impact in the society, 
however it is worth considering that many factors can fluctuate time trend rates and not be 
related with real changes in incidence of these tumors e.g. demographic changes, changes in 
classification or changes in registration procedures. In cancer overall incidence rates have 
decreased over time (McCarthy et al., 2013). Regarding to malignant brain and other CNS 
tumors, between 2000 and 2016, CBTRUS has registered a small but statistically significant 
decrease of incidence. However, there has been an increase in incidence of these tumors in 
children at age 0-14 years. Moreover, the annual incidence rate of malignant tumors has 
always been higher that of non-malignant ones in children at 0-14 years (since the beginning 
of non-malignant registration procedures started, in 2004), whereas all the older ages 








Figure 3. Annual age-adjusted incidence rates of CNS tumors and incidence trends between 2000 
and 2016, ordered by behavior and age group.  
CBTRUS statistical report: US Cancer Statistics - NPCR and SEER 2000–2016 (Ostrom et al., 2019). 
 
 
In synthesis, this study reflects that although cancer overall is a disease far more prevalent in 
eldest population, the high incidence and mortality of CNS tumors in children and young adults 
when relative to other cancer types highlights its relevance in youngest patient sector. Thus, 
the study and understanding of glioma carcinogenesis is a crucial milestone to overcome for 
the future of our society. Before analyzing the detailed classification of CNS tumors, we will 
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1.2. Gliomagenesis 
The origin of gliomas represents nowadays a controversial research area. It is not clear 
whether these tumors arise from differentiated glial cells or neural precursor cells since there 
is experimental evidence supporting both. Yet, gliomagenesis is likely linked to intrinsic 
plasticity rather than cancer stem cell (CSC) multipotency (Laug et al., 2018, Dirkse et al., 
2019, Neftel et al., 2019).  
Neuroglia. Glial cells, also known as neuroglia, are non-synaptic nervous cells with different 
functions of support of neural tissue. There exist different types of glia in both central nervous 
system (CNS) and peripheral nervous system (PNS), with astrocytes and oligodendrocytes 


























Figure 4. Different types of neuroglia.  
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Astrocytes are star-shaped cells which represent the most abundant glial cell type in the CNS. 
Astrocytes have different functions such as provision of nutrients to neurons, formation of the 
blood-brain barrier (BBB), buffering neurotransmitter levels or formation of synapses (Molofsky 
and Deneen, 2015). A detailed explanation on the metabolic interactions of astrocytes within 
the CNS will be forthcoming discussed in section 3.2. Oligodendrocytes are cells in charge of 
the myelination of neuronal axons in the CNS. The myelin sheath formed by these cells 
provides insulation across the axon and is essential for saltatory nerve conduction (Baumann 
















Figure 5. Glial cells.  
A. Immunopanning imaging of an astrocyte from a rat pup. Used from (Landhuis, 2018). B. Scanning 
electron microscope (SEM) imaging of an oligodendrocyte ensheathing an axon. Used from Dr John 
Zajicek/science Photo Library, fineartamerica.com 
 
 
Origin of gliomas. Diffuse gliomas are amongst the most common glioma subtype and bear 
the worst patient prognosis. The three main categories of diffuse gliomas are 
oligodendrogliomas, astrocytomas and glioblastomas (Louis et al., 2016b). As suggested by 
their names, oligodendrogliomas and astrocytomas share histological features with their 
natural counterpart cell types. In addition, astrocytomas can as well give rise to secondary 
glioblastoma (Laug et al., 2018). As noted previously, the exact mechanism behind 
gliomagenesis is yet unknown. Different perspectives have been considered in an attempt to 
understand how gliomas are originated. Some studies are currently investigating the link 
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molecular factors which are essential in glial differentiation (e.g. NFIA, Sox9), have also been 
found to play important roles in tumorigenesis (Glasgow et al., 2013, Glasgow et al., 2017).  
On the other hand, other groups argue that differentiated glial cells may bear an advanced 
grade of plasticity that in some cases enable them to undergo malignancy and initiate 
tumorigenesis. In fact, the hypothesis of cancer stem cell (CSC) as driver of tumor initiation is 
contradicted by the observation that glioma cells expressing CSC associated cell membrane 
markers do not represent a clonal entity with distinct functional properties, but rather a plastic 
state that can be adopted by any cancer cell (Dirkse et al., 2019, Neftel et al., 2019).   
An important breakthrough with regard to gliomagenic aberrations, was the discovery of a point 
mutation in the enzyme isocitrate dehydrogenase (IDH) during early stages of tumorigenesis 
(Parsons et al., 2008). In fact, recent large-scale sequencing studies demonstrated that IDH 
mutation may be linked to the acquisition of a variety of tertiary alterations related with tumor 
progression including PI3k/Akt, K-ras, PDGFRA, Met and n-Myc pathways (Bai et al., 2016, 
Brat et al., 2015). The direct implications of IDH mutation in tumorigenesis and epigenetic 
reprogramming will be discussed in section 2.2. Before that, we will first review the specific 
classification of the different glioma subtypes, in which IDH plays a central role. 
 
1.3. Glioma classification 
As we have already introduced there is not just a unique type of glioma. In fact, during the past 
decades there has been a constant refinement and evolution of glioma classification. At the 
onset of glioma research, the first grouping variables were based on histological features 
observed through different microscopic techniques, such as hematoxylin-eosin staining, 
immunohistochemistry or ultrastructural characterization (Figure 6). With the beginning of the 
present millennium, the exponential development of molecular based studies has revealed a 
new step on the classification of the tumors of the central nervous system. Although within the 
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System (2007 CNS WHO) some of these molecular findings were already mentioned (Louis et 
al., 2007), it was not until the most recent report (2016 CNS WHO) that these parameters have 




























Figure 6. Histological classification of gliomas.  
Microscopic hematoxylin and eosin (H&E) staining of A. Astrocytoma. Cells with hyperchromasia 
(intensely stained nuclei) and irregular contours. B. Oligodendroglioma. Cells typically show increased 
mitotic activity (arrows). C. Glioblastoma. Large, highly pleomorphic and multinucleated cells. Adapted 
from (Perry and Wesseling, 2016). D. Coronal brain section of glioblastoma tumor showing necrotic core 
with hemorrhages (PubCan, 2014). 
 
 
To update the new CNS WHO report an international collaboration of 35 neuropathologists, 
neuro-oncological clinical advisors and scientists from 10 countries during a three-day 
conference held in 2014 in Haarlem, the Netherlands, established the guidelines for how to 
incorporate molecular findings into brain tumor diagnoses. Therefore, the new standards 
stipulate that each glioma subtype may be classified taking into account both the original 
D 
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histological phenotype and the specific genotypic signature altogether. In case of discordant 
results, the genotype trumps the histological phenotype.  
The classical WHO grading system of CNS tumors (Burger, 1995) is also included in the 2016 
CNS WHO. With this regard, grade I corresponds to slow-growing tumors, non-malignant and 
associated with long-term survival; grade II are relatively slow-growing tumors that can recur 
as higher grade tumors and can be malignant or non-malignant; grade III are always malignant 
tumors that often recur as higher grade; grade IV tumors reproduce rapidly and are very 
aggressive malignant tumors.  
Diffuse glioma, the most frequent and aggressive type of CNS tumors, include astrocytomas, 
oligodendrogliomas and glioblastoma. Commonly, astrocytomas and oligodendrogliomas 
represent grade II or III tumors, therefore are also known as low grade gliomas (LGG). On the 
other hand, glioblastomas are commonly grade IV, and known as high grade gliomas (HGG). 
The most relevant update on gliomas in the new 2016 CNS WHO is indeed within these diffuse 
gliomas. Currently, all diffusely infiltrating gliomas are classified based on point mutations in 
the isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2) genes. Thus, in 
this new classification IDH mutation define astrocytomas, oligodendrogliomas, whereas IDHwt 
genotype define primary glioblastoma (Figure 7). Furthermore, in order to differentiate IDH 
mutant oligodendroglioma from IDH mutant astrocytoma there are other established molecular 
markers. The most consensual one is the presence of a 1p/19q chromosomal co-deletion in 
the oligodendroglial tumors. As a complementary testing, although not required for diagnosis, 
the ATRX loss and TP53 mutation are specific markers in astrocytoma (Figure 7). With regard 
to glioblastomas, around 90% of the tumors are IDH wild type which corresponds most 
frequently with the clinically defined primary glioblastoma and predominates in patients over 
55 years of age. The rest of glioblastomas correspond to so-called secondary glioblastoma 
which bear the IDH mutation since it arises from prior lower grade astrocytoma, frequently 






























Figure 7. Molecular classification of diffuse gliomas.  




Each specific molecular subtype of diffuse glioma bear different clinical outcomes (Figure 8). 
IDHwt glioblastoma (GBM) is the most aggressive glioma type with an average survival time 
of 12-18 months. Only 25% of patients survive more than one year and 5% more than five 
years. IDHm gliomas are associated with a better patient prognosis when compared to GBM, 
although yet averaging a poor survival time of 7 years (Claus et al., 2015). Within IDHm 
gliomas the different life expectancy is as well disparate. Whereas IDHm 1p/19q codeleted 
gliomas (i.e. oligodendrogliomas) show a 80% of 5-year survival rate, this number decays 
















Figure 8. Overall survival time of glioma patients.  
Kaplan-Meier estimates of overall survival among patients with different gliomas classified according to 
molecular subtype. Used from (Brat et al., 2015). LGG: Low grade glioma; GBM: glioblastoma. 
 
 
Table 1 summarizes the main classification and epidemiologic features of the three most 
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Table 1. Summary of genetic characteristics of diffuse gliomas. 
All data is based on (Ostrom et al., 2019), except IDHm % (Yan et al., 2009). GBM: glioblastoma, AS: 
astrocytoma, OD: oligodendroglioma, HGG: high grade glioma, LGG: low grade glioma. * considering 















Improving classification based on molecular profiling. In order to develop a more accurate 
pathological diagnosis and improve clinical outcome of glioma patients some recent studies 
have shown notable advances in the molecular profiling of gliomas. In a study of 1,122 diffuse 
grade II-III-IV gliomas it was integrated new parameters of classification such as DNA 
methylation patterns or telomere length correlating with the official CNS WHO groups 
(Ceccarelli et al., 2016). In this study they analyzed six different cytosine-phosphate-guanine 
(CpG) island methylation clusters (LGm1-6) and compared its presence in both IDHm and 
IDHwt glioma sub-groups. They observed that the methylation clusters associated with 
genome-wide hypermethylation (LGm1/LGm2/LGm3) were enriched in IDH mutant tumors, 
documenting the association between IDH mutation and increased DNA methylation 
(Noushmehr et al., 2010, Turcan et al., 2012). In fact, profound analysis of different CpG status 
in tumors lead to the observation that IDH1m 1p/19q intact gliomas (i.e. astrocytomas), can be 
subsequently divided in Glioma-CpG island methylator phenotype (G-CIMP) high and G-CIMP 
low tumors, further refining glioma classification (Ceccarelli et al., 2016). Moreover, a recent 
study on the approximately 100 different CNS tumor entities shows a comprehensive approach 
for DNA methylation-based classification and demonstrates its application in a routine 
diagnostic setting (Capper et al., 2018). These studies lay the groundwork of DNA-methylation 
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role. In section 2 we will describe its DNA and histone methylation and other epigenetic 
repercussions associated with IDH mutation.  
Besides the methylation factors, different important signaling pathways have been shown to 
be altered in glioma tumors, promoting tumor malignancy and aggressiveness. Whether these 
pathways occur in parallel or in later steps of tumorigenesis has not yet been clarified (Laug et 
al., 2018). As aforementioned, besides IDH mutation, loss or mutation of ATRX and TP53 are 
among the most common molecular aberrations in astrocytomas (Ceccarelli et al., 2016). TP53 
signaling, plays a key role in several cellular processes including cell cycle, cell differentiation, 
and neovascularization. In fact, this pathway is found to be mutated not only in astrocytomas 
but also in secondary GBM (Bögler et al., 1995). Oligodendrogliomas, known for their 1p/19q 
chromosomal co-deletion as well as IDH mutation, bear commonly wild type expression of 
ATRX and TP53. However, these tumors usually present TERT mutation, an alteration also 
observed in the majority IDHwt GBM (Ceccarelli et al., 2016). Indeed, within GBM group, the 
diverse signaling pathways involved in malignancy have been more extensively studied. 
Among these pathways EGFR signaling plays a key role in primary GBM development (Figure 
9). The overexpression of EGFR through amplification of the EGFR gene initiates a molecular 
cascade that involves PI3K and PIP3 and activates Akt and mTOR pathways, resulting in cell 
proliferation and increased cell survival by stimulating energetic and biosynthetic metabolism 
and blocking apoptosis. PTEN, which normally stops this cascade by inhibiting PIP3 signal, is 
mutated in most of these primary GBM (Mellinghoff et al., 2005) (Figure 9). Interestingly, 
PI3K/Akt cascade seems to be inhibited by IDH1 mutation (Birner et al., 2014). Moreover, 
P16INK4a/RB1 pathway is important in both primary and secondary GBM. These tumors 
commonly bear P16INK4a deletion or promoter methylation, what impedes to enter in cell cycle 
arrest due to the over activation of cyclin D family and RB1 protein phosphorylation (Ohgaki 



































Figure 9. Major signaling pathways involved in glioblastoma malignancy.  
Pathways highlighted in red are common for pGBM (primary glioblastoma), in blue for sGBM (secondary 
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2. Isocitrate dehydrogenase  
Isocitrate dehydrogenase (IDH) enzymes are essential in several major metabolic processes, 
such as tricarboxylic acid (TCA) cycle, lipogenesis, glutamine metabolism or reduction-
oxidation (redox) regulation (Lee et al., 2002, Badur et al., 2018). There exist three different 
isoforms of IDH. While mutations in IDH1 and IDH2 lead to a carcinogenic gain-of-function (i.e. 
neomorphic allele), IDH3 mutations have not been reported in cancer. Besides gliomas, IDH 
mutations are also found in acute myeloid leukemia (AML; 16% of all clinical cases), 
intrahepatic cholangiocarcinoma (23%) and central/periostal chondrosarcoma (56%) (Han et 
al., 2020). Thus, the study and comprehension of the role in tumor malignancy of this frequent 
mutation is nowadays one of the main goals in the field of cancer, and especially of glioma 
research, aiming to improve the clinical outcome of patients. In order to understand the 
molecular mechanisms derived from the mutation in IDH we will first analyze the physiological 
roles of these enzymes. 
 
2.1. IDH structure and function 
IDH1 is located in the cytoplasm and cell peroxisomes while IDH2 and IDH3 are present in the 
mitochondria (Leighton et al., 1969). Yet, IDH1 and IDH2, presenting 70% of gene sequence 
similarity in humans (Waitkus et al., 2016), bear a more comparable structure and function. 
IDH1 gene is present on 2q33.3 chromosomal region and IDH2 gene on 15q26.1. Both 
enzymes are homodimers that catalyze the reversible oxidative decarboxylation of isocitrate 
to α-ketoglutarate (α-KG). They have one active site per monomer with affinity to a divalent 
metal cation (e.g. calcium or magnesium) and to nicotinamide adenine dinucleotide phosphate 
(NADP+). The reaction leads to reduction of NADP+ to NADPH liberating CO2 (Stoddard et al., 
1993) (Figure 10A). Individual IDH subunits contain a large domain, a small domain and a 
clasp domain (Figure 10B), and IDH2 has an additional mitochondrial targeting sequence. The 
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characterized by a regulatory loop segment involving the residue Ser94 of the large domain. 
Isocitrate binding displaces the regulatory loop by its interaction with residues of both dimer 
subunits, including Ser94 and multiple conserved arginines in the active site (Figure 10C). 
Isocitrate interaction induces a conformational change to a closed catalytically active state that 































Figure 10. IDH1/2 reaction and structure.  
A. Reversible oxidative decarboxylation of isocitrate to generate α-ketoglutarate (α-KG) using NADP+ 
and producing NADPH and CO2. B. Crystal structure of IDH1 homodimer. Each monomer is composed 
by a large domain (blue), small domain (red) and clasp domain (green). Only one monomer is colored 
for clarity. The substrate binding pocket contains isocitrate (yellow), calcium (blue) and NADP+ (purple). 
Used from (Waitkus et al., 2016). C. Residue interaction in IDH1 active site. Hydrophilic interactions 
between active site residues, cofactor (Ca2+) and substrate (isocitrate) are depicted as dashed lines. 
Used from (Waitkus et al., 2016). 
 
 
On the other hand, IDH3 is an evolutionary distinct multisubunit complex composed of 3 
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encoded by IDH3A gene on 15q25.1-q25.2, one β-subunit encoded by IDH3B on 20p13, and 
one γ-subunit encoded by IDH3G on Xq28. The α-subunits are catalytic and β, γ-subunits are 
regulatory (Ramachandran and Colman, 1980). Unlike its homologous counterparts, IDH3 is 
nicotinamide adenine dinucleotide (NAD)-dependent and is in charge of the conversion of 
isocitrate to α-KG while generating NADH, a central reaction in the tricarboxylic acid (TCA) 
cycle. The high negative free energy change during mitochondrial isocitrate to α-KG 
conversion and the increased number of regulatory domains make IDH3 reaction virtually 
irreversible (Ramachandran and Colman, 1980). The α-KG generated by IDH3 continues being 
metabolized within the TCA cycle and the NADH is used as electron donor in the electron 
transport chain (ETC) to generate ATP in the process of oxidative phosphorylation. This IDH 
isoform is regulated by substrate availability and cell requirements: whereas calcium, ADP and 
citrate activates it, ATP and NADH inhibit its activity (Gabriel et al., 1986). Therefore, when 
there is high NADH/NAD ratio due to high energy levels or there is increased α-KG due to high 
production from secondary sources (e.g. glutamate and glutamine), mitochondrial isocitrate 
will increase due to IDH3 inhibition (Al-Khallaf, 2017). Some isocitrate molecules will be then 
consumed by IDH2 within the mitochondria in order to generate NADPH, which is used as 
reducing power for antioxidant synthesis such as glutathione (GSH) (Dickinson and Forman, 
2002). Other isocitrate molecules may be converted back to citrate by mitochondrial aconitase 
(ACO) and subsequently transported to the cytosol where can be used to produce acetyl-CoA 
by ATP-citrate lyase (ACL) or to generate cytoplasmic NADPH by IDH1 (Srere, 1959) (Figure 
11). Both cytosolic acetyl-CoA and NADPH are required in lipogenesis. The α-KG that is not 
processed in the TCA cycle or biosynthetic pathways, will act as cofactor for dioxygenases. 
There are more than 60 different α-KG-dependent dioxigenases in humans and they are 
associated with DNA and histone demethylation, HIF-1α degradation and collagen folding and 
maturation (Ohba and Hirose, 2016).  
The reverse reaction carried out by IDH1 and 2 of reductive carboxylation of α-KG to isocitrate, 
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CO2 consumption, largely depends on the relative Km values of forward/reverse reactions as 






















Figure 11. IDH isoforms and their role and localization. IDH3 is in charge of α-KG and NADH 
production in the mitochondrial TCA cycle. IDH2 (mitochondrial) and IDH1 (cytosolic) are both NADP-
dependent enzymes with roles in different biosynthesis pathways. 
 
 
In summary, IDH1 and IDH2 are in charge of regulation of synthetic pathways when energy 
levels are high enough to keep IDH3 inhibited, enabling to redirect isocitrate or α-KG out of the 
TCA cycle (Al-Khallaf, 2017). From a physiological perspective, the roles of IDH1/2 enzymes 
are thought to have a crucial impact in human metabolic regulation. Indeed, IDH represents 
the major NADPH source in various tissues, together with the pentose phosphate pathway 
(PPP). Depending on the tissue, the importance of IDH over PPP for NADPH synthesis will 
vary, e.g. IDH is the main producer of this reducing agent within the human brain (Atai et al., 
2011). Diverse studies point to a key impact of IDH1/2 in oxidative stress defense. It has been 
shown that NADPH production via IDH1/2 has a direct effect in the protection against 
replicative senescence by reducing oxidative DNA damage and lipid peroxidation in cell culture 
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show how its NADPH-producing activity protects against UVB-induced phototoxicity (Jo et al., 
2002), reduces reactive oxygen species (Kim and Park, 2003) and limits ischemia-reperfusion 
injury in the kidney (Kim et al., 2009, Kim et al., 2011). IDH1 has been also probed to display 
an important lipogenic role. During hypoxia, IDH1 reverse reaction of α-KG to isocitrate 
reductive carboxylation is stimulated in order to increase the cytosolic acetyl-CoA pool for lipid 
synthesis (Metallo et al., 2011). Overexpression of liver and adipose IDH1 leads to diverse 
metabolic diseases such as obesity, hyperlipidemia and fatty liver in transgenic mice (Koh et 
al., 2004). Within the CNS, IDH1 has shown to regulate phospholipid metabolism in astrocytes 
of developing mice (Bogdanovic et al., 2014). Regarding IDH2, the reductive carboxylation of 
α-KG has also been shown to promote synthesis of lipids by reductive glutamine metabolism 
(Ward et al., 2010). In addition, it has been shown how mitochondrial IDH2/3 regulate glucose-
stimulated insulin secretion in pancreatic cells (MacDonald et al., 2013). 
 
2.2. IDH mutation and epigenetic reprogramming 
The contribution of IDH in multiple biochemical pathways makes the study of IDH mutation in 
cancer highly relevant for the understanding of the disease. Nevertheless, before discussing 
in section 4 all the diverse effects in glioma metabolism that IDH mutation may inflict, we will 
first address the different repercussions of this mutation in epigenetic reprogramming, an 
extensively studied mechanism in the field of IDH mutant tumors. 
IDH mutation. IDH mutations are universally missense substitutions and tend to occur in the 
arginine residue on the active site. Missense mutations in IDH1/2 genes result in the 
replacement of a strong positively charged residue such as arginine (R) with a lower-polarity 
amino acid such as histidine (H), lysine (K) or cysteine (C). In IDH1, the most common 
missense is from the arginine in position 132 (Arg132) for a histidine (R132H). IDH2 mutations 
occur at Arg172, the analogous residue to IDH1 Arg132, and are most commonly substituted by 
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evolutionary conserved residues that participate in isocitrate binding in the catalytic pocket 
(Figure 10C).  
 
Table 2. Frequency of each specific IDH mutation in glioma patients according to (Yan et al., 2009, 
Hartmann et al., 2009). In the mutation nomenclature c refers to change of a DNA base, the number of 


















The substitution from a high positively-charged amino acid to a low polar one impedes the 
formation of hydrogen bonds with the α-carboxyl and β-carboxyl groups of isocitrate, which 
translates in a loss of affinity for isocitrate and an elevated preference for α-KG. This substrate 
affinity switch triggers a gain-of-function activity which leads to the reduction of α-KG to 
produce the metabolite D-2-hydroxyglutarate (D-2HG). Due to the reductive nature of this 
neomorphic activity, mutant IDH will consume NADPH (Figure 12A), unlike for the oxidative 
wildtype reaction where NADP+ is required (Dang et al., 2009b).  
Nevertheless, this being a heterozygous mutation, only one copy of IDH gene is mutated in 
these tumors, resulting in the protein translation of a heterodimer that contains an IDH wildtype 
(IDHwt) and an IDH mutant (IDHm) subunit. As a result, the IDHwt monomer produces α-KG 
from isocitrate generating NADPH whereas the IDHm monomer consumes both the α-KG and 
NADPH to generate D-2HG. Biochemical studies indicate that a homodimer formed by two 
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in either IDH1 or IDH2 and only very rare cases showed both mutations at the same time 



























Figure 12. IDH1/2 mutant reaction and dimerization. A. IDH gain-of-function mutation leads to the 
neomorphic reduction of α-KG into D-2HG consuming NADPH. B. Wildtype IDH1 enzyme is composed 
of two wildtype monomers which transform isocitrate into α-KG. In IDH1 mutant cells, a heterodimer is 
formed with one wildtype monomer and one R132H mutant. This enzyme is able to generate D-2HG. 
The rare case of homodimer formed by two IDH1m subunits it has been shown to be catalytically 
inactive. Used from (Han et al., 2020). 
 
 
IDHm epigenetic reprogramming. Due to its tumorigenic potential, D-2HG is commonly 
categorized as an oncometabolite. 2HG molecule is a five-carbon dicarboxylic acid and its 
second carbon is chiral, meaning that it has two enantiomers: D-2HG and L-2HG. The D 
enantiomer is the one exclusively produced by the neomorphic reaction of IDHm cells (Dang 
et al., 2009b). In healthy tissue both enantiomers can also be found although they are thought 
to be metabolic “waste” originated in the mitochondria in a small amount, and that can be 
converted into α-KG by D-2HG and L-2HG dehydrogenases (D2HGD, L2HGD) (Steenweg et 
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normal tissue (Dang et al., 2009b).  D-2HG and α-KG are two structurally similar metabolites 
which only differ in the presence of a C2 hydroxyl group in D-2HG instead of the C2 carbonyl 
group of α-KG (Figure 12A). This similarity is what confers to D-2HG the capacity of 
competitively inhibit α-KG-dependent dioxygenases, enzymes in charge of hydroxylating target 
proteins by using α-KG as substrate and incorporating both atoms of molecular oxygen (O2).  
One of the most important dioxygenases in which D-2HG has a direct inhibitory effect are 
histone demethylases, and some of the most frequently inhibited are JHMD1A, JMJD2A, 
JMJD2C and FBXL11, members of Jumonji-C (JmjC) domain-containing family. These histone 
demethylases commonly act by removing methyl groups from lysine residues of different 
histones, and for these reason they are also known as histone lysine demethylases (KDM) 
(Waitkus et al., 2016) (Figure 13). It has been reported that administration of D-2HG is 
sufficient to increase methylation of H3K9 and H3K79 histones in U87 GBM cells (Xu et al., 
2011a). Moreover, it has been observed how IDH1R132H and IDH2R172K overexpression lead to 
trimethylation of histone H3 at Lys9 and Lys27 in immortalized human astrocytes (Lu et al., 
2012).  
As mentioned in section 1.3 IDH mutation is closely associated with CpG island 
hypermethylation (G-CIMP). Indeed, several studies showed that neomorphic IDHm activity 
triggers as well a direct DNA methylation mechanism. Similar as with the competitive inhibition 
of histone demethylases, D-2HG is also able to block the activity of TET 5-methylcytosine 
hydroxylases (Xu et al., 2011a). TET family are α-KG-dependent enzymes that catalyze the 
first step of the DNA demethylation process. This first step consists of the hydroxylation of 5-
methylcytosines to convert them into 5-hydroxymethylcytosines (5-hmC), which are 
intermediates that will be eventually turned into cytosines (Han et al., 2020) (Figure 13). The 
observations in clinical glioma tissues that 5-hmC levels are lower in IDHm tumors relative to 
IDHwt are consistent with in vitro and in vivo mechanistic studies in which the overexpression 
of IDH1R132H and IDH2R172K lead to a decrease in 5-hmC abundance by direct D-2HG-mediated 
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Epigenetic aberrations generated after histone and DNA hypermethylation in IDHm gliomas is 
reported to inhibit cell differentiation (Lu et al., 2012). In fact, IDHm activity increases histone 
methylation at promoters of astrocytic lineage markers. This mechanism has shown to confer 
a block in differentiation in patient-derived glioma xenografts (PDX). Furthermore, it has been 
demonstrated how IDH1m inhibition leads to differentiation of neural stem cells as well as 
tumor growth delay of an IDHm subcutaneous xenograft model (Rohle et al., 2013). A similar 
differentiation mechanism has been observed after IDH1m inhibition of glioma stem like cells 
(GSCs) in vitro (Rohle et al., 2013). Surprisingly, this differentiation effect did not lead to a 
change in DNA hypermethylation. Moreover, a study in which IDH1m GSCs were treated with 
the hypomethylating agent decitabine observed a similar differentiating effect without observed 
change in D-2HG levels (Turcan et al., 2013). It is possible that IDH mutation occurring in 
progenitor glial cells may lead to a specific stop in differentiation that promotes malignant 
transformation and gliomagenesis. Yet, further work is required to definitively identify IDHm-
dependent epigenetic reprogramming mechanism in glioma.  
The association of IDHm with hypoxia-inducible factor 1-α (HIF1-α) regulation has also raised 
controversial hypotheses. HIF1-α is considered as the master transcriptional regulator of 
cellular and developmental response to hypoxia (Ivan et al., 2001). Accumulation of D-2HG 
was also shown to inhibit α-KG-dependent prolyl-hydroxylases (PHDs). Under normoxia, these 
enzymes hydroxylate specific proline residues of HIF1- α creating a binding site for the von 
Hippel-Lindau (VHL) ubiquitin-ligase protein complex and therefore leading to HIF1-α 
proteasomal degradation. On the other hand, under hypoxic conditions, oxygen-dependent 
hydroxylation of PHD dioxygenases does not occur, which results in HIF1- α accumulation. 
This leads to the translocation of HIF1-α into the nucleus and activation of its downstream 
target genes such as VEGF, GLUT1 or PGK1 (Ivan et al., 2001). Competitive inhibition of D-
2HG block similarly the degradation of HIF1- α leading to the overexpression of its target genes 
which might promote tumor proliferation, invasion, angiogenesis and metastasis (Xu et al., 
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mechanism and promote a decrease in HIF1-α levels (Zhao et al., 2009). However, the 
controversy was propelled by a study which showed that D-2HG indeed enhanced PHD2 
activity leading to a decreased expression of HIF1-α, an effect that led to cellular 
transformation (Koivunen et al., 2012). Although further work will be required to fully elucidate 
the link between HIF1-α and IDHm in gliomas, it is possible that environmental factors play a 























Figure 13. Epigenetic reprogramming in IDHm glioma cells.  
The mutation of IDH in glioma cells lead to the accumulation of D-2HG which competitively inhibits 
several α-KG-dependent dioxygenases. The inhibition of KDMs leads to a block in the histone 
demethylation process. TETs inhibition promotes an accumulation of methylated citosines within the 
genome leading to hypermethylation of DNA. Both DNA and histone methylation may promote a 
dedifferentiated status in glioma cells. On the other hand PHD enzymes inhibition prevents HIF1-a 
degradation which may lead to different carcinogenic effects such as tumor cells invasion or 
angiogenesis. Used from (Waitkus et al., 2016).  
 
 
It has been extensively investigated how IDH gain-of-function mutation and subsequent D-
2HG generation lead to numerous epigenetic mechanisms that alter and reprogram the cellular 
and developmental fate of glioma cells. However, these are not the only repercussions derived 
from this frequent mutation. Being such an important metabolic enzyme, IDH plays a central 




 CHAPTER I 
more crucial for the understanding of glioma malignancy, and uncovering potential 
vulnerabilities. In section 4 we will dissect the IDHm-related metabolic alterations so far 
discovered, in the special context of brain tumors.  
 
2.3. Experimental models for IDH mutant gliomas 
Cancer models should ideally present biological features similar to those encountered on 
human cancers. Experimental models for the study of cancer include human cell lines and 
organisms such as mice or rats to investigate cancer biochemical mechanisms and pathology. 
Cell lines are commonly known as in vitro models, which are obtained from normal human 
tissue and are kept in long term culture under special sterile conditions. The use of cell lines 
allows the study and manipulation of cancer under ideal growth and analytical conditions. 
Commonly, these cells are genetically immortalized to improve their growing capacities and to 
grow adhered to the culture surface in serum-containing medium, and that are commonly kept 
and commercialized in different laboratories internationally. On the other hand, patient-derived 
cancer cell lines are directly resected from patient tumors and kept in culture preserving the 
original genetic background. Such cells have long been grown as adherent cell lines and have 
spread over many years and different laboratories, which led to the accumulation of additional 
genetic aberrations not found in the parental tumors (e.g. U87, U251). More recently, 
researchers have switched to glioma patient-derived cell lines grown as 3D spheres in serum-
free medium, thought to better recapitulate the tumor of origin (e.g. NCH551b). With regard to 
animal experimental systems, these are commonly known as in vivo models. When generated 
from implantation of human tumor cells, these are referred to as xenograft models, meaning a 
tissue or cellular transplant that belongs to a donor from a different species than the host. Mice 
are commonly used as animal model, which in most cases are genetically modified to attenuate 
the immunological response to the transplant (e.g. immunodeficient mice). Mouse models can 
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derived xenografts (PDXs). Indeed, certain human cancer cells are not capable of growing in 
vitro, but they are stable once implanted into a mouse host. Finally, human samples can also 
be analyzed in order to collect genomics or proteomics blueprints of the cancer entity. 
However, these samples are not amenable to manipulation, thus they are not considered 
experimental models per se.  
In the study of IDHm gliomas there are a number of different experimental models that have 
been used. Whereas GBM cell lines are normally easy-to-handle models, the presence of IDH 
mutation is generally associated with increased vulnerability and slower growth. Diverse stable 
cell lines genetically engineered to present IDH mutation, have facilitated the analysis of this 
cancer type (Dang et al., 2009b). On the other hand, patient-derived cells are usually more 
difficult to manipulate displaying slow growth capacity or frequent loss of IDHm heterozygosity 
(Luchman et al., 2013). Within the last decade there has been promising improvements in the 
design and maintenance of appropriate models for this elusive cancer type, ranging from the 
direct use of human samples, to the basic principles of in vitro cell lines and the in vivo 
implantation of tumors in mice. 
Human samples. The first report of the existence of the IDH mutation within gliomas was 
observed in a set of 22 human samples where a complete genomics analysis was applied 
(Parsons et al., 2008). In fact, in order to preserve the material, 15 of these samples were 
implanted in mice to be analyzed later, unlike the other 7 samples which were directly used for 
sequencing. Since then, different groups made key findings in the research of IDHm glioma by 
using human samples, not only analyzing their genetic features but also protein or metabolite 
profiles. The clear advantage of using clinical material is the direct analysis of the patient 
reality. Yet, clinical samples represent a snapshot in time and most studies using clinical 
samples are restricted to the classification and molecular characterization of tumors. For this 
reason, several studies use clinical samples as complementary material to validate more 
detailed mechanistic observations made on in vitro or in vivo models (Dang et al., 2009b, Zhao 
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strategies to analyze in situ the features of IDHm gliomas in patients, such as the use of 
metabolic mapping (Bleeker et al., 2010). Nonetheless, this approach is far less versatile than 
the direct manipulation of cell lines and animal models. When the purpose is to present a 
complete characterization of IDHm gliomas, large scale patient cohorts have been used, which 
led to the establishment of genomic databases with a thorough molecular profiling of the 
disease (i.e. TCGA, ICGC, NCT) (Hartmann et al., 2009, Ceccarelli et al., 2016, Bowman et 
al., 2017, Capper et al., 2018).  
In vitro models. The most commonly used in vitro model consists of the transfection of the 
IDH1m gene into a stable fast growing cell line. Diverse groups have opted for this easy-to-
handle cellular set-up in order to understand the cellular impact of the IDH mutation. In some 
cases the IDHm is directly introduced into a fast growing GBM cell line which also expresses 
the IDHwt enzyme. Some of the most common GBM cell lines used for this purpose are U87, 
U373, LN229 or LN18 (Dang et al., 2009b, Zhao et al., 2009, Li et al., 2013, Pusch et al., 2017). 
However, sometimes researchers use cell lines that are not even derived from gliomas, but 
are routinely used for transgenic manipulation, such as HEK293T derived from human 
embryonic kidney cells, A549 from epithelial cancer or NCIH82 from lung cancer (Dang et al., 
2009b, Zhao et al., 2009, Turcan et al., 2012, Pusch et al., 2017, McBrayer et al., 2018). These 
IDHm transfected cell lines are normally generated by using IDHm overexpression plasmids, 
which carries the disadvantage of increasing vastly the expression of this enzyme which 
recedes from the patient reality. In order to circumvent this, recently some groups have made 
use of clustered regularly interspaced short palindromic repeats (CRISPR)-cas9 technology to 
introduce the IDH mutation (Brabetz et al., 2017). The main advantages of using this IDH1m 
transfection set-up is that it generates isogenic models of IDHm with a heterozygous 
expression of IDHm. The transfected and the parental wild type cell line have the same genetic 
background (isogenic) with the exception of the transgenic IDHm insert, which is only 
expressed from one allele, thus reproducing IDHm heterozygosity of patient tumors. This 
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patient-derived tumor cells with or without the mutation, since they represent different tumor 
entities which bear various other mutations and chromosomal alterations. However, patient-
derived tumor models with endogenous IDH mutation better reflect IDHm glioma biology, since 
they carry the genetic background of the original tumor. In any case, the drawback of slow 
growing capacity and vulnerability of these cell lines, often determines the decision of which 
model to use. So far only few groups have used these patient-derived IDHm cell lines such as 
NCH551b, TS603, MGG152 or BT142 (Rohle et al., 2013, Chesnelong et al., 2014, Pusch et 
al., 2017, McBrayer et al., 2018). Moreover, in some cases non-glioma IDHm patient-derived 
cell lines have also been used as complementary model to brain tumors, such as the 
fibrosarcoma cell line HT1080 (Rohle et al., 2013, Pusch et al., 2017).  
In vivo models. In order to mimic the physiological environment of the tumor, in vivo 
approaches are essential. This is particularly important for investigation of tumor metabolism 
which is highly dependent on the surrounding microenvironment and nutrient supply. 
Commonly used in vivo models are immunodeficient mouse xenografts. Once more, the slow 
growing nature of IDHm cells limits the development of these tumors after implantation. Some 
groups perform these tumor cell implantation in the flanks of the mice, subcutaneously (Rohle 
et al., 2013, Schumacher et al., 2014, McBrayer et al., 2018), an easier procedure than 
orthotopic implantation, i.e. transplantation into the original organ of the tumor. However, 
orthotopic xenografts are crucial to understand the behavior of the tumor in the particular 
context of the brain (e.g. BBB, microenvironment, myelin sheaths). In our group we have 
showed the efficacy of establishing IDH1m patient-derived orthotopic xenografts (PDOXs) 
(Figure 14) (Golebiewska et al., 2020). Our PDOX models are generated from primary tumors 
directly resected from patients, without intermediate in vitro amplification, and have proven to 
be suitable models for metabolomics and drug efficacy studies (Fack et al., 2017, Golebiewska 
et al., 2020). Interestingly, many IDH mutant tumors, do not grow in vitro but do grow in vivo 
as PDOX. In addition to in vivo models, in the recent years different groups including us, have 
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preserve intra-tumor heterogeneity and to some extent can be adapted to recapitulate the 
immune compartment (Figure 14) (Klein et al., 2020, Golebiewska et al., 2020). These models 
can be manipulated in culture therefore representing an intermediate level between an in vitro 
and in vivo set up, commonly known as ex vivo. Nonetheless, while GBM organoids have been 





Figure 14. Glioma organoids and PDOX generation 
Schematic representation of derivation of PDOXs, organoids and patient-derived cells from primary and 
recurrent patient gliomas. Longitudinal PDOX model refers to different mice orthotopic implantation of 
primary organoids from same patient during different stages of tumor development (primary tumor, 
recurrence I and recurrence II), treatment refers to patients. PDOX models can be kept in the laboratory 
via serial transplantations to perform in vivo assays. Primary organoids can be preserved in culture for 
short-term in vitro assays. Some organoids can also be kept for long-term in vitro manipulation in serum-
free medium as glioma stem-like cell (GSC) spheres. Used from (Golebiewska et al., 2020). 
 
 
The specific purpose of the study will be decisive for the choice of the most appropriate IDHm 
glioma model. E.g. when aiming to understand the specific metabolic behavior of IDHm 
gliomas, the selection of the model plays a critical role, most often requiring to preserve or 
mimic the metabolic environment of the tumor as best as possible. While genetic blueprints 
may remain relatively stable, cellular metabolism is a process in motion, rapidly responding to 
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3. Principles of metabolism in health and cancer 
Metabolism, which encompasses more than 8,700 reactions and 16,000 metabolites, can be 
defined as all biochemical processes involving organic compounds which either produce or 
consume energy in living organisms (DeBerardinis and Thompson, 2012). Metabolism 
represents the essential event of life in which macronutrients obtained from food are 
decomposed in building blocks which are processed for energy production and recycled for 
biosynthesis of new compounds. In cancer, the metabolic behavior of tumors depend on the 
constant communication and competition of malignant cells with its environment, what allows 
them to proliferate and invade neighboring tissues. These intricate metabolic interactions are 
possible due to adaptive mechanisms that may be conserved in different cancer types, but 
may also be specifically determined by the physiological scenario of each tumor.  
In section 2.2, we discussed the repercussions in epigenetic reprogramming and 
tumorigenesis linked to D-2HG accumulation. In section 4 we will analyze how IDH mutation 
alters the specific metabolic landscape of glioma cells. To understand the specific metabolic 
pathways altered in IDHm gliomas, we will first review the general principles of metabolism in 
health and cancer, including: the basic metabolic regulation in normal cells, the specificities of 
brain metabolism and the general hallmarks of cancer metabolism. 
 
3.1. Basics of cellular metabolism 
In general terms, all biochemical pathways participating in cellular metabolism can be 
classified in four groups: 1) Nutrient uptake from the extracellular space towards the cell; 2) 
Anabolism: the synthesis or polymerization of molecules, which requires energy; 3) 
Catabolism: the degradation of molecules, which releases energy; 4) Waste disposal: the 
elimination of toxic compounds derived from the previous reactions (DeBerardinis and 
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carbohydrates, amino acids and fatty acids. These nutrients are the building blocks for the 
anabolism of macromolecules, which will serve either as energy storage (lipids and 
polysaccharides) or to promote cellular growth (proteins, nucleic acids and lipids), but they can 
also be re-catabolized back to building blocks. This represents a continuous loop driven by 
energy availability where micronutrients and macronutrients are constantly interconverted. 
Catabolism of building blocks promotes energy release. At the same time, secondary 
metabolites are formed which can be either re-utilized as metabolic intermediates (such as 
pyruvate or acetyl-CoA) or might be waste to be removed (such as CO2 or NH3). Thousands of 
intermediary metabolites shape the overall landscape of metabolic regulation, and although 
some are directly related with molecular recycling or energy production, others bear their own 
cellular functions such as signaling molecules, vitamins, neurotransmitters or enzymatic 






















Figure 15. Overview of cellular metabolism regulation. 
Schematic representation of the different processes involved in cellular metabolism as well as the most 
important compound groups involved.  
 
 
Energy is the primal force that drives life against entropy. As mentioned, anabolic metabolism 
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“molecular currency” which stores and transports chemical energy obtained from catabolic 
reactions (Nelson et al., 2009). When required, ATP will be used as energy boost to allow 
anabolic synthesis. Moreover, all metabolic reactions will require the action of specific catalysts 
that force reactivity of substrates: enzymes. In order to catalyze specific reactions, enzymes 
need particular cofactors. These are organic (e.g. NADH) or inorganic (e.g. metal ions such as 
Fe2+) molecules and atoms, that interact with the enzyme triggering the reaction catalysis. 
Finally, all these reactions will be influenced by the electron charge carried by each compound. 
Therefore, the pH of the cell and the electronegativity of certain molecules will create the need 
of electron donors and acceptors (e.g. NAD(P)H and NAD(P)+ respectively) which will promote 
reductions and oxidations in order to preserve the pathway flow. These reduction and oxidation 
(redox) reactions are essential in multiple metabolic events, such as oxidative phosphorylation 
and ATP synthesis or anabolic pathways such as biosynthesis of fatty acids (He et al., 2017). 
Taking into account the different principles aforementioned, in the present section we will 
review cellular metabolism in three different parts: 1) Intermediary metabolism: anabolic and 
catabolic reactions involving processing of building blocks, macromolecules and secondary 
metabolites thereof; 2) Energy metabolism: reactions aiming to produce energy in form of ATP; 
3) Redox metabolism: reactions that lead to reduction or oxidation of compounds and the 
machinery of the cell to balance this process.  
 
3.1.1. Intermediary metabolism 
The physical-chemical properties of the carbon atom, makes it ideal for the generation of living 
organisms. Carbon erects the central skeleton of all organic compounds, and together with 
hydrogen, oxygen and nitrogen, they account for more than 99% of all atoms in life (Koolman 
and Röhm, 2013). In addition, sulfur and phosphate are also highly represented elements. 
Metabolites are the basic organic compounds that make life possible, by allowing energy 
production and growth. Intermediary metabolism is the field that attempts to understand how 
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thousands of different metabolites is yet unfathomable and although much is already known, 
the field of intermediary metabolism is still under constant investigation. Between the 1920s-
1960s most of today’s known metabolic networks have been defined. These networks are 
mainly related to nutrient utilization and energy production, such as glycolysis (Embden, 
Meyerhof and Parnas), the TCA cycle (Krebs), or respiration (Warburg). Nowadays, with the 
advance of mass-spectrometry metabolomics techniques and in silico simulations, different 
public databases (e.g. KEGG or Expasy) have considerably improved the classification and 
understanding of the intricate metabolic organization (Okuda et al., 2008, Gasteiger et al., 
2003). In brief, all intermediary metabolism revolves around the processing of the four base 
building blocks: sugars, amino acids, fatty acids and nucleotides.  
Sugars. The carbohydrates are a group of carbonyl compounds (aldehydes or ketones), 
containing several hydroxyl groups (Figure 16A). Monosaccharides, or sugars, are the 
simplest unit of this group, which may polymerize into oligosaccharides or polysaccharides. In 
nature, monosaccharides are found in cyclic conformation due to the reactivity of one of the 
hydroxyl groups with the aldehyde. Glucose is the most common sugar, an aldehyde with six 
carbons (i.e. aldohexose), which lies at the core of intermediary and energy metabolism. Most 
monosaccharides have a similar configuration as glucose, there exist many sugar derivatives 
or metabolic intermediates. Within the cell, glucose is rapidly phosphorylated into glucose-6-
phosphate (Glc-6-P), which is the starting point or endpoint of many metabolic pathways 
(Nelson et al., 2009). Besides biosynthesis of metabolic intermediates, the main function of 
glucose metabolism is chemical energy production in form of ATP. In this process, glucose is 
consumed into pyruvate via glycolysis, which in the presence of O2 will enter the mitochondrion 
to be metabolized into acetyl-CoA to generate ATP through the TCA cycle. Glycolysis alone 
gives ATP, although in a much limited amount than within the complete mitochondrial 
respiration. In the absence of oxygen, glycolysis can still promote ATP formation due to positive 
feedback of pyruvate-derived lactate, a process known as anaerobic glycolysis or lactic 
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amino acids (e.g. alanine or glutamine), and also lactate and glycerol, a process known as 
gluconeogenesis. In cases of excess of glucose, it can be polymerized into long monomeric 
chains known as glycogens, which serve as energy reserve. The PPP (pentose phosphate 
pathway) is another important metabolic route of glucose which lead to the generation of 
nucleotide precursors, as well as electron donors in form of NADPH (Koolman and Röhm, 
2013).  
Amino acids. Amino acids are compounds containing amino and carboxyl groups alongside 
another specific chemical group which will confer them different polarities (Figure 16B). Their 
characteristic amino group (NH2) makes amino acids an essential source of nitrogen. The most 
commonly known amino acids serve as building blocks for proteins (i.e proteinogenic, e.g. 
cysteine or glutamine), however many are non-proteinogenic and participate in the synthesis 
and breakdown of other proteinogenic amino acids or as intermediates in different metabolic 
pathways (e.g. homocysteine or ornithine) (Nelson et al., 2009). Proteins can be classified into 
distinct groups, such as transport, regulatory or structural proteins, however in terms of 
metabolism, catalytic proteins or enzymes are the most relevant ones, since they drive the flow 
of all different pathways. Besides protein synthesis, amino acids are pivotal in diverse 
metabolic events. TCA anaplerosis is the alternative pathway to fuel TCA cycle independently 
of glycolysis. This serves as a glucose-independent alternative to promote synthesis of 
intermediates and/or ATP. Directly or indirectly, several amino acids such as glutamate, 
glutamine, aspartate or proline may perform TCA anaplerosis. On the other hand, certain 
amino acids serve as precursors for acetyl-CoA and synthesis of lipids (ketogenic amino acids, 
e.g. glutamine, leucine and lysine). Amino acids can as well be grouped as essential (i.e. they 
cannot be synthesized by animal cells, e.g. arginine or methionine), and nonessential (i.e. they 
can be synthesized, e.g. serine or cysteine). Glutamate is a key precursor in the synthesis of 
several other amino acids via transamination (e.g. alanine, arginine, proline or aspartate). 
Other similarly structured amino acids, such as glycine, serine and cysteine, can as well be 
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Fatty acids. Fatty acids are carboxylic acids with unbranched hydrocarbon chains of 3-24 
carbons (Figure 16C). Lipids represent a heterogeneous group of hydrophobic compounds, 
made up of fatty acids. In most cases, fatty acids are esterified with alcohols (e.g. glycerol, 
sphingosine). Fat, for instance, which is the main energy storage in animals, is formed as 
esters of glycerol with three fatty acids, also known as triacylglycerols (fatty acid residue = acyl 
group). On the other hand, fat or glycerolipids can as well be linked to a phosphate group, 
forming phospholipids. This phosphate group confers phospholipids an amphipathic potential 
(both hydrophobic and hydrophilic potential), making them the ideal constituent of biological 
membranes (Nelson et al., 2009). In order to be broken down or incorporated into other 
molecules, fatty acids are linked to coenzyme A (CoA), forming the more reactive derivative 
acyl-CoA in a process known as fatty acid activation. The degradation of acyl-CoA promotes 
the synthesis of acetyl-CoA in a process called β-oxidation which takes place within the 
mitochondrion. Through this process, acetyl-CoA can enter the TCA cycle for ATP synthesis 
independently of glucose, thereby making lipids an important source of energy. Inversely, 
when fatty acids are scarce, they can be synthetized from acetyl-CoA coming from different 
sources such as mitochondrial citrate from TCA cycle or cytosolic citrate derived from a multi-
step process of glutaminolysis, where IDH is involved. Other important pathways such as 
lipogenesis (i.e. synthesis of fats), cholesterol and steroid hormone synthesis, and ketone body 
processing, play as well key roles in lipid metabolism (Koolman and Röhm, 2013).  
Nucleotides. The nucleotides are organic compounds formed by a pentose, a phosphate 
residue and a nucleobase (Figure 16D). Nucleobases or nitrogenous bases, are aromatic 
heterocyclic molecules which can be classified as purines or pyrimidines. Polymerizing 
sequences of nucleotides form the nucleic acids, such as deoxyribonucleic acid (DNA) and 
ribonucleic acid (RNA) (Koolman and Röhm, 2013). Besides generation of nucleic acids, 
nucleotides may have independent functions such as enzymatic cofactors or signaling 
molecules. In fact, the most important function of a nucleotide within metabolism is the storage 
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adenosine triphosphate, i.e. ATP. Moreover, pyridine nucleotides NAD and NADP are the most 
common redox cofactors in the cell. Carbohydrate and amino acid metabolism is directly linked 
to the synthesis of nucleotides, either in order to produce pentoses (via PPP), or for synthesis 
of purines and pyrimidines. For instance, aspartate and glutamine are important precursors of 













Figure 16. Building blocks  
A. Chemical structure (represented as Haworth projection) of the carbohydrate monosaccharide 
glucose. B. Chemical structure of the amino acid glycine. C. Structure of the fatty acid hexanoic acid. D. 
Structure of the nucleoside adenosine.  
 
 
In summary, intermediary metabolism is composed by a network of pathways involving 
synthesis and break down of building blocks, macromolecules and their derivatives. All these 
pathways interconnect since in many cases some metabolites can enter different routes 
depending on the cellular requirements. Intermediary metabolism supplies the cell with the 
organic compounds that it needs to undergo growth and division. In order to cope with the 
amount of energy needed to maintain metabolic functioning, the animal cells produce ATP in 
a multi-pathway process in which redox homeostasis gets altered.   
 
 
3.1.2. Energy metabolism 
The energy system in the cell is organized as an energetic coupling. This means all 
biochemical reactions that require energy (endergonic), are coupled to another reaction that 
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most important chemical energy storage in cells. ATP acts as an energy supplier molecule for 
endergonic reactions (e.g. biosynthesis, movement and transport processes) since its 
cleavage is strongly exergonic. Synthesis of ATP is essential for living cells to maintain their 
metabolic machinery in motion (Nelson et al., 2009). Animals are chemoheterotrophic 
organisms, which means they need to ingest organic compounds from the diet and catabolize 
them in order to synthesize ATP. Although they can produce ATP independently of O2, animal 
cells rely mostly on O2 to drive energetic metabolism, in a process known as oxidative 
phosphorylation or cellular respiration, taking place in the mitochondria. In brief, during 
oxidative phosphorylation, electrons obtained from degradation of organic compounds within 
the TCA cycle, are transferred from electron donors (e.g. NADH) onto an oxygen molecule. 
Due to the wide difference in redox potential between the electron donor, NADH, and the 
acceptor, oxygen, this reaction is strongly exergonic. The energy released then is used to 
establish a proton gradient across the mitochondrial membrane which enables the synthesis 
of ATP (Koolman and Röhm, 2013).  
The process of cellular respiration starts with acetyl-CoA. This molecule will fuel the TCA cycle, 
within mitochondria (Figure 17). In this pathway, tricarboxylic acid compounds (such as 
isocitrate) are oxidized releasing CO2. Coupled to each oxidation there is a reduction of an 
electron acceptor (i.e. NAD+) to produce a reducing equivalent (i.e. NADH). All the NADH 
molecules produced within the cycle will then serve as electron donors within the respiratory 
chain. This, also known as electron transport chain (ETC), is a sequence of large protein 
complexes (complex I, II and III as well as ubiquinone and cytochrome c, and the ATP 
synthase) that are embedded within the inner mitochondrial membrane. Since mitochondria 
possess a double membrane, these ETC complexes tunnel between the mitochondrial matrix 
and the intermembrane space (Figure 17). Electrons coming from NADH are transferred 
alongside the mitochondrial membrane via ETC complexes attracted by the high redox 
potential against the oxygen molecule located at the end of the chain, in the complex IV. When 
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the process of electron transfer, each of the ETC complexes pump H+ from the mitochondrial 
matrix, generating a cumulus of H+ within the intermembrane space. Finally, the ATP synthase 
pumps all H+ accumulated in the intermembrane space back into the mitochondrial matrix. This 
drastic change in the proton charge from both sides of the membrane releases enough free 
energy to promote the highly endergonic addition of a phosphate residue into an ADP 
molecule, and ATP is produced (Figure 17) (Nelson et al., 2009). This complex multi-step 
process is a highly efficient source of ATP. Although glycolysis alone leads to ATP synthesis, 
this is far less productive than cellular respiration. Only 2 molecules of ATP per molecule of 
glucose are gained during glycolysis whereas oxidative phosphorylation has a yield of 36 ATPs 


























































Figure 17. Cellular respiration.  
Scheme of main metabolic pathways involved in cellular respiration.  
ATP: Adenosine triphosphate; NADH: nicotinamide adenine dinucleotide; I: complex I; Q: cytochrome 
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3.1.3. Redox metabolism 
The presence of electron donors and acceptors is essential to maintain the flow of reduction-
oxidation (redox) metabolism. As we have seen previously, these redox reactions are common 
in diverse metabolic pathways: in cellular respiration NADH acts as electron donor for O2, 
generating the force that drives ATP synthesis. Apart from NADH, NADPH is another common 
electron donor, which is mostly used during biosynthesis reactions, but also plays an essential 
role in the production of antioxidants and the defense against excessive oxidation within cell 
structures (oxidative stress) (Koolman and Röhm, 2013).  
Redox reactions are chemical processes in which electrons are transferred from one reactant 
to the other. This reactions always involve pairs of compounds. Each pair is known as a redox 
system, in which one component is richer in electrons (i.e. reduced) than the other (i.e. 
oxidized). The redox potential of a system determines the capacity to transfer electrons. 
Therefore, in redox reactions, the reduced form from one system donates electrons to the 
oxidized form of the other system and vice versa. At the end of the reaction, the reducing 
agents become oxidized and the oxidizing agents are reduced (Koolman and Röhm, 2013). 
Within the cell the majority of redox reactions are catalyzed by enzymes known as 
oxidoreductases, which require specific redox cofactors. Indeed, the redox cofactors are the 
other member of the pair in the redox system in order to perform a specific reduction or 
oxidation of a molecule (and therefore acting as electron donors or acceptors). The most 
common redox cofactors are the pyridine nucleotides NAD and NADP, which transfer hydride 
ions (H-). In their oxidized form, they are electron acceptors represented as NAD+ and NADP+ 
and in their reduced form they are electron donors represented as NADH and NADPH. 
Whereas NAD(H) is commonly used in catabolic pathways such as the ones leading to the 
respiratory chain, NADP(H) is essential during anabolic pathways such as biosynthesis (e.g. 
fatty acids, cholesterol) or biotransformation. There are other redox cofactors such as flavin 
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O2 contains two unpaired electrons (i.e. diradical). Due to the high electronegativity of the 
oxygen atom, O2 tend to accept instead of donating electrons, therefore oxidizing other 
molecules (hence the term “oxidation”). If the molecule takes up extra electrons generates 
reactive oxygen species (ROS) such as superoxide radical (O2-) or hydrogen peroxide (H2O2) 
(Koolman and Röhm, 2013). ROS, also known as free radicals, are highly reactive molecules 
that interact with chemical compounds of biological structures (e.g. lipids, DNA, proteins) 
forcing their degradation, a process commonly known as oxidative stress. Therefore, 
excessive exposure to oxygen can be toxic to the cell. During oxidative phosphorylation the 
electron charged oxygen ion (O2-) gets neutralized by addition of protons giving rise to H2O. 
However, the higher the activity of this process the higher the chances to generate more ROS. 
In fact, besides directly degrading biological structures, ROS can also act as signaling 
molecules that can trigger a wide variety of physiological events, such as apoptosis or cell 
cycle arrest (D'Autréaux and Toledano, 2007). Increasing evidence supports a role for other 
sources of reactive species, such as reactive nitrogen species (RNS, e.g. NO) or reactive sulfur 
species (RSS, e.g. H2S), all molecules containing highly electronegative atoms. However the 
specific impact of RNS and RSS in human physiology is still under investigation (Cortese-Krott 
et al., 2017).  
In order to combat the serious hazard promoted by oxidative stress, the cells generate 
antioxidants. These are specific reducing agents that react readily with those oxidizing agents 
thereby preventing damage against more important molecules. There exist different types of 
antioxidants: either enzymatic, such as thioredoxin (Trx), superoxide dismutase (SOD) and 
catalase (CAT); or non-enzymatic, such as ascorbic acid (AA or vitamin C) or reduced 
glutathione (GSH) (He et al., 2017). The glutathione system is also composed of various 
enzymes that reinforce the antioxidant capacity of this molecule, making it the most important 
antioxidant in humans (Forman et al., 2009). The antioxidant mechanism of glutathione 
consists of a redox reaction in which the reduced form (i.e. GSH) interacts with a ROS. Through 
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while oxidizing GSH into its oxidizing form, glutathione disulfide (GSSG) (Figure 18). Besides 
ROS, GSH has also the ability to conjugate with xenobiotic molecules via a glutathione s-
transferase (GST) reaction. The importance of GSH relies in its versatility but also in its 
reusability, and GSSG can be recycled back to GSH by glutathione reductase (GR), using 
NADPH as reducing power (Forman et al., 2009) (Figure 18). The chemical advantage that 
makes GSH an excellent antioxidant lies in its free thiol group (SH), which interacts with the 
different ROS. GSSG, is created by assembling two oxidized GSH molecules by their thiol 
groups, generating a disulfide bond (S-S) that masks the reactivity of the molecule (Figure 
18). Hence, NADPH plays a pivotal role maintaining the pool of GSH and securing redox 























Figure 18. Glutathione redox reactions.  
Glutathione peroxidase (GPx) catalyzes the oxidation of reduced glutathione (GSH) into oxidized 
glutathione (GSSG) what neutralizes reactive oxygen species (ROS). For instance, this reaction will 
lead to H2O2 (i.e. a common ROS) conversion into H2O and O2. Every two molecules of GSH will oxidize 
into one molecule of GSSG. Glutathione reductase (GR), will be in charge of the reduction of GSSG into 
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3.2. Specificities of brain metabolism 
Due to the specific physiological compartmentalization of the brain, its metabolic regulation 
represents a specifically exclusive process within the human body. The most important 
substrate that will mediate the metabolic activity of the brain is glucose. This molecule lies at 
the apex of central carbon metabolism and will be key to sustain the energetic needs of the 
brain, but as we saw previously, it will as well trigger the synthesis of a wide range of metabolic 
intermediates important in many different pathways. In principle, neurometabolism is 
essentially oxidative, thus both glucose and oxygen are crucial substrates that must be 
administrated via blood irrigation. About 20% of oxygen and 25% of glucose consumed by the 
human body are dedicated to cerebral functions, yet the brain represents only 2% of the total 
body mass (Alle et al., 2009). Other metabolic substrates can compensate energetic needs in 
the brain during particular situations, such as ketone bodies during development and starvation 
(Belanger et al., 2011) or lactate during periods of intense physical activity (van Hall et al., 
2009). In fact, it has been observed that there is a high metabolic plasticity in the brain, been 
able to switch between anaerobic glycolysis and oxidative metabolism depending on the 
momentary cellular needs. Constant maintenance of synaptic and action potentials together 
with synthesis and recycling of neurotransmitters and building blocks contribute to the high 
brain energy demand (Belanger et al., 2011).  
CNS barriers. The exclusivity of neurological tissue, forces the brain to be semi-isolated from 
the rest of the body, being the blood stream that enters the brain permanently filtered by the 
blood-brain barrier (BBB). Together with the blood influx, another fluid with a less restrictive 
brain contact covers the organ, the cerebrospinal fluid (CSF). The CSF is secreted by 
ependymal cells from the choroid plexus to then travel around the spinal cord and the 
subarachnoid space that covers the brain (Figure 19A). This fluid provides mechanical 
protection and different molecular factors that enhance brain homeostasis, complementing 
those provided by blood. Moreover, CSF allows the removal of waste products from the brain, 
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the body (Huff et al., 2020) (Figure 19A). CSF can be extracted and analyzed and may serve 
as a good indicator of brain metabolic composition.  
The highly selective semi-permeability of the BBB prevents solutes in the circulating blood 
crossing into the interstitial fluid of the brain and CNS. This barrier is formed by blood capillary 
endothelial cells, pericytes and astrocytes (Figure 19B). This cellular complex restricts the 
passage of pathogens and diffusion of solutes and large or hydrophilic compounds (such as 
proteins), while allowing passive diffusion of hydrophobic molecules (e.g. O2, CO2, hormones) 
and small polar molecules. Specific proteins across the barrier actively mediate the selective 
transport of essential ions and metabolites, such as glucose. On the other hand, CSF and brain 
extracellular fluid are separated by a thin layer of ependymal cells. Finally, in addition to the 
BBB, a blood-CSF barrier (BSCFB) also prevents the flow of large or hydrophilic molecules 
from blood to CSF. This BCSFB is formed by ependymal cells, some pericytes and the 
endothelial layer of the blood capillary. (D'Agata et al., 2017) (Figure 19B). In brief, blood 
molecular supply is tightly restricted into the brain and into the CSF, but this restriction is mild 
between brain and CSF.  
The presence of these different barriers creates the necessity to have an internal source of 
metabolic production within the brain. Astrocytes are the main cell type in charge of brain 
metabolism regulation, on one hand uptaking filtered compounds through the BBB, and on the 
other hand providing neurons with the necessary factors for them to function and endure. Thus, 
the key of brain metabolism lies at the center of astrocyte-neuron communication. As we 
introduced in section 1.2 astrocytes are the most abundant glial cell in the CNS. In fact, 
astrocytes outnumber even neurons in the human brain (Nedergaard et al., 2003). They carry 
numerous functions such as ion and water homeostasis, neurotransmitter and nutrient 
regulation, antioxidant defense, energy production, tissue repair and synapse maintenance 
(Bélanger and Magistretti, 2009). These cells are able to dynamically respond to changes in 
their microenvironment in order to assist neurons in their synaptic activity. They are star-
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vessels in order to uptake necessary nutrients, and ensheath neuronal synapses to provide 

























Figure 19. Physiological and cellular distribution of fluids within the brain.  
A. Cerebrospinal fluid secreted by the ependymal cells of the choroid plexus travels around the brain 
through the subarachnoid space. On the other hand, the blood stream enters into the brain through 
capillary innervations. CSF carrying neuronal waste is absorbed at the arachnoid granulations, drained 
out into the superior sagittal sinus and returned to venous circulation. Adapted from kenhub.com.  
B. BBB is formed by endothelial cells of the capillary walls closely linked by tight junctions, as well as 
pericytes embedded to the capillary and the end-feet of astrocytes from the brain interstitial fluid 
ensheathing all. CSF and brain extracellular fluid are separated by a layer ependymal cells with no tight 
junctions. The BCSFB is formed by tightly linked ependymal cells, some pericytes and the endothelial 
layer of the capillary, with fenestrations or space among cells. Used from (D'Agata et al., 2017).  
 
 
Glucose supply. Cerebral metabolism is mainly oxidative due to the high energetic 
requirements of neurons to sustain the synaptic transmission (Lebon et al., 2002). It has been 
observed that neurons display a low glycolytic rate, due to the low expression of key enzymes 
such as the phosphofructo-kinase Pfkfb3, in charge of fructose-2,6-biphosphate formation 
(Almeida et al., 2004). They therefore lack not only the capacity of producing their own pyruvate 
for TCA cycle and oxidative phosphorylation (Bolaños et al., 2010). These deficiencies make 
them largely dependent on the external supply from astrocytes. Astrocytes, on the contrary, 
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display a disrupted TCA cycle, due to downregulation of pyruvate dehydrogenase (PDH) 
(Laughton et al., 2007). Thereby, both cell types complement energetically: astrocytes obtain 
glucose from the blood through glucose transporter 1 (GLUT1), and metabolize it into lactate 
due to their increased glycolytic rate, they then release the excessive lactate and neurons 
uptake it via monocarboxylate transporters (MCTs) (Magistretti and Allaman, 2015, Allaman et 
al., 2011). Within their cytosol, neurons are able to convert lactate to pyruvate to then carry on 
with oxidative phosphorylation and ATP production. This process is commonly termed the 
astrocyte-neuron lactate shuttle (ANLS) (Belanger et al., 2011) (Figure 20). Neurons also have 
the possibility to uptake glucose from the extracellular fluid with their specific transporter 
GLUT3. Nevertheless, it has been proven that the astrocyte specific transporter GLUT1 is 
essential for brain cells to survive, since its absence results in severe neurological phenotype 
(Wang et al., 2006), whereas GLUT3 inhibition do not represent any neurological or brain 
metabolism abnormalities (Schmidt et al., 2008). In order to maintain a pool of rapidly 
accessible glucose, astrocytes store deposits of glycogen in their cytosol. Experimental 
increase of astrocytic glycogen storage have been proven to preserve neuronal function and 
viability during limited energy supply, such as hypoglycemia (Brown, 2004). In fact, the 
machinery to trigger glycogen synthesis and breakdown is inactive in neurons, and glycogen 
deposition induced in cultured neurons caused apoptosis (Vilchez et al., 2007). Therefore, 
astrocytic glycogen pool is thought to be an essential energy store to maintain the metabolic 
demands of the different cerebral functions (Figure 20).  
Ketone bodies. Fatty acids may as well be used as energy source during certain specific 
circumstances, such as brain development, starvation periods or during high-fat diets. 
Although still partially understood, increasing evidence suggests as well an astrocyte-neuron 
interaction for fatty acid metabolism. With this regard, astrocytes may use different fatty acids 
to generate water-soluble ketone bodies (e.g. β-ketobutyrate, acetoacetate) that can be 
released to the interstitial fluid and uptaken by neurons via MCTs (Le Foll and Levin, 2016, 
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precursors for acetyl-CoA, to finally enter into the TCA cycle and promote ATP synthesis 
(Nehlig, 2004) (Figure 20). In addition, astrocytes have been shown to be responsible of 
phospholipid regulation, interestingly, via IDH1-mediated reductive carboxylation (Bogdanovic 
et al., 2014). 
Glutamate-glutamine shuttle. Another well studied process in which astrocyte’s assistance is 
essential is the removal of excessive glutamate molecules within the synaptic cleft. Glutamate 
is the primary excitatory neurotransmitter in the brain and overstimulation of glutamate 
receptors is highly toxic in neurons (excitotoxicity). To avoid this, astrocytes uptake glutamate 
through specific excitatory amino acid transporters (EAATs) (Bak et al., 2006), in an ATP-
dependent mechanism. In fact, this ATP consumption in astrocytes is a positive regulator of 
glycolysis and lactate production, what stimulate the ANLS (Bélanger and Magistretti, 2009). 
When required, astrocytes release glutamate in form of glutamine, after previous conversion 
via glutamine synthetase (GS), to be then uptaken by neurons and deaminated back into 
glutamate by glutaminase (GLS), a process known as glutamate-glutamine cycle (Belanger et 
al., 2011) (Figure 20). It is worth mentioning that neurons rely entirely on astrocytes for de 
novo synthesized glutamate, as they are the only neural cell type that express pyruvate 
carboxylase (PC), being able to produce glutamate from glucose (Belanger et al., 2011, Bak 
et al., 2006, Gamberino et al., 1997). However, the deficient astrocytic PDH activity 
aforementioned may limit this de novo glutamate production. 
GSH synthesis. One of the most important roles of astrocytes is to provide neurons with the 
required antioxidant products. Being highly oxidative, neurons are subjected to the toxic effect 
derived from increased ROS. Yet, these cells lack the metabolic substrates to synthesize 
important redox compounds, such as glutathione GSH, the most relevant antioxidant in the 
brain (Bélanger and Magistretti, 2009, Paul et al., 2018). Indeed, astrocytes have proved to be 
the mayor provider of these substrates, and co-culture of neurons with astrocytes rescues the 
damage caused by oxidative agents (e.g. H2O2, NO) (Calkins et al., 2009). GSH (or γ-L-
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glycine and cysteine. As we previously described, astrocytes sustain neurons with glutamate 
through the glutamate-glutamine cycle. In order for them to provide with glycine and cysteine, 
the limiting metabolite for GSH production, astrocytes release GSH to the extracellular space. 
GSH, instead of been directly absorbed by neurons, is cleaved into L-cysteineglycine and 
subsequently to both cysteine and glycine to be used as GSH precursors by neurons when 
required (Paul et al., 2018, Dringen, 2000, Aoyama et al., 2008) (Figure 20). The highly 
oxidative landscape of the brain forces it to maintain a stable GSH pool. To do so, NADPH is 
indispensable as reducing power to maintain a constant recycling of GSH. Interestingly, it has 
been shown that IDH is the main source of NADPH in the human brain (Atai et al., 2011). 
Although not yet confirmed, considering their main role as metabolic suppliers, astrocytes are 
most probably in charge of this function. Another antioxidant that can be provided by astrocytes 
to neurons is ascorbic acid (AA), a metabolite that requires GSH oxidation (into its disulfide 
form GSSG) to be formed and once in the neuron, favors lactate metabolism over glucose via 
MCTs stimulation (Castro et al., 2009) (Figure 20). Brain susceptibility to oxidative damage is 
observed in different neuropathological conditions such as stroke, traumatic brain injury or 
neurodegenerative diseases, what highlights the importance of astrocytes in neuroprotection 
(Dringen, 2000).  
Besides what it has been discussed above, there are other relevant astrocyte-neuron 
interactions. The release of H+ and Na+ from astrocytes enables MCTs shuttling activity and 
pH buffering. In addition, astrocytic K+ buffering after neuronal activity alleviates its 
accumulation in the extracellular space (Allaman et al., 2011) (Figure 20). 
Blood nutrient supply. A factor noteworthy to consider with regard to brain amino acid and 
small molecule supply is the balance between blood uptake and biosynthesis via astrocytes. 
The exact ratio of income of each amino acid from either blood or astrocytes still remains 
elusive, however, some studies suggest that the importance of each source will depend on the 
grade of auxotrophy for each molecule. Therefore, generally, all non-essential amino acids that 
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precursors. On the other hand, all the essential molecules that may not be generated de novo 
are transported from blood supply (Banos et al., 1975, Cakir et al., 2007). For instance, serine 
may be synthesized via glucose via PHGDH reaction. Moreover methionine and serine might 
be combined to produce cysteine, via transsulfuration pathway, which has been shown to be 
an important cysteine source in astrocytes, especially during increased antioxidant demands 
(McBean, 2018). However, neither glucose nor methionine are de novo synthesizable within 
the brain.  
In summary, there is a wide set of mechanisms that make astrocytes crucial support cells, 
complementing neurons in a constant symbiosis. Astrocytes act as the perfect engines that 
enable the motion of neuronal machinery. The biology of these cells is essential to study glioma 
metabolic behavior, not only because allows to understand general brain metabolism, but also 
because the majority of IDHm gliomas arise from this specific cell type (e.g. astrocytomas or 
secondary GBMs). In section 4 we will analyze all the specific metabolic pathways that had 
been found altered in IDHm gliomas, however, first we will present an introductory section on 




















































Figure 20. Schematic representation of astrocyte-neuron metabolic interactions.  
(I) pH buffering (orange). NHE, sodium-hydrogen exchange; NBC, sodium-bicarbonate (HCO3-) co-
transporter; MCTs, monocarboxylate transporters; CA, carbonic anhydrase. (II) FAO (Yellow). FAO, 
Fatty acid oxidation; KB, ketone bodies; FA, fatty acids. (III) ANLS (green). ANLS, astrocyte-neuron 
lactate shuttle; GLUT3, glucose transporter 3; EAAT, excitatory amino acid transporter; GLUT 1, glucose 
transporter 1. (IV) AA recycling (purple). AA, ascorbic acid; DHAA, dehydroascorbic acid. (V) Glu-Gln 
shuttle (red). Glu, glutamate; Gln, glutamine; GS, glutamine synthetase; GluR, glutaminergic receptors. 
(VI) K+ buffering (blue). Kir, inwardly rectifying K+ channels, GJ, gap junctions. (VII) GSH metabolism 
(pink). Cys, cysteine; Gly, glycine; ApN, ectopeptidase aminopeptidase N; CysGly, cysteine-glycine 
dipeptide; γGT, γ-glutamyl transpeptidase; X, potential γ-glutamyl acceptor; γGluX, complex of γ-
glutamyl and X. 
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3.3. Introduction to cancer metabolism 
The discovery of aberrant metabolic pathways has unveiled a new paradigm in the study of 
cancer. Their altered role might have a great impact in the malignancy of the disease since it 
can trigger a metabolic rewiring that promotes the proliferation of malignant cells, either by 
increasing macromolecule synthesis (anabolism), energy production (catabolism) or 
antioxidant defense. However, mutations in metabolic enzymes not always are advantageous 
for the tumor but may lead to certain metabolic constraints and thus revealing new therapeutic 
strategies.  
The underlying meaning of cancer metabolism lies on the idea that in order to maintain their 
uncontrolled proliferation, cancer cells reprogram their metabolic activity, thus fueling cell 
growth and division. In fact, reprogramming cancer metabolism is nowadays considered one 
of the emerging hallmarks of cancer overall (Hanahan and Weinberg, 2011). Although the new 
advances in cancer metabolism have nowadays considerably widen this hallmark, its initial 
conception was entirely sustained by the seminal discovery of Otto Warburg, which occurred 
nearly a century ago, and gained him the Nobel Prize of Medicine in 1931. Warburg, who is 
generally credited to be the “father” of cancer metabolism, observed an anomalous 
characteristic of cancer cell energy production. Under aerobic conditions, normal differentiated 
tissue (i.e. non-proliferating cells) process glycolytic-derived pyruvate in the TCA cycle within 
the mitochondria for ATP production. In anaerobiosis, the absence of oxygen constrains 
respiration, forcing the cells to redirect glycolytic pyruvate into lactate synthesis, what favors 
more glycolytic activity. This anaerobic glycolysis is a bacterial mechanism yet conserved in 
eukaryotes that leads to ATP production, although minimal when compared to the highly 
evolved oxidative phosphorylation. Warburg observed that cancer cells tend to convert glucose 
to lactate regardless the cellular oxygen levels, a state that has been termed “aerobic 
glycolysis” (Warburg et al., 1927). In fact, it has been observed that normal proliferative cells, 
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proliferative cells, continue using some cellular respiration in a small extent, since their 
mitochondria remains functional. However, this aerobic glycolysis is still very inefficient when 























Figure 21. Modes of ATP production of differentiated and proliferative cells.  
Schematic representation of the differences among oxidative phosphorylation, anaerobic glycolysis and 
aerobic glycolysis (Warburg effect). Used from (Vander Heiden et al., 2009). 
 
 
Such glycolytic switch is seemingly unproductive, and cancer cells must compensate the lower 
ATP efficiency relative to mitochondrial oxidative phosphorylation. It has been shown that 
cancer cells indeed upregulate glucose transporters such as GLUT1, thus increasing the 
glucose uptake into the cytoplasm (DeBerardinis et al., 2008, Hsu and Sabatini, 2008). 
Moreover, such a short pathway as glycolysis might occur in a much faster way than the 
multistep process of cellular respiration, therefore by the time one molecule of glucose is 
completely metabolized to produce ATPs in the mitochondria, the same number of ATPs might 
have been produced by the overactive aerobic glycolysis. Yet, a robust explanation for the 
preference of aerobic glycolysis by proliferative cells has been elusive. The most established 
hypothesis, states that increased glycolysis allows the diversion of its intermediate metabolites 
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This effect may enhance the formation of the macromolecules required for active cell growth 
and proliferation (Potter, 1958, Vander Heiden et al., 2009). 
Boosted by the advances in biochemical and molecular biological tools, cancer metabolism 
has gained renewed interest in the past decades expanding our understanding of the 
mechanisms behind tumor-associated metabolic alterations. Thus, nowadays reprogramming 
metabolism is understood as a set of different key mechanisms that go beyond energy 
production. Inspired by the initial work of Hanahan and Weinberg (Hanahan and Weinberg, 
2011), a more recent publication exposed and organized known cancer-associated metabolic 
changes into six hallmarks of cancer metabolism: (1) deregulated uptake of glucose and amino 
acids, (2) use of opportunistic modes of nutrient acquisition, (3) use of glycolysis/TCA 
intermediates for biosynthesis and NADPH production, (4) increased demand for nitrogen, (5) 
alterations in metabolite-driven gene regulation, (6) metabolic interactions with the 
microenvironment (Pavlova and Thompson, 2016). Based on the cellular metabolism stage, 
these hallmarks can be sub-divided in three different groups. The first two hallmarks would 
correspond to (a) altered nutrient uptake. The next two hallmarks would be part of (b) 
reprogramming intracellular metabolism. The last two hallmarks would exert (c) changes in cell 




































Figure 22. The hallmarks of cancer metabolism.  
Six emerging hallmarks of cancer metabolism, subdivided in three layers of cell-metabolite interaction, 
all of which become reprogrammed in cancer. Used from (Pavlova and Thompson, 2016). 
 
 
Deregulated uptake of glucose and amino acids. It has been reported that tumors bear a high 
consumption rate not only of glucose but also of glutamine, compared to normal tissue (Som 
et al., 1980, Almuhaideb et al., 2011). Catabolism of these metabolites is key to maintain pools 
of diverse carbon and nitrogen intermediates, such as nucleotides and amino acids, but also 
to capture reducing power either for ATP production (NADH) or for redox maintenance 
(NADPH) (Pavlova and Thompson, 2016). It has been shown how these increased nutrient 
uptake is strictly regulated by growth factor signaling and interactions with extracellular matrix 
(Lindsten et al., 2003, Grassian et al., 2011). Moreover, the accumulation of different 
oncogenic alterations such as PI3k/Akt signaling or c-myc, can as well induce high nutrient 
uptake in the absence of those external requirements (Pavlova and Thompson, 2016).   
Use of opportunistic modes of nutrient acquisition. Due to the increased rates of consumption, 
cancer cell environment often experience situations of nutrient shortage. In this scenario, 
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acquisition. The mutation of RAS or c-Src have been shown to enhance the capacity of cells 
to recover amino acids via lysosomal degradation of extracellular proteins (Commisso et al., 
2013). In addition, free amino acids can be as well obtained by entosis: the engulfment and 
digestion of entire living cells; or by phagocytosis of apoptotic cellular corpses (Krajcovic et al., 
2013, Stolzing and Grune, 2004). Thus, mutations that lead to these alternative nutrient 
procurements, may not only be an advantage but a direct threat over neighbor cells, creating 
a competition that leads to more aggressive cell populations. 
Use of glycolysis/TCA intermediates for biosynthesis and NADPH production. Metabolic 
reprogramming not only leads to an increased nutrient uptake but also to a change in the way 
nutrients are used. This metabolite rewiring, will depend on the specific cellular demands. 
While quiescent tumor cells still conduct their glycolysis and TCA derivatives for oxidative 
phosphorylation, proliferating cells use these intermediaries for biosynthesis of a diverse array 
of compounds. Moreover, this reprogramming in central carbon metabolism also permits 
production of NADPH for most biosynthetic reactions and antioxidant defense (Vander Heiden 
et al., 2009). Glycolytic-derived glucose-6-phosphate can be redirected into the pentose PPP, 
one of the main sources of NADPH and ribose-5-phosphate, a structural component of 
nucleotides (Wang et al., 2011) (Figure 23). Other glycolytic intermediates such fructose-6-
phosphate or dihydroxyacetone phosphate (DHAP) are crucial precursors of hexosamines 
(which regulate the stability of certain oncogenic proteins such as c-myc) and phospholipids 
respectively (Itkonen et al., 2013, Pavlova and Thompson, 2016). Moreover, 3-
phosphoglycerate, plays a key role in biosynthesis of serine and glycine (Figure 23). Around 
50% of all cancer cell-serine is derived from glucose (Locasale et al., 2011). Subsequently, 
serine is the major substrate for one-carbon metabolism or folate cycle, where one-carbon-
tetrahydrofolate (THF) species are precursors for purines, thymidines and NADPH production 
(Fan et al., 2014). Moreover, the redirection of pyruvate from excess glycolytic flux, into lactate 
helps maintaining NAD+ levels to sustain glycolysis (Pavlova and Thompson, 2016). However, 
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also used by cancer cells to keep their high biosynthetic rate. The pyruvate that enters TCA 
cycle may be as well converted into citrate and subsequently secreted into the cytosol to be 
re-turned into acetyl-CoA for lipid biosynthesis (Bauer et al., 2005). TCA cycle also provides 





































Figure 23. Use of glycolysis/TCA cycle intermediates for biosynthesis and NADPH production. 
Diverse metabolite regulation of central carbon metabolism. RTK, receptor tyrosine kinase; GLUT1, 
glucose transporter 1; PKM2, pyruvate kinase M2; ACSS2, acetyl-CoA synthetase 2; LDH-A, lactate 
dehydrogenase A; PDH, pyruvate dehydrogenase; PDK1, pyruvate dehydrogenase kinase 1; ACLY, 
ATP-citrate lyase; MCT1, monocarboxylate transporter 1; ASCT2/SN2, glutamine transporter. Adapted 
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To maintain TCA cycle active independently of glucose, cancer cells use anaplerotic influx into 
the cycle. This anaplerotic influx can be derived from different sources such as glutamine and 
glutamate but also glucose-independent pyruvate or aspartate (DeBerardinis et al., 2007) 
(Figure 23).   
Increased demand for nitrogen. Besides carbon metabolism, increasing evidence points to the 
importance of nitrogen regulation in tumorigenesis. One of the main nitrogen sources in cancer 
cells is glutamine, which amine group is crucial for synthesis of nucleotides, as well as 
glutamate and other non-essential amino acids via transamination (Gaglio et al., 2009).  
Arginine, can also be important for a wide variety of nitrogen compounds such as creatine, 
proline and polyamines, which accumulation have been shown to inhibit apoptosis and 
promote tumor invasion (Casero and Marton, 2007). Elevated synthesis of proline have been 
observed in different tumors, and its accumulation is thought to facilitate collagen production 
and new extracellular matrix deposition, enabling tumor invasion (Phang et al., 2008).   
Alterations in metabolite-driven gene regulation. Certain metabolic network alterations not only 
influence direct nutrient regulation, but may as well drive genomic reprogramming by 
deposition and removal of epigenetic marks on chromatin. We already discussed in section 
2.2 how the production of D-2HG by IDHm leads to competitive inhibition of α-KG-dependent 
dioxygenases what leads to an increase in DNA and histone methylation. However, it has been 
found that succinate and fumarate accumulation may as well lead to dioxygenases inhibition 
and subsequent increase in methylation. Different cancer types show these effect due to 
succinate dehydrogenase (SDH) or fumarate hydratase (FH) mutation (Janeway et al., 2011, 
Tomlinson et al., 2002). Moreover, recent reports have shown that S-adenosylmethionine 
(SAM), a product of the one-carbon metabolism mediated by serine, acts as an important 
methyl group donor directly influencing the levels of histone and DNA methylation (Chiang et 
al., 2009). In addition, recent studies demonstrate that when cells metabolize more glucose 
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methylation, leads to an increased accessibility of genomic DNA for assembly of transcription 
factors (Cai et al., 2011).  
Metabolic interactions with the microenvironment. The metabolic state of a cell not only affects 
its own fate but may as well influence the microenvironment to assist tumor growth and 
invasion. In this sense, lactate secretion during aerobic glycolysis, may play a central role. It 
has been observed that increased extracellular lactate levels promote immunosuppression by 
attenuating the activity of dendritic cells, T cells, macrophages or monocytes (Fischer et al., 
2007, Goetze et al., 2011, Gottfried et al., 2006, Colegio et al., 2014). Besides, lactate 
secretion together with the hypoxic environment of certain tumor areas, may promote 
stabilization of HIF1α and activation of vascular endothelial growth factor (VEGF), facilitating 
the surge of angiogenesis (Constant et al., 2000). In addition, the extracellular acidification due 
to high lactate levels stimulates the proteolytic activity of matrix metalloproteinases (MMPs), 
leading to degradation of extracellular matrix and enhancing tumor invasion (Rothberg et al., 
2013). 
In conclusion, cancer metabolism may be composed of a wide variety of mechanisms, either 
intrinsic or extrinsic, that provide cells with the raw materials needed to sustain their invasive 
and uncontrolled growth. For this reason, the specific physiological context where each tumor 
originates will be fundamental for its progression. In the case of glioma, the brain acts as a 
semi-closed system with a particular metabolic landscape, essential to address the 
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4. Metabolic alterations of IDH mutant gliomas 
Isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) are the metabolic enzymes most 
frequently mutated in cancer, being commonly observed in gliomas, acute myeloid leukemia 
(AML) and chondrosarcoma. Other important metabolic enzymes, central in the fueling of the 
TCA cycle such as succinate dehydrogenase (SDH) or fumarate hydratase (FH), have also 
shown to be mutated in different cancers e.g. paraganglioma, renal carcinoma or T-cell 
leukemia among others (Sciacovelli and Frezza, 2016). The essential difference between 
these mutations, is that they represent loss-of-function mutations whereas in the case of IDH 
it constitutes a gain of function mutation. This leads to a neomorphic reaction that produces 
the oncometabolite D-2HG.  
Besides D-2HG production, various metabolic pathway alterations in IDHm tumors may be 
triggered by the stoichiometric imbalance of IDH reaction after the mutation. Hence, the impair 
of normal enzymatic conversion of isocitrate to α-KG and NADPH generation, may have 
profound impacts in cellular metabolism by altering metabolic flux of α-KG, depleting NADPH 
and impairing canonical biosynthetic pathways that require wild type IDH activity. In this section 
we will review some of the most important metabolic routes that are affected by IDH mutation. 
 
4.1. Glucose metabolism 
As we addressed previously, cancer cells predominantly upregulate their glycolytic flux, and 
these may be induced through a diverse number of signaling pathways. One of these pathways 
is PI3K/Akt cascade, which contributes to growth and aggressiveness in gliomas (Bleau et al., 
2009, Bai et al., 2016). This cascade is commonly downregulated in IDHm gliomas what 
suggests a potential vulnerability in glucose metabolism. Specifically, this pathway stimulates 
metabolic biosynthesis and glycolysis by favoring the expression of nutrients transporters, 
such as GLUT1, and boosting the activity of glycolytic enzymes such as Pfkfb3 (DeBerardinis 
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glioblastoma cells bearing the IDH1 mutation promote a decrease in Akt expression both from 
genetic and protein perspective, as well as decreased phosphorylation-derived activation 
(Bralten et al., 2011, Birner et al., 2014). Moreover, in vivo inhibition of PI3K pathway has 
shown to not only increase survival, but also lead to a reduced D-2HG production of IDHm 
tumor cells (Batsios et al., 2019). This suggests that IDH mutation interacts with PI3K/Akt 
pathway and may attenuate the glycolytic impact in the cell. Indeed, some of the top 
downregulated genes in IDH mutant tumors are proteins directly linked with PI3k/Akt activation 
(e.g. PDPN1 and RBP1) (Noushmehr et al., 2010). However, it has been found that IDH1m 
oligodendroglioma tumors, exhibit high PI3K/Akt activation (Parker and Metallo, 2015). Thus, 
the exact mechanism by which IDH mutation affects Akt activity in either oligodendrogliomas 
or astrocytomas remains unclear, especially taking into account that normal astrocytes are 
indeed highly glycolytic and overexpress Pfkfb3 (Belanger et al., 2011). It has been shown, 
however, that D-2HG may activate mTOR, a downstream factor of Akt, independently of this 
pathway (Carbonneau et al., 2016). Therefore, this would be a compensatory mechanism by 
which IDH mutant cells undergo glycolysis despite low PI3k/Akt activation (Cheng et al., 2014). 
Yet, it has been proven that IDHm tumors display an overall low glucose turnover into TCA 
cycle intermediaries and an overall low ATP production (Fack et al., 2017). 
Another common feature of glycolytic cancer cells is the upregulation of lactate dehydrogenase 
A (LDHA), which is indeed a critical enzyme for GBM aggressiveness (Daniele et al., 2015). 
This enzyme is in charge of the final step of glycolytic metabolism leading to the transformation 
of pyruvate into lactate, and maintaining glycolysis via NAD+ regeneration (Metallo and Vander 
Heiden, 2013). This is also a common pathway used by normal astrocytes (Belanger et al., 
2011), however, in line with the low PI3k/Akt activity, IDH1m gliomas show decreased levels 
of LDHA when compared to IDH wild type (Parker and Metallo, 2015). Indeed, it has been 
observed that both IDH1m glioma and brain tumor-derived stem cells silence LDHA expression 
through promoter hypermethylation (Chesnelong et al., 2014). In addition, IDHm AML patients 
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suggesting a common phenotype between IDH mutant tumors (Chou et al., 2011). LDHA 
expression is commonly regulated by HIF1-α (Keith et al., 2011), however, its role in IDHm 
tumors is not clear due to the contradictory findings with regard to D-2HG-dependent HIF1- α 
stabilization (Zhao et al., 2009) or degradation (Koivunen et al., 2012). Studies that support 
the hypothesis of a HIF1-α degradation in IDHm gliomas, have found upregulated gene 
expression of factor inhibiting HIF1 (FIH-1) in these tumors (Mustafa et al., 2014). Moreover, 
it has been observed that LDHB, is increased in glioma cells with IDH mutation when compared 
with IDHwt gliomas or normal brain tissue (Mustafa et al., 2014). LDHB is a HIF1-α-
independent enzyme that, although capable to convert pyruvate to lactate, it has shown to be 
more sensitive to substrate inhibition, been able to perform the reverse reaction and convert 
lactate to pyruvate (Dang, 2013) (Figure 24). Taking into account the metabolic scenario of 
the brain, it is possible that glioma cells uptake the lactate secreted by astrocytes, converting 
it into pyruvate via LDHB. 
The canonical entry into the TCA cycle requires the conversion of glucose-derived pyruvate 
into acetyl-CoA via pyruvate dehydrogenase (PDH) (Pavlova and Thompson, 2016). 
Interestingly, the activity of this enzyme is mediated as well by HIF1-α, which stimulates the 
expression of PDK1 that displays the inactivating phosphorylation of PDH (Kim et al., 2006). 
The altered activity of HIF1- α in IDHm tumors, may be therefore directly related with changes 
in flux of pyruvate-derived acetyl-CoA into the mitochondria (Parker and Metallo, 2015). Thus, 
in the scenario where IDH mutant gliomas express high HIF1- α (Xu et al., 2011b), PDH activity 
would be expected to be attenuated. Different anaplerotic entries into the TCA cycle may be 
also active in these tumors, such as oxaloacetate income via pyruvate carboxylase (PC) or α-
KG entry via glutaminolysis (Cheng et al., 2011). Whereas IDHwt GBM activate both PDH and 
PC (Marin-Valencia et al., 2012), it has been shown that overexpression of IDH mutant enzyme 
in normal astrocytes leads to and increased flux through PC as well as its increased gene 
expression (Izquierdo-Garcia et al., 2014). This implies that PC activity is important for IDH 
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As we will forthcoming address, the other alternative entry into the TCA cycle via gluaminolysis-
derived α-KG, plays a critical role in the overall IDH mutant regulatory metabolism.  
 
4.2. Glutaminolysis, reductive carboxylation and acetyl-
CoA 
Glutamine is an important contributor to TCA metabolism in cancer, entering as α-KG after 
previous conversion into glutamate, a process commonly denominated glutaminolysis (Maus 
and Peters, 2017). Moreover, glutamate is also important to direct biosynthesis of different 
molecules such as nucleotides, hexosamines or asparagine (Gaglio et al., 2011). During 
glutaminolysis two enzymes play crucial roles; glutaminase (GLS) performs the conversion of 
glutamine to glutamate, and glutamate dehydrogenase (GDH or GLUD) converts glutamate to 
α-KG (Figure 24). During the hypoxic conditions at the core of most solid tumors, the normal 
glucose oxidation for TCA metabolism gets restricted, and glutaminolysis serves then as a 
compensatory mechanism against this effect (Fan et al., 2013). Furthermore, as we have 
previously discussed, the canonical entry into TCA cycle through PDH activity may be altered 
in IDHm gliomas, what makes glutaminolysis flux especially necessary. In addition, the 
presence of IDH mutation restricts the α-KG availability for either mitochondrial TCA cycle or 
cytosolic usage (i.e. dioxygenases activation or glutamate and lipid biosynthesis) (Maus and 
Peters, 2017). Whether the mutation occurs in IDH1 (cytosolic) or IDH2 (mitochondrial) will tilt 
the balance to either pathway. Yet, IDH mutation rarely occurs in both isoforms at the same 
time, and the wild type isoenzyme can attempt to compensate the imbalance generated by the 
mutant one. 
Different studies highlight the importance of glutaminolysis in IDHm tumors. Indeed, high 
extent of the D-2HG produced by IDH1 mutant cells is derived from glutamine, suggesting that 
glutaminolysis may as well serve as source of α-KG, besides the IDHwt monomer of the 
IDHm/wt heterodimer (Grassian et al., 2014). In fact, IDHm glioma cells may possibly uptake 
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glutamine cycle, in order to satisfy their high glutaminolysis rate. IDHm-transfected GBM cells 
and astrocytes have showed to be especially sensitive to GLS inhibition (Seltzer et al., 2010).  
Moreover, it has been observed that IDH1m gliomas overexpress both GDH1 and GDH2, and 
GDH1/2 knockdowns of IDH1m glioma in vivo models, showed decreased tumor growth (Chen 
et al., 2014). In addition, IDHm-transfected GBM cells and astrocytes showed to be especially 
sensitive to GLS inhibition (Seltzer et al., 2010). 
During normoxic conditions, healthy cells favor the IDH oxidative decarboxylation of isocitrate 
to α-KG. However, under conditions of hypoxia or mitochondrial dysfunction, IDH catalyzes the 
reductive carboxylation of α-KG to isocitrate. This reverse reaction, which entails NADPH 
consumption, will further favor synthesis of citrate and acetyl-CoA, a basic source of fatty acids, 
phospholipids, cholesterol or amino acids (Metallo et al., 2011, Kaelin and McKnight, 2013) 
(Figure 24). Whereas the reverse IDH2 reaction may serve as a switch in the directionality of 
TCA cycle, in IDH1 this reverse reaction has a key biosynthetic role. Therefore, the 
biosynthesis requirements during hypoxia may be fulfilled by cytosolic IDH1 reverse activity. 
This is at the same time associated with a higher flux of glutaminolysis towards α-KG, 
facilitating these biosynthetic reactions (Metallo et al., 2011). As we described in section 2.2, 
IDHm cells express a heterodimeric enzyme formed by the complex of an IDHm monomer with 
an IDHwt one. It has been shown that the reductive carboxylation reaction is inactive upon 
these IDH1 or 2 mutant/wild type heterodimers (Leonardi et al., 2012). Thus, only IDH wildtype 
cells expressing the normal IDH homodimer are able to perform both forward and reverse 
reactions. The inefficiency of IDHm cells to produce isocitrate may rely in the preference of 
IDHm monomer for α-KG consumption and D-2HG synthesis. This aberrant hoarding of IDHm 
enzyme for α-KG, would explain as well the high levels of glutamine-derived D-2HG, and 
subsequent low glutaminolysis-derived citrate and acetyl-CoA synthesis during hypoxic 
conditions (Grassian et al., 2014). Indeed it has been shown that not only IDHwt but also 
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IDH1m cells, suggesting the importance of cytosolic IDH for this pathway (Parker and Metallo, 
2015) (Figure 24).  
Due to their defective glycolytic machinery (e.g. low PI3K/Akt signaling), IDHm cells are 
thought to be rather oxidative. In fact, it has been observed that during hypoxic conditions, 
these cells increased their cellular respiration but decrease cell growth (Grassian et al., 2014). 
This suggests that, due to their inactive reductive carboxylation, IDHm cells focus in the use 
of their scarce acetyl-CoA to gain ATP by oxidative phosphorylation to detriment of their 
biosynthetic metabolism, what decelerates cell growth. The dependence of these cells on 
oxidative phosphorylation is seconded by their observed sensitivity to ETC/respiration 
inhibitors and changes in oxygen consumption rates under hypoxia (Grassian et al., 2014). 
Moreover, it has been shown that D-2HG can additionally inhibit complex IV of the ETC, 
increasing their energetic limitations (Chan et al., 2015).  
Acetyl-CoA is an essential metabolite which production directly affects the synthesis of lipids 
but also of acetylated amino acids (Kaelin and McKnight, 2013). It has been reported that 
certain N-acetylated amino acids including N-acetyl-aspartyl-glutamate (NAAG) and N-acetyl-
aspartate (NAA) are decreased in IDH1m glioma cells (Reitman et al., 2011). These may be 
directly linked with the restricted flux fueling acetyl-CoA pools, due to defects in reductive 
carboxylation or PDH activity. IDH1m tumors show as well dysregulated phospholipid profile 
when compared to IDHwt tumors (Fack et al., 2017), especially pools of phospholipid 
metabolites such as phosphoethanolamine and glycerophosphocholine (Esmaeili et al., 2014). 
Interestingly, the dysregulated lipid metabolism in IDHm gliomas may be as well altered by 
PI3k/Akt oncogenic signaling pathway. For instance, ATP-citrate lyase (ACL or ACLY), the 
enzyme in charge of synthesis of acetyl-CoA from citrate, is a major Akt substrate (Berwick et 
al., 2002). In addition, Akt also induces the activation of other lipid and fatty acid synthesis 
enzymes (e.g. FAS, ACC) via mTOR and SREBP-1 (Porstmann et al., 2008). Apart from de 
novo synthesis, lipids can be as well scavenged from the extracellular fluid. LDL receptor, 
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et al., 2011). In fact, IDH1 is a transcriptional target of SREBP-1, which further supports a 
dysregulated lipogenic environment in IDHm gliomas. Interestingly, it has been observed that 
the excess of ketone bodies, such as the one promoted by astrocyte release, may be used by 
glioma cells as an alternative acetyl-CoA source via upregulation of monocarboxylate 
transporters (MCTs) (De Feyter et al., 2016). However this may contradict the idea that a 

































Figure 24. Biochemical pathways involved in IDHm intermediary metabolism.  
The activity of lactate dehydrogenase B (LDHB) may facilitate the input of pyruvate into the 
mitochondrion. PC-mediated Pyruvate fueling into the TCA cycle in form of oxaloacetate may be the 
leading way of entry. Glutamine-derived α-KG may as well serve as anaplerotic TCA cycle fueling. In 
addition, DH mutation hampers the isocitrate availability as fatty acid precursor.  AcCoA: acetyl-
coenzyme A, ACL: ATP-citrate lyase, Aco1/2: aconitase 1/2, Cit: citrate, Fum: fumarate, ICT: isocitrate, 
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4.3. Antioxidant defense 
The main similarity between IDH1 and IDH2 is the NADP(H) dependency, unlike IDH3 which 
is NAD(H) dependent. Both NAD and NADP are essential electron donors (at their reduced 
state; NADPH, NADH) or acceptors (at their oxidized state; NADP+, NAD+) in biochemical 
reduction or oxidation reactions respectively (section 3.1.3). Generally, NAD(H) cofactor is 
preferentially used during catabolic energy-producing reactions (e.g. TCA cycle-derived ATP 
production), whereas NADP(H) is more common in biosynthetic reactions (e.g. lipids 
synthesis) and redox homeostasis (e.g. antioxidants recycling) (Al-Khallaf, 2017). Indeed, the 
ratio NADP+/NADPH has a critical impact in cellular physiology (Pollak et al., 2007). In cancer, 
NADPH pool is rapidly replenished. In 20 minutes can be completely regenerated, a much 
higher pace than in normal tissue (Fan et al., 2014). Although initially it was thought that the 
PPP was the main source of NADPH, recent evidence suggests that several other enzymes 
are also important contributors. IDH is among them, as well as malic enzymes (ME), aldehyde 
dehydrogenases (ALDH) or methylene tretrahydrofolate dehydrogenases (MTHFD) (Pollak et 
al., 2007, Fan et al., 2014, Lunt and Vander Heiden, 2011). In fact, the preference for each 
enzyme is tissue-dependent. Interestingly, IDH has been shown to be the main contributor of 
NADPH in human brain, however this mechanism is not reproduced in rodents, suggesting the 
exclusive complexity of human brain metabolism (Atai et al., 2011). Moreover, NADP(H) 
cannot be directly transported across organelle membranes, therefore the maintenance of this 
cofactor is independently regulated in each subcellular compartment (Parker and Metallo, 
2015). This suggests that whereas IDHwt isoform can replenish metabolite imbalances 
generated by the IDHm one (e.g. α-KG transport), this is not the case with regard to NADPH 
compensation.  
As expected, the presence of the IDHm heterodimer, not only hoards most of the α-KG 
available, but also the NADPH, required for D-2HG generation. Therefore, IDH mutation de-
activates the NADPH-producing capacity of these enzymes, and IDHm cells may require to 
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al., 2020). The direct consequence of this type of imbalance is, on one hand, an alteration of 
NADPH-dependent biosynthetic reactions, but most importantly a dysregulated redox 
homeostasis. This redox homeostasis is reached in normal cells when the ROS are properly 
neutralized. The uncontrolled proliferation and growth of cancer cells make them highly 
susceptible to oxidative stress. In fact, the therapeutic effect of certain strategies, such as 
radiation, is based on inflicting oxidative damage in the tumor (Perillo et al., 2020). For this 
reason, due to the relevance of IDH in the production of NADPH and maintenance of 
antioxidant defense, various groups are studying the potential redox vulnerabilities of IDHm 
tumors. Moreover, the highly oxidative metabolism of the brain make gliomas especially 
interesting targets for redox-based therapeutic strategies (Han et al., 2020). As a matter of 
fact, IDHm gliomas have been proved to be highly sensitive to oxidative stress-inducing 
radiotherapy or chemotherapy (Juratli et al., 2015, Mohrenz et al., 2013, Li et al., 2013).  
GSH synthesis. As explained in section 3.1.3, GSH is the most important antioxidant in animal 
cells, due to its abundance and its potent mechanism of action. Increasing efforts are been 
directed to determine the precise impact of IDH mutation in NADPH, GSH and ROS production, 
however, the lack of appropriate models carrying the endogenous IDH mutation and the 
reactive nature of redox compounds, makes it an elusive challenge. Different studies carried 
out with in vitro (Shi et al., 2014) and in vivo (Sasaki et al., 2012) models as well as patient 
cohorts (Bleeker et al., 2010), show how IDH mutant tumors display lower NADPH levels, as 
well as lower GSH and/or higher ROS generation. However, some studies show that, although 
IDH1m gliomas exhibited increased NADP+/NADPH ratio, decreased GSH and decreased 
ascorbic acid in the brain, intracellular ROS were significantly lower when compared to IDH1wt 
(Sasaki et al., 2012). More recent studies continue exposing unexpected data. Whereas some 
appreciate no differences in NADPH in IDHm gliomas despite a decrease in GSH, (McBrayer 
et al., 2018), others observe the inverse effect (Fack et al., 2017). Several factors may be 
driving these contradictory results. Due the complexity of redox metabolism, it is possible that 
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Recently, novel perspectives are studying alternative routes by which IDHm gliomas maintain 
their GSH storage, overcoming their potential imbalance of reducing power. Indeed, before 
been able to recycle their antioxidant pool, cells need to acquire GSH in order to store it for the 
first time. As we explained in section 3.2, in the particular metabolic landscape of the brain, 
astrocytes are the main suppliers of GSH precursors (cysteine, glutamate and glycine) 
(Belanger et al., 2011). Therefore, in order to create a sufficient GSH pool, glioma cells may 
uptake GSH precursors released by astrocytes in the extracellular fluid in order to synthesize 
their own GSH de novo in a NADPH-independent manner. This would explain how, despite 
bearing IDH mutation, these tumors could keep their GSH storage full. Interestingly, astrocytic 
gliomas may even have the intrinsic machinery to produce their own GSH precursors. In the 
process of GSH (γ-L-glutamyl-L-cysteineglycine) synthesis, a cysteine and a glutamate 
molecules are first combined via glutamate-cysteine ligase (GCL) to form γ-glutamylcysteine. 
Subsequently, glycine and γ-glutamylcysteine are condensed by glutathione synthetase (GSS) 
to produce GSH (Forman et al., 2009) (Figure 25). Therefore, the amount of GSH that will be 
able to be newly synthesized will depend on the availability of the cysteine, glutamate and 
glycine. Some recent studies in IDHm gliomas, propose to stop GSH biosynthesis by blocking 
the source of its precursor amino acids. In one study carried out with in vitro and in vivo models 
transfected with or without IDH1m overexpressing vectors, it was observed that D-2HG directly 
inhibits the activity of branch chain amino acid transaminase 1 and 2 (BCAT1/2). These 
enzymes are in charge of the production of glutamate via branch chain amino acids (BCAA, 
i.e. valine, leucine and isoleucine). This study defended that IDHm gliomas are restricted to 
use glutamine as their only source of glutamate and subsequently of GSH. Thus, they 
observed that inhibition of GLS with CB-839 sensitized IDHm glioma cells to oxidative stress, 
due to GSH depletion. Moreover, the specificity of the approach was lost when used the GCL 
inhibitor buthionine-sulfoximine (BSO), which was highly toxic for both IDHm and IDHwt cells 
(McBrayer et al., 2018). A more recent study observed that IDHm glioma cells were vulnerable 
as well to the block of NRF2 signaling pathway, in charge of transcriptional regulation of GSH 
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Cysteine availability. Yet, among the three amino acids required for synthesis of GSH, the least 
abundant of them is cysteine, which represents the limiting factor for the production of the 
antioxidant (Griffith, 1999). Indeed, cysteine contains the thiol group that will confer GSH its 
particularly high reactivity against ROS. Cysteine, as a free amino acid in the extracellular fluid, 
is very unstable and tend to oxidize into its dimeric form cystine, by forming disulfide bonds 
from the thiol groups of every two molecules (Forman et al., 2009). The supply of cysteine is 
very restricted in the brain, where it is ~ 100 times less concentrated than in blood 
(Engelborghs et al., 2003). Cells may uptake it from extracellular sources in form of cystine 
through the cystine/glutamate antiporter (xCT) or synthesize it de novo via transsulfuration 
pathway (Paul et al., 2018). The use of xCT to acquire cysteine may be counterproductive 
when aiming to generate GSH, since by using this antiporter glutamate will be released out of 
the cell. Moreover, in order to reduce cystine into cysteine, additional reducing power would 
be required. Thus, in an oxidative stress scenario where extra cysteine is required for GSH 
production, astrocytic transsulfuration pathway (TP) is thought to be highly active in the brain 
(McBean, 2012, McBean, 2017). The TP consists of a number of different reactions where the 
thiol group from methionine will be transferred into various intermediate metabolites (such as 
homocysteine or cystathionine) to finally result in cysteine formation (Sbodio et al., 2019). 
Serine will as well play here a key role. On one hand because will be required in the TP for the 
synthesis of cystathionine, and on the other hand because it can be interconverted into glycine 
by the action of serine hydroxymethyltransferase (SHMT) (Locasale, 2013). As 
aforementioned, besides glutamate and cysteine, glycine is the other precursor amino acid for 
GSH synthesis. In addition, cysteine can also be catabolize to produce taurine, which may 
have an important role in the CNS as neurotransmitter, as a trophic factor during development 
(Wu and Prentice, 2010) (Figure 25). A recent publication suggests that TP may be an 
essential source of cysteine from GSH in IDHm gliomas (Fack et al., 2017). In this study, 
performed in patient derived xenografts, cystathionine, the substrate for cysteine synthesis, 
showed to be decreased in IDHm gliomas when compared to IDHwt, suggesting higher 
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genetically upregulated in IDHm glioma patients according to The Cancer Genome Atlas 
(TCGA) database (Fack et al., 2017). These findings open the door to a new therapeutic 
perspective for IDHm gliomas, in which cysteine production could be blocked by targeting 






























Figure 25. Cysteine metabolism and de novo GSH synthesis.  
Cysteine can be synthesized via transsulfuration pathway, in which methionine and serine are key 
substrate metabolites. In addition, cysteine may be uptaken via xCT antiporter, which incorporates 
oxidized cysteine (cystine) in the cell and releases glutamate to the extracellular fluid. Cysteine (blue) 
may be used as substrate for taurine, or for GSH de novo synthesis, being the limiting factor in the 
assembling with glutamate (green) and glycine (red) for GSH formation. CBS: cystathionine β-synthase, 
CDO1: cysteine dioxygenase 1, CSA: cysteine sulfinate, CSE: cystathionine γ-lyase, GCL: glutamate-
cysteine ligase, GSS: glutathione synthetase, SAH: S-adenosyl homocysteine, SAM: S-adenosyl 
methionine, xCT: cystine/glutamate antiporter. Adapted from (Fack et al., 2017). 
 
 
Overall, the field of redox metabolism encompasses a broad spectrum of chemical reactions 
which is nowadays yet under elucidation. Despite the recent advances in the area, there is still 
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wide amount of evidence point to oxidative damage as a key approach that could be 
therapeutically harnessed for the improvement of patient prognosis of such a deadly and 
elusive disease. Before addressing the specific strategic perspectives in line with these ideas 
of the present PhD, we will review the different therapeutic approaches against IDHm gliomas 
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5. Therapeutic strategies targeting IDH mutant gliomas  
The high prevalence of IDH mutations in gliomas and other tumors has led to intensive 
research efforts to identify small-molecule inhibitors of IDHm or related downstream targets. 
Moreover, the advances in the field of immunotherapy has disclosed new medical 
opportunities. Ongoing pre-clinical and early clinical studies of potential therapies in the context 
of IDHm gliomas, highlight a promising development for anti-cancer therapy. Prior to any other 
chemical approach, surgical resection represents the therapeutic strategy that currently bears 
a more favorable outcome for IDHm glioma patients, especially in astrocytomas (Beiko et al., 
2014, Kawaguchi et al., 2016). The development of non-invasive imaging techniques to detect 
D-2HG as a method to discriminate between IDHm and IDHwt tumors, may have significant 
clinical implications (Andronesi et al., 2013, Emir et al., 2016). In addition, radiotherapy also 
represents an important therapeutic tool,  likely enhanced by the potential sensitivity of IDHm 
tumors against the oxidative damage generated by this type of treatment (Juratli et al., 2015, 
Li et al., 2013).  
IDHm inhibitors. Due to the wide variety of malignant aberrations linked to IDH mutation and 
its neomorphic activity, the direct targeting of this mutant enzyme has been laboriously studied 
(Figure 26). Some promising results were achieved by the use of the pan-inhibitor 
BAY1436032. This inhibitor has shown to efficiently inhibit both IDH1 and IDH2 mutant 
isoenzymes and lower considerably the D-2HG production in both an in vitro and in vivo set 
up (Pusch et al., 2017). The inhibition lead to a certain increase in xenograft mice survival after 
a bi-daily dose of 75mg/kg of the drug, although this has so far not been reproduced in other 
models (Pusch et al., 2017). Other tested IDHm inhibitors also did not show very satisfactory 
results. A study carried out with MRK-A IDH1R132H/WT inhibitor showed no alteration in tumor 
growth or survival of patient derived-GB10 glioma xenografts. However, the same MRK-A dose 
prolonged survival in BT142 xenografts (Kopinja et al., 2017). It is noteworthy to mention that 
BT142 xenografts are derived from an IDHm heterozygous cell line that has already been 
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homozygous (Luchman et al., 2013). This might be an effect to consider when analyzing the 
outcome generated by MRK-A inhibitor. Regarding IDHm inhibitors, Agios pharmaceuticals© 
was the first company to commercialize active compounds. The IDH1R132H/WT inhibitor, AGI-
5198 has been extensively studied, although showing contradictory results by inducing 
increased viability in several IDH1m glioma patient-derived cell lines (Tateishi et al., 2015). 
Moreover, AGI-5198 did not show improvements in survival of SCID mice bearing patient-
derived intracranial IDH1m GBM xenografts. In fact, it was reported that incubation of glioma 
cell lines with AGI-5198 prior intracranial implantation into mice, shortened the latency period 
of the tumor and decreased median survival (Tateishi et al., 2015). This suggests that this 
IDH1m inhibitor may cause the xenograft to be even more aggressive. Due to the role of IDH1 
mutation in sensitizing cells to oxidative stress due to the NADPH imbalance, it is possible that 
in cases where there is an increased oxidative activity, these inhibitors may have a 
counterproductive effect (Molenaar et al., 2015). Some studies attempt to augment the 
oxidative dependency of these tumors. It has been observed that IDH1m gliomas display a 
downregulation of nicotinate phosphoribosyltransferase 1 (NAPRT1) in charge of NAD+ 
generation. Treatment of IDH1m cells with inhibitors of the alternative NAD+ producer, 
nicotinamide phosphoribosyltransferase (NAMPT) decreased viability of these cells (Tateishi 
et al., 2015) (Figure 26). IDH1m gliomas may be sensitive to NAD+ blockade due to their 
dependence for this molecule as substrate for oxidative energy production.   
GLS and GDH inhibitors. Other strategies focus in targeting IDH1m-derived metabolic 
liabilities. One of the most commonly investigated is the effect of GLS inhibition (Figure 26). 
Studies carried out with bis-2-(5-phenylacetomido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES), 
showed how GLS inhibition blocks cell growth in both IDHm GBM and AML cells (Emadi et al., 
2014, Seltzer et al., 2010). In fact, the GLS inhibitor CB-839, is being currently assessed in 
clinical trials for several clinical indications including IDHm myeloid malignances. As explained 
in section 4.3, the therapeutic effect of GLS inhibition may lie in its potential to block GSH 
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another perspective, increasing research is investigating the potential of GDH2 inhibition in 
IDHm tumors, which is expected to cut their TCA cycle fueling (Figure 26). As it has been 
demonstrated, GDH2 is crucial in IDHm gliomas as anaplerotic input into the TCA cycle (Chen 
et al., 2014). It has been recently reported that the role of GDH2 is hominid-specific due to a 
late evolved amino acid substitution in the allosteric domain (Waitkus et al., 2018b).  
Inhibitors of epigenetic modulators. Other therapeutic strategies focus in targeting tertiary 
oncogenic alterations linked to IDH mutation. For instance, proliferation of IDHm cell lines 
harboring MYCN amplification can be blocked by treatment with BET inhibitor JQ1, which 
suppresses n-Myc overexpression (Puissant et al., 2013) (Figure 26). In addition, it has been 
observed that inhibition the BCL-2 apoptotic regulator promotes a lethal phenotype in IDH1m 
glioma cells (Karpel-Massler et al., 2017) (Figure 26). The concept of inhibiting D-2HG-derived 
methylation has as well been experimentally exploited. DNA methyltransferase 1 (DNMT1) 
inhibitor showed to suppress IDH1m cell proliferation both in vitro and in vivo (Turcan et al., 
2013). Similarly, azacytidine, a molecule that compromises the activity of DNA 
methyltransferases, was shown to reduce growth of IDHm glioma xenografts (Borodovsky et 
al., 2013) (Figure 26).  
Immunotherapy. Promising evidence suggests that IDH mutation and D-2HG may play critical 
roles in shaping the immunological scenario of the tumor, revealing the potential of 
immunotherapy in these types of cancer (Amankulor et al., 2017). It has been reported that 
IDHm gliomas has decreased tumor-infiltrating lymphocytes and low programmed death-ligand 
1 (PDL1) expression (Berghoff et al., 2017). Moreover, these tumors suppress expression of 
the ligands ULBP1 and ULBP3 which may trigger a mechanism for evading NK cell 
surveillance (Zhang et al., 2016). Additional studies with in vitro, in vivo and patient material, 
show that D-2HG attenuates T cell accumulation by downregulating T lymphocyte-associated 
genes and cytokines (Kohanbash et al., 2017, Bunse et al., 2018). This strongly suggests that 
D-2HG contributes to immune suppression, raising the possibility of sensitizing IDHm gliomas 
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inhibition enhanced the activity of peptide vaccines, specific for glioma, in mice intracranial 
xenografts. Moreover, since the IDHm is specific to cancer cells, it represents a tumor-specific 
neoantigen that may be exploited for vaccine or other targeted approaches. In this regard, the 
neo-epitope generated by IDH mutant enzyme is currently used in clinical trials with peptide- 
and RNA-based vaccines (Schumacher et al., 2014, Platten et al., 2018, Weller et al., 2017). 
A study carried out with transgenic IDH1m MHC-devoid mice, showed that peptide vaccination 
elicited specific anti-tumor responses, correlating with an increased survival, and apparent 
curative responses in 25% of treated mice (Pellegatta et al., 2015). Overall, these data suggest 
that IDH mutation may alter the production of immunogenic cytokines and receptors facilitating 
immunosuppression. Although, the specific mechanism by which IDHm and/or D-2HG mediate 
this response is still under investigation, this supposes a promising strategy in the future of 
IDHm glioma therapies.   
 
In summary, besides the arduous and extensive efforts dedicated to stop the aggressive and 
highly elusive IDHm gliomas, there is still lack of a clear and effective treatment that can 
considerably improve patient prognosis. The present PhD dissertation is a comprehensive 
study of IDHm glioma malignant behavior with the aim to identify and target its aberrant 
metabolic escape mechanisms. In this chapter we have widely exposed the theoretical 
background encompassing IDHm glioma research, especially within the field of metabolism. 
This has served us as the groundwork to present the specific strategy and findings of this PhD 
project investigations, in which we wish to contribute in the understanding and fighting against 


































Figure 26. Therapeutic strategies against IDHm gliomas.  
Inhibitors of IDHm 1 and 2 as well as IDHm derived altered enzymes and pathways, are currently under 
per-clinical and early clinical investigation, aiming to block the tumorigenic and invasive potential of 
these tumors, and improve the clinical outcome of IDHm glioma patients. In addition, increasing 
evidence suggests immunotherapy as a promising novel therapeutic approach. * Pan-inhibitors of both 
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Diffuse gliomas are still one of the most deadly cancer types. Although displaying a disparate 
average life expectancy among tumor sub-types, ranging from 1 year for GBM to about 7 years 
for lower grade gliomas, no curative treatments are currently available (Ostrom et al., 2019). 
With the advance in molecular diagnosis, it has been found that the presence of a point 
mutation in isocitrate dehydrogenase (IDH) gene, delineates the classification of glioma 
tumors. IDH mutation is present in most of low grade gliomas (LGG) and secondary 
glioblastomas (GBM), tumors arising in younger patient population (<50 years) (Ostrom et al., 
2019). IDH mutant (IDHm) malignancies are also found in other cancer types such as acute 
myeloid leukemia (AML), chondrosarcomas or cholangiocarcinomas (Han et al., 2020).  
Increasing research focus is directed to understand the impact of this mutation in cancer 
malignancy. IDHm tumors display a gain-of-function mutation that leads to the synthesis of the 
oncometabolite D-2HG. The epigenetic reprogramming derived from this neomorphic activity 
has being extensively studied, e.g. the role in histone and DNA methylation or HIF1-α 
regulation (Turcan et al., 2012, Zhao et al., 2009). Yet, IDH being an important metabolic 
enzyme, the consequences of this mutation in cellular metabolism are yet to be fully elucidated. 
Increasing evidence suggests that IDHm tumors may have a relevant impact on glutamine 
metabolism and lipid synthesis (Metallo et al., 2011). In addition, it has been suggested that 
IDH mutation might be detrimental for GSH synthesis and cellular redox homeostasis, due to 
the limited NADPH production, characteristic of the wild type reaction (Shi et al., 2015).  
One of the biggest impediments that has hampered the collection of metabolic data is the 
availability of adequate IDHm glioma models. The slow-growing nature of IDHm cells hinders 
both in vitro and in vivo handling. To overcome this difficulty, many research groups have 
focused on the use of highly proliferative IDHm transgenic GBM cells and xenografts, an easier 
experimental set-up that eludes the tedious work with original LGG IDHm models. This 
approach obviates the tumor-specific genetic background that may be crucially influencing the 
metabolic organization of the cells. Thus, in our group we chose to use patient-derived cell 
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lag. In a recent publication from our group, in-house patient-derived orthotopic xenografts of 
both DHm and IDHwt gliomas were used to investigate the metabolic disparities between these 
tumor-types (Fack et al., 2017). Via different metabolomic techniques, such as liquid 
chromatography mass spectrometry (LC-MS) or matrix-assisted laser desorption/ionization 
(MALDI) imaging, it was observed that IDHm glioma tumors displayed a dysregulated 
phospholipid regulation as well as a slower energetic rate. In addition, both in vivo metabolite 
detection and clinical gene expression analysis from public datasets, suggested that IDHm 
gliomas upregulate cysteine synthesis through transsulfuration pathway (TP) in order to 
generate GSH independently of NADPH. In fact, TP has been shown to be readily active in 
normal astrocytes, leading to increased GSH production (McBean, 2012). Further investigation 
yet awaits to confirm this mechanism in gliomas. 
Today there is still lack of a clear and effective treatment against diffuse gliomas. The high 
sensitivity of IDHm tumors to oxidative stress-inducing radiation suggests they display a 
deficient antioxidant defense. Based on what has been proposed by our group (Fack et al., 
2017), the hypothesis of this PhD project proposed that IDHm gliomas rely on de novo 
synthesis of cysteine via TP in order to produce GSH, regardless of their defective NADPH 
production. Therefore, this would uncover an IDHm-specific vulnerability in which blocking TP 
would leave these tumors openly exposed against oxidative insults. In order to explore our 
hypothesis, in this project we dispose of patient-derived glioma cell lines with and without the 
endogenous IDH mutation, orthotopic xenografts derived thereof and patient material clinically 
provided after surgical resection.  Making use of these models we aimed to: 
̶ Characterize the general metabolic behavior of IDHm gliomas, through an integrative 
and LC-MS-based metabolomics and proteomics analyses, including cell, animal and 
patient material, as well as consulting public genomic datasets. 
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̶ Address whether glutathione synthesis relies on an increased transsulfuration pathway 
in IDHm gliomas through metabolomic flux analysis. 
̶ Analyze the effect of genetic and chemical blockade of TP and/or GSH de novo 
synthesis, on cell viability, ROS and metabolite regulation, in glioma cells and xenograft 
tumors. 
Based on our study, our prospective goal is to design a novel therapeutic strategy, to our 
knowledge not yet exploited, that could improve the clinical outcome of IDHm glioma patients 
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1. Clinical samples 
 
Clinical samples for LC-MS analysis were obtained from 22 patients (10 IDHwt glioblastomas; 
8 IDH1m astrocytomas; 4 IDH1m oligodendrogliomas) from the Haukeland Hospital, Bergen, 
Norway. Tissue fragments were stereotactically sampled (25mg) during the operation and 
snap-frozen. Diagnosis was first determined by classical histopathology, followed by molecular 
diagnosis through DNA methylation profiling (Infinium® MethylationEPIC, Illumina) as 
described (Golebiewska et al., 2020). In brief, genomic DNA was extracted using the QIAamp 
Blood & Tissue Kit. Bisulfite conversion was done using up to 250ng of extracted gDNA. DNA 
methylation-based glioma classification was performed by referencing data to the dataset of 
over 2800 neuropathological tumors at https://www.molecularneuropathology.org/mnp as 
described previously (Capper et al., 2018) . For samples where methylation profiling was not 
possible due to limited sample amount, IDH status was confirmed by droplet digital PCR 
(ddPCR) as previously described (Golebiewska et al., 2020).  Patient characteristics are shown 
at Chapter IV-2 Supplementary Table 1. Patient sample collection was approved by the local 
ethics committee (Haukeland University Hospital, Bergen (REK 2010/130-2) and in line with 
the Declaration of Helsinki.  
 
2. Patient-derived glioma cell lines and xenografts 
 
Patient-derived cell lines were generated in the laboratory of Dr Christel Herold-Mende and 
grown as 3D spheres under serum-free conditions (Chapter IV-2 Figure S1A). These glioma 
stem-like cells (GSCs) have been previously used in other studies (Trong et al., 2020, Dao 
Trong et al., 2018, Dettling et al., 2018, Bougnaud et al., 2016a). NCH644, NCH601 and 
NCH421k correspond to patients with IDH1wt Glioblastoma. NCH1681 and NCH551b were 
from patients with IDH1m astrocytoma; NCH612 from a patient with an IDH1m 
Oligodendroglioma. All IDH1m cells were slow growing and sensitive to culture conditions. For 
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BE04-687F/U1) supplemented with 20% BIT100 (Provitro), 2mM L-Glutamine, 30 U/ ml Pen-
Strep, 1U/ml Heparin (Sigma), 20 ng/ml bFGF (Miltenyi, 130-093-041), and 20ng/ml EGF 
(Provitro, 1325950500). Cells were incubated under standard normoxic conditions at 37°C and 
5% CO2 and were regularly tested for mycoplasma. The presence of the IDH mutation was 
regularly validated by Western blot.  Glioma patient-derived orthotopic xenografts (PDOX) 
generated in NOD/Scid mice (male or female, at least 2 months of age) were described 
previously (Bougnaud et al., 2016b, Golebiewska et al., 2020). 
 
3. Western blot 
 
Cells were lysed in RIPA extraction buffer supplemented with protease inhibitor cocktail 
(Roche). Protein quantification was performed with 2D-Quant (GE Healthcare). Protein lysates 
were resolved in NuPage 4-12 % BisTris gels (ThermoFisher), and blotted onto a PVDF 
membrane. Membranes were blocked with TBST buffer in 2% milk. Blots were incubated with 
primary antibodies at 4°C overnight with: anti-IDH1m R132H (DIANOVA DIA-H09), anti-
Cystathionase (Abcam ab189916), anti-GAPDH (Cell Signaling 5174S) and anti-LaminB1 
(Abcam ab16048). Secondary antibodies anti-mouse and anti-rabbit (Jackson 
ImmunoResearch) were applied, and blots were developed with a chemiluminescent substrate 
(ThermoFisher) using ImageQuant analyzer (GE Healthcare).  
 
4. Seahorse XF analyzer 
 
Cells were seeded in Seahorse XFe96 plates (Agilent)  at 5 x 104 cells per well using 200 µl of 
our DMEM-F12 medium (Lonza, BE04-687F/U1) supplemented as aforementioned. The plates 
were previously coated with 20 µg/ml of laminin in 200 µl per well, left during 2 hours at 37º. 
After the 2 hours the laminin solution was removed before starting the cell seeding. Cells were 
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Base Medium (Agilent) supplemented with 2mM Glutamine (pH=7.4) and cells were incubated 
for 30 minutes at 37º and no COs. Oxygen consumption rate (OCR) and extracellular 
acidification (ECAR) was recorded using Seahorse XFe96 Extracellular Flux Analyzer (Agilent) 
at baseline. InCucyte was used to normalize the data with cell density (IncuCyte ZOOM 2018A 
software). Raw density data was taken from Phase Object Confluence (POC), which measures 
the percentage of the phase contrast image area that is occupied by objects (cells). 
 
5. CRISPR/Cas9-mediated IDH1m knock-in GBM cell line  
 
Our strategy consisted in the binding and double strand break (DSB) of a single guide RNA 
(sgRNA)-Cas9 complex into IDH gene, followed by homologous directed repair (HDR) with a 
donor plasmid containing the IDH1 R132H mutation (adapted from (Brabetz et al., 2017)). In 
order to do so, we selected a sgRNA with predicted minimal off-target activity that recognized 
IDH gene 3’ of exon 4 (Sulkowski et al., 2017). This sgRNA was cloned in a vector expressing 
Cas9 as well as GFP reporter. We tested sgRNA efficiency after transfection of the sgRNA 
plasmid into HEK293T cells by T7 endonuclease assay. We fused a reporter gene (mCherry) 
to the IDH1 cDNA sequence via a P2A self-cleaving peptide. Therefore, random genomic 
integration or out of frame integration of the donor plasmid are not expected to result in 
mCherry expression. In order to avoid recutting of the target site after HDR, the guide 
recognition sequence was omitted from the 3’HDR sequence of the donor plasmid. 
The donor plasmid was then transfected together with the sgRNA-Cas9 plasmid into NCH644 
GBM cell line via electroporation. In order to obtain clonal lines with integration of the donor 
plasmid, mCherry positive cells were single cell sorted and allowed to recover. Clonal lines 
were later analyzed on for correct integration of the donor construct by PCR and sequencing 
of the 5’ and 3’ HDR borders. Selected heterozygote and homozygous clonal lines were further 
analyzed for IDH1R132H expression by Western Blot and by Sanger sequencing of cDNA as 
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6. Quantitative RT-PCR 
 
RNA was isolated following the Trizol protocol (ThermoFisher) and cDNA was synthesized 
using iScript Reverse Transcriptase (BioRad). cDNA was applied for real-time PCR reactions 
in a Via7 instrument using Fast SYBR Green (Applied Biosystems). Relative gene expression 
levels were normalized against elongation factor 1 alpha (EF1α) housekeeping gene, and 
calculated using the ΔCT method. Reactions were performed in triplicates. Specific primers 
used were: CSE (Fw: GGCCTGGTGTCTGTTAATTGT, Rv: 
GCCATTCCGTTTTTGAAATGCT), CBS (Fw: GGCCAAGTGTGAGTTCTTCAA, Rv: 
GGCTCGATAATCGTGTCCCC), EF1 α (Fw: TTGTCGTCATTGGACACGTAG, Rv: 
TGCCACCGCATTTATAGATCAG), EZRIN (Fw: TGCCCCACGTCTGAGAATC, Rv: 
CGGCGCATATACAACTCATGG) (Eurogentec). 
 
7. TCGA analysis 
 
Gene expression data from glioma patients was obtained from The Cancer Genome Atlas 
(TCGA) dataset via the GlioVis data portal (Bowman et al., 2017). 
 
8. Untargeted proteomics analysis by LC-MS/MS 
 
For the proteomic analysis, all cell lines were extracted by two different preparation methods 
for a total of two replicates per cell line. In the first preparation, proteins were extracted using 
methanol/chloroform and protein pellets were dissolved in 8M urea buffer, while in the 2nd 
preparation the cells were lysed with 1% sodium deoxycholate detergent (SDC).  Protein 
concentrations were determined by EZQ assay (Invitrogen, cat#R33200). Equal amounts of 
proteins were used for the analysis. Samples were reduced with 5 mM dithiothreitol for 1 h at 
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sequential protein digestion with Lys-C (Wako, cat#125-05061) for 3 h at 37°C, and trypsin 
(Promega, cat#V5111) at 37°C overnight. Tryptic peptides were desalted on C18 SPE (Sep 
Pak tC18, 25 mg, Waters) and dried using a vacuum centrifuge. Peptides were analyzed on a 
Q-Exactive HF mass spectrometer (Thermo Scientific) coupled with a Dionex Ultimate 3000 
RSLC chromatography system operated in column switching mode. Peptides were trapped on 
a 75 µm x 2 cm pre-column (C18 pepmap 100, 3 µm) and separated onto a 75 µm × 50 cm 
column (C18 pepmap 100, 2 µm) by a 240 min linear gradient starting from 2 % solvent A (0.1% 
formic acid in water) to 35% solvent B (0.1% formic acid in 100 % acetonitrile) at a flow rate of 
300 µl/minute. The mass spectrometer was operated in a data-dependent acquisition mode 
with a survey scan acquired at a resolving power of 120,000 at 200m/z. The 12 most intense 
multiple-charged ions (z ≥ 2) were isolated and fragmented at normalized collision energy of 
28 and the resulting fragment ions acquired at a resolution of 15,000 at 200 m/z. Fragmented 
precursors m/z were excluded for another fragmentation for 20 s. MS files were analyzed in 
the MaxQuant (Cox and Mann, 2008) software version 1.6.7.0. MS/MS spectra were searched 
by the Andromeda search engine (Cox et al., 2011) against the TrEMBL UniProt Homo sapiens 
(February 2019, 73,928 entries). Cysteine carbamidomethylation was set as a fixed 
modification and methionine oxidation and N-terminal protein acetylation as variable 
modifications. For protein quantification, label‐free quantitation (LFQ) was performed with a 
minimum ratio count of 2 (Cox et al., 2014) with match between runs activated. The FDR cut-
off for peptide and protein identifications was set to 1%. Bioinformatic analysis was performed 
in the Perseus platform version 1.6.2.1 (Tyanova et al, 2016). Two‐sample Student's t‐test was 
used to determine the significantly changed proteins between IDH1wildtype and IDH1mutant 
cell lines with a permutation‐based FDR of 0.05 for multiple testing correction. Results were 
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9. Generation of stable shRNA-mediated knockdown cell lines 
 
Since patient-derived glioma cells were not amenable to standard transfection procedures, all 
gene knockdown (KD) experiments were performed with lentiviral vectors to establish stably 
transduced KD lines. To target the CSE gene in NCH1681 cells, two different shRNA variants 
were used: shCSE1 (ATAGCTTTAGGTTCTTGAG; Code: V2LHS_151012) and shCSE2 
(ATGAAAGATAATGAGGTGC; Code: V2LHS_151015), and one non-targeting scrambled 
shRNA was used as control: shCTR (CTTACTCTCGCCCAAGCGAGAG; Code: RHS4346) 
(Dharmacon). Plasmids containing shRNAs and GFP (pGIPZ-shRNA-targets and pGIPZ-
shRNA-scramble) were amplified by midi-prep (Machery-Nagel).  Lentiviral particle production 
was done in HEK293T (5x105 cells in 5ml of DMEM 2% FBS) using the core packaging 
construct pCMVR8.74 and envelope protein vector pMD2.G. The supernatant containing viral 
particles was harvested and 1ml was used to transfect NCH1681 (8x105 cells in 3ml of DMF12 
specific medium for IDH1m cells). After lentiviral transduction, cells were passaged five times 
in the presence of 1ug/ml puromycin as selection marker to obtain stable GFP-positive KD 
cells.  
 
10. Cysteine titration in medium 
 
The optimal culture medium for IDH1m cell lines is based on DMEMF12 (Lonza, BE04-
687F/U1) (containing 100 µM cysteine and 100 µM of its oxidized dimer cystine) supplemented 
with 20% BIT100 (containing 600 µM cysteine), thus the final cysteine concentration 
(combining both cysteine and cystine) in the medium being 360 µM. With cysteine-free 
DMEMF12 (see below) plus 20% BIT the final cysteine concentration was still at 120 µM. Since 
BIT contains essential hormones for cell growth (transferrin, insulin and BSA), completely 
eliminating BIT was too deleterious for the sensitive IDHm cells. Therefore to further decrease 
the concentration of cysteine we applied serial BIT dilutions, at 10% BIT (60 µM cysteine) and 
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effect of PAG in low BIT/cysteine medium was due to the lack of cysteine by rescuing the cells 
with extracellular cysteine (Chapter IV-2 Figure S4D). The cysteine-free medium consisted of 
DMEM high glucose, no glutamine, no methionine, no cysteine (ThermoFisher, 21013024), 
supplemented with an amino acid mix to reach these final concentrations: 115 µM methionine, 
250 µM glycine, 50 µM alanine, 50 µM asparagine, 50 µM aspartic acid, 50 µM glutamic acid, 
50 µM proline, RPMI 1640 Vitamins Solution 1X (Sigma, R7256), 2mM L-Glutamine, 30 U/ml 
Pen-Strep, 1 U/ml Heparin (Sigma), 20 ng/ml bEGF (Miltenyi, 130-093-041), 20 ng/ml EGF 
(Provitro, 1325950500). 
 
11. Sphere size measurement  
 
Sphere growth assays were performed in an IncuCyte imaging incubator. Cells (1x103 
cells/well) were seeded in a 384 well plate in 75 µl. The plate was briefly centrifuged (3 min, 
300 rpm) and placed in the incubator at 37ºC to allow sphere formation. Twelve hours later, 
once the spheres were properly formed, each single sphere per well was imaged every 4 hours 
during 7 days. For quantification of sphere size a specific mask was applied (IncuCyte ZOOM 
2018A software) and raw data was taken from Phase Object Confluence (POC), which 
measures the percentage of the phase contrast image area that is occupied by objects (cells). 
 
12.  GFP fluorescence as a proxy for cell viability 
 
GFP fluorescence was measured in an IncuCyte imaging incubator. Cells (1x103 cells/well) 
were seeded in a 384 well plate in 50 µl. The plate was briefly centrifuged (3 min, 300 rpm) 
and placed in the incubator at 37ºC to allow sphere formation. Twelve hours later, the spheres 
were properly formed and each single sphere per well was imaged every day during 6 days. 
Raw data was taken from mean green fluorescent values from IncuCyte ZOOM 2018A 
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13. Toxicity assay 
 
Toxicity was determined with the CellTox Green Cytotoxicity assay® (Promega). The CellTox 
working solution consists of a compound that emits green fluorescence after reacting with free 
extracellular DNA. Cells (1x103 cells/well) were seeded in a 384 well plate in 75 µl of the desired 
medium, the plate was briefly centrifuged (3 min, 300 rpm) and 25 µl of CellTox working 
solution were added. The plate was then placed in the incubator under normoxia at 37ºC. 
Twelve hours later, green fluorescence was measured in a CLARIOstar Plus microplate reader 
(BMG LABTECH) and again every day for up to 4 days. 
 
14.  ROS measurement 
 
1.5x105 cells/ml/well were seeded in a 12 well plate. Each well contained a specific cysteine 
concentration medium (360, 60, 30 µM cysteine). The plate was placed in the incubator under 
normoxia at 37ºC for 3 days to allow ROS formation. After 4 days, 2′,7′-Dichlorofluorescin 
diacetate (DCFDA) probe was applied at 10 µM. After 30 minutes, cells were washed, 
harvested in PBS and seeded in 8 replicates in a 96-well plate (3x104 cells/well in 100 µl). 
Green fluorescence was determined in a CLARIOstar Plus microplate reader (BMG 
LABTECH). 
 
15.  In vivo experiment in orthotopic xenografts  
 
3x105 NCH1681 cells were stereotactically injected into the frontal cortex of NSG mice 
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) (n=20). Tumor growth was monitored by MRI (FSE-T2 
sequence, 3T MRI system, MR Solutions) as described previously (Golebiewska et al., 2020). 
MRI data was analyzed by ImageJ and the tumor volume (mm³) was determined by tumor 
delineation in each slice and multiplying by slice thickness (1mm). Two months after 
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groups (8 mice per group). The experimental group received intraperitoneal injections of PAG 
(35mg/kg), 5 times/week during 3 months, while the control group received saline injections. 
The treatment dose was based on previous reports (Cho et al., 1991). Tumor growth rate (GR) 
was calculated using the tumor volume (TV) measurement at 2 different time points as GR = 
100 * log (TVf/TV0) / (tf-t0), where TVf and TV0 are the tumor volumes at the last and first time 
points respectively, and tf-t0 is the difference in days between the time points (Mehrara et al., 
2007). Mice were observed daily, about two months after treatment start, mice from the control 
group started to present neurological symptoms and body weight loss. The experiment was 
halted 3 months post-treatment after two control mice had died.  
For in vivo flux analysis, 130mg/kg/h of L-serine (U-13C3, 99%) (CLM-1574-H-0.1 Eurisotop) 
was intravenously (tail vein) infused in 2 mice of each group during 4 hours, as well as in 2 
healthy mice without tumors (healthy brain controls). Mice were maintained anesthetized with 
2.5% of isoflurane during the infusion. The 4 hours and 130mg/kg concentration of serine tracer 
infusion which was based on (Ducker et al., 2016), was confirmed in our pilot experiment where 
metabolite steady state in the brain was reached after 4 hours (Chapter IV-2 Figure S5A). 
After infusion brain, liver, kidney and heart were dissected and flash frozen in isopentane at -
80ºC LC-MS analysis 
All procedures were approved by the animal welfare structure of LIH and the national 
authorities responsible for animal experiments in Luxembourg under the reference LUPA. 
  
16.  Metabolite and flux analysis in cell lines and tissues 
Cell lines (5x105 cells/well) were seeded in triplicates in 12 well plates in a total volume of 2ml 
at 30 µM cysteine. For the tracing experiments 400 µM of L-serine (U-13C3, 99%) (CLM-1574-
H-0.1 Eurisotop) was added to the culture medium which already contained 400 µM natural 
serine (ThermoFisher, 21013024) (ratio 13C3-Serine/Serine 1:1). After 4 days, cells were 
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metabolite extraction solvent (30% Acetonitril 50% MeOH 20%H2O). Samples were put on a 
shaker (1000 rpm at 4ºC for 5 minutes) and centrifuged at 4ºC for 10 minutes. 150 µl of 
supernatant was collected and stored at -80ºC for downstream LC-MS. The cell pellets were 
kept for protein quantification using the Lowry method for sample normalization.  
Frozen tissue of human or mouse samples were cut with a scalpel on dry ice and weighed to 
obtain pieces of 15-25mg. Mouse tumor samples were carefully collected by cryomicrotome 
sectioning of the frozen brains. 25 µl/mg tissue of metabolite extraction buffer (30% Acetonitril 
50% MeOH 20%H2O) was added and samples were homogenized via bead-mill (Qiagen 
Tissuelyzer) mechanical disruption with 5 mm beads  (2 times x 20 seconds shake at 20 Hz 
frequency). Samples were shaken at 1400 rpm (12 minutes at 4ºC) and centrifuged at 16000 
g (15 minutes at 4ºC). Metabolite extracts in the supernatant were recovered and stored at -
80ºC until LC-MS analysis was performed.  
A pilot GC-MS-based approach to determine steady state levels of 13C3-serine in different mice 
tissues (Chapter IV-2 Figure S5A) was performed as described in (Meiser et al., 2016). LC-
MS analysis was performed as previously described (Vande Voorde et. al 2019 Science 
Advances).  Briefly, analysis was carried out on an Ultimate 3000 HPLC coupled to Q Exactive 
Orbitrap mass spectrometer with electrospray (ESI) ionization (Thermo Scientific, Waltham, 
MA, USA). Metabolite extracts (5µl) were separated on ZIC-pHILIC column (SeQuant, 150 x 
2.1mm, 5µm, Merck KGaA, Darmstadt, Germany) held at 45°C. The gradient started at 20% 
A (20mM ammonium carbonate, pH 9.2) and 80% B (acetonitrile), decreasing to 20% B at a 
flow rate of 200μL/min over 15 minutes. Data was acquired using Thermo Xcalibur software 
over a mass range of 75-1000 m/z at a resolution of 35,000 (at 200m/z) with polarity switching. 
Data analysis was carried out in TraceFinder (v4.0, Thermo Scientific) software. Metabolites 
were identified using an in-house library of exact mass and known retention time generated 
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17. Statistical analysis 
 
All statistical analyses were performed using GraphPad Prism 8 software. Statistical 
comparisons were based on two-tailed Student’s t-test between the corresponding groups, 
except where otherwise stated. Number of replicate experiments (n), errors and p-values are 
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ABSTRACT 
Isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations determine diffuse glioma subtypes. This 
mutation leads to a gain-of-function synthesis of D-2-hydroxyglutarate (D-2HG) that impacts 
tumor epigenetics and metabolism. IDH are central metabolic enzymes participating in various 
intermediary pathways such as tricarboxylic acid (TCA) cycle, redox or lipid metabolism, yet 
the specific implications of this mutation are only partially understood. Here, we make use of 
patient material with and without IDH1 mutation as well as patient-derived cell lines and 
xenografts, and CRISPR/Cas9 generated IDH1m isogenic in vitro models. We performed an 
integrative characterization of the metabolic regulation in these models by mass spectrometry-
based proteomics and metabolomics analysis combined with energy metabolic reading via 
Seahorse analyzer. We found that IDH1m gliomas have a decreased energetic yield although 
they upregulate master regulators of central carbon metabolism, especially within glucose and 
glutamate processing pathways as well as GSH synthesis. Our data suggests that IDH1 
mutation leads to an increased production of glucose derivatives for nucleotide, lipid and amino 
acid synthesis, whereas they upregulate anaplerotic input into the TCA cycle via glutamate or 
glucose-independent pyruvate to cope with their vast D-2HG production. Moreover, we 
propose that these tumors upregulate de novo synthesis of GSH in order to maintain their 
antioxidant pool from a NADPH-independent manner. Thus, here we show a comprehensive 
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1.1. Introduction 
 
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) are frequent in various cancer types, 
especially in gliomas, defining their classification. Low grade astrocytic and oligodendroglial 
tumors are IDH mutant (IDHm), whereas glioblastomas (GBM) are IDH wild type (IDHwt) (Louis 
et al., 2016b). Wild type IDH catalyzes the oxidative decarboxylation of isocitrate to α-
ketoglutarate (α-KG) generating NADPH, an important reducing agent in various metabolic 
pathways. The IDH mutation (R132H), most often affects the cytosolic isoform IDH1 and leads 
to the neomorphic consumption of α-KG and NADPH, to generate the oncometabolite D-2HG 
(Dang et al., 2009a). Competitive inhibition of α-KG-dependent dioxygenases by D-2HG, 
triggers epigenetic reprogramming, e.g. DNA and histone methylation and HIF1-α stabilization 
(Xu et al., 2011b, Turcan et al., 2012).  
Diverse studies show that IDHm tumors may alter different metabolic pathways. It has been 
observed that tricarboxylic acid (TCA) cycle anaplerosis via glutamine and glutamate is altered 
in these tumors. Indeed, α-KG from IDHwt reaction is not the only source of D-2HG, since 
much of this metabolite is derived from glutamine (Grassian et al., 2014). TCA cycle alterations 
has shown to restrict oxidative metabolism in these tumors, sensitizing them to electron 
transport chain (ETC) inhibitors (Grassian et al., 2014, Reitman et al., 2011). Mutations in IDH 
has also been found to alter redox metabolism, due to reduced NADP+-dependent IDH activity 
(Bleeker et al., 2010). This decrease in reducing agents may impact the glutathione (GSH) 
availability and oxidative damage of these cells (Shi et al., 2015). In addition, phospholipid 
production has also been found altered by IDH mutation (Esmaeili et al., 2014). In our group, 
we have studied the metabolic landscape of IDHm gliomas in patient derived orthotopic 
xenografts (PDOX), and we also reported a dysregulated phospholipid metabolism as well as 
low energetic yield and a potential redox vulnerability (Fack et al., 2017). Recent studies have 
performed untargeted proteomic analyses, in order to characterize the overall metabolic 
regulation in IDHm and IDHwt gliomas (Oh et al., 2020, Doll et al., 2017, Dekker et al., 2020). 
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suggested IDH1m metabolism may be rewired by an increased input of lactate and glutamate 
to preserve TCA-cycle activity (Dekker et al., 2020). Moreover, IDH mutant tumors showed 
decreased oxidative-phosphorylation proteins, suggesting a constrained respiration capacity 
(Oh et al., 2020). Overall, these latest findings suggest an impaired TCA cycle and oxidative-
derived energy production in IDHm gliomas. There is still a need of comprehensive studies 
which combine metabolomics and proteomics regulation, and it remains to further investigation 
the metabolic vulnerabilities thereof and the specific targetable proteins to explore them. 
In the present study, we profiled IDHm glioma metabolic environment through an integrative 
approach which combined proteomics, genomics and metabolomics as well as functional 
assays (e.g. Seahorse). This comprehensive analysis was conducted in a varied range of 
glioma models, including glioma patient samples obtained from surgical resection, patient 
derived cell lines expressing the endogenous IDH1 mutation and orthotopic xenografts thereof, 
as well as CRISPR/Cas9-generetad IDH1m knock-in GBM cells. Collectively, we observed that 
IDHm tumors display a significant dysregulation in key protein and metabolite intermediaries 
of central carbon metabolism, especially in those pathways derived from glucose and 
glutamate processing. In addition, we observed mayor differences in GSH redox system, fatty 
acid and phospholipid regulation. Overall we present a comprehensive study and data 
resource of the metabolic blueprint of IDHm gliomas, from which potential targets for future 
investigations are proposed. We expect to enlarge our understanding of glioma biology, 
providing a clearer perspective of the metabolic vulnerabilities of this elusive disease. 
 
1.2. Results 
Metabolomics dysregulation of central carbon intermediates in IDH1m 
gliomas 
In order to first address the differential metabolic regulation of IDH1m and IDHwt gliomas, we 
performed liquid chromatography-mass spectrometry (LC-MS)-based metabolomics analysis. 
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IDHwt) (Chapter IV-2; Supplementary Table 1). These samples were kindly provided by 
Haukeland Hospital in Bergen, Norway. For this study we made use of TraceFinder software 
where we created a compound database of ~ 100 metabolites that are considered important 
in the overall intermediary metabolism. Moreover, as a complementary validation, the 
metabolomics analysis was performed in four patient-derived cell lines (PDCs). Two of these 
cell lines correspond to IDHwt GBM (NCH644, NCH421k), Two correspond to IDH1m 
astrocytomas (NCH1681, NCH551b). The IDH1m lines are glioma stem-like (GSC) cells which 
grow as neurospheres and have already been reported (Trong et al., 2020, Dao Trong et al., 
2018). Moreover, we analyzed as well metabolomics regulation in an IDH1m mouse xenograft 
model generated by orthotopic implantation of one IDH1m cell line (NCH1681), and compared 
metabolite levels with control mice without the disease. In line with what shown by previous 
studies, we observed significant dysregulation of key metabolites within glucose, glutamate, 
GSH and lipid metabolism. In addition to patient sample analysis (Figure 1), metabolomics 
analysis in cells (Figure S1) but also in xenografts (Figure S2), complemented our patient 
data with additional metabolites that largely matched within the same metabolic pathways. 
Interestingly, the central glycolytic metabolites, glucose, glucose 6-phosphate and fructose 
1,6-biphosphate were significantly increased in IDH1m gliomas (Figure 1A). As products of 
secondary catabolism of glucose, we found that different nucleotides or nucleosides were 
increased in IDH1m gliomas, such as GMP or adenosine (Figure 1B). On the other hand there 
was a significant decrease of glutamate in IDH1m patients, which we previously reported (Fack 
et al., 2017), as well as the expected upregulation of D-2HG. Moreover, leucine, a branch chain 
amino acid (BCAA) which may serve as precursor of glutamate, was also significantly 
decreased in IDH1m patients (Figure 1C). Glutamine and α-ketoglutarate (α-KG) were not 
differential in patients. With regard to GSH metabolism certain precursors of de novo synthesis 
of this antioxidant were also differential in IDH1m gliomas, such as S-adenosyilmethionine 
(SAM) and α-ketobutyrate (Figure 1D). However, as we previously reported (Fack et al., 2017), 
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phosphate, which acts as phospholipid precursor, was found increased in IDH1m gliomas, as 
well as hexanoic acid, a common short chain fatty acid (Figure 1E).  
Overall, here we confirmed that IDH1m gliomas display differences in intermediaries of central 
metabolic pathways compared to IDHwt GBM. Specifically, it appears that glucose catabolism 
may be dysregulated. It is not clear whether increase in glucose intermediates means a faster 
or slower pathway activity. Further functional assays should be performed to address this. The 
observed shortage in glutamate, may suggest an increased consumption for the generation of 
α-KG to fuel TCA cycle or catalyze D-2HG production. Glutamine and α-KG were indeed 
significantly upregulated in IDH1m cell lines, as well as glutamate and other glutamate 
derivatives such as GABA (Figure S1C). Disparity of results between in vitro and patients with 
regard to glutamine-glutamate intermediates might be explained by the high glutamine 
concentration (2 mM) supplemented in the culture medium. The increase in GSH precursors 
may indicate a higher de novo synthesis flux to cope with GSH demands in a NADPH-
independent manner. The observed increase in glycerol 3-P confirms a potential imbalance in 
synthesis of phospholipids in IDH1m tumors (Fack et al., 2017). Accumulation of the short 
chain fatty acid hexanoic acid suggests an altered fatty acid processing.  
Proteomics analysis reveals altered metabolic processes in IDH1m 
gliomas 
 
To combine the observed metabolomics dysregulation with the differential enzymatic 
abundance derived from IDH mutation, we performed a label-free quantitative (LFQ) LC-MS 
proteomic comparison. For the proteomics analysis we added to the aforementioned patient 
cohort another cohort of 13 patients (6 IDH1m and 7 IDHwt) which was previously reported 
(Fack et al., 2017). Hence we analyzed a total of 33 patient samples (16 IDH1m and 17 IDHwt). 
In addition, we also analyzed proteomics differences in six PDCs, three IDHwt (NCH644, 
NCH601, NCH421k) and three IDH1m (NCH1681, NCH551b (astrocytomas), NCH612 
(oligodendroglioma)). In order to eliminate patient specific differences, we generated an 
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Figure 1. Metabolite distribution of central carbon intermediates in IDH1m gliomas.  
LC-MS-based detection of differentially regulated metabolites in IDHwt and IDH1m glioma patients 
corresponding to the specific metabolic pathways revealed by proteomic analysis, (A), (B), (C) and (D). 
Each dot of the charts corresponds to one independent tumor. IDHwt (n=10), IDH1m (n=12). Data 
presented as means ± S 
 
 
CRISPR/Cas9 technology. Therefore, the proteomics comparison was performed between the 
IDH1m knock-in (KI) model (i.e. NCH644 sgIDH1m) and its isogenic counterpart, NCH644 (i.e. 
NCH644wt). Based on the different proteomics analyses we found a total of 808 proteins 
differentially expressed between IDH1m and IDHwt patients, 590 in the cell lines, and 250 in 
the KI model. These proteins presented a fold change (FC) >1.5 and a false discovery rate 
(FDR) <0.05 (Figure 2A). We primarily aimed to uncover all differential metabolic proteins in 
IDH1m glioma patients. In addition, we combined this with the proteomics analysis in PDCs 
and KI models as complementary validation. Most of the proteins upregulated in IDH1m 
gliomas patients were related to metabolic pathways. However, significantly downregulated 
proteins in these tumors were rarely metabolic, and most commonly related with other 
pathways such as growth factor transport and uptake, extracellular matrix organization or 
protein translation and post-translation processing. Since the aim of our study was to address 
the metabolic vulnerabilities of IDH1m gliomas, we focused in the metabolic enzymes, mostly 
upregulated in our proteomics analysis.  
We found four proteins that were significantly increased in IDH1m entities from the three 
different models: patients, PDCs and KI (Figure 2B). Of those four, two of them are directly 
linked to metabolism, glutathione S-transferase 2 and 3 (GSTM2 and GSTM3), which are in 
charge of detoxification of xenobiotic agents using GSH as redox cofactor. The higher 
expression of GSTM1/2 may be the consequence of an increased demand for antioxidant 
protection that may be caused by an IDHm-dependent redox vulnerability. The other two 
enzymes, dystrobrevin alpha (DTNA) and guanine nucleotide-binding protein G subunit 
gamma-7 (GNG7) are specific modulators of molecular signaling within the brain and CNS. In 
order to identify common biological processes we analyzed the Gene Ontology Biological 
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were often participating in metabolic processes, e.g. small molecule catabolic process, 
monocarboxylic acid metabolic process, or organic acid catabolic process (Figure 2C). In 
order to get more insightful in the specific metabolic pathways involved in these processes, we 
performed a pathway analysis from different databases such as KEGG pathways, Canonical 
pathways and Reactome Gene Sets (source: metascape.org) of the differentially expressed 
proteins in IDH1m models. All three models pointed to a dysregulation of pathways related to 
cellular metabolism, which could be classified in 3 major metabolic groups: 1) Central carbon 
metabolism, 2) GSH metabolism, 3) lipid and fatty acid metabolism (Figure S3).  
Although most of pathways associated with upregulated proteins in IDH1m patients were 
related with metabolism, in the in vitro models (PDCs and KI cells) downregulated proteins 
were also associated with metabolic pathways. This might be explained by the differential 
nutrient supply encountered within culture conditions. However, as observed in patient material 
similar metabolic pathways related with glucose, glutamate, TCA or GSH metabolism were 
found differential as well in the in vitro models.  
 
Integrative characterization of IDH1m differential metabolism 
 
For visualization of dysregulated pathways we merged our proteomics and metabolomics 
studies of IDH1m vs IDHwt glioma patients. In vitro and in vivo models were checked for 
complementary validation. To do so, we made use of the Cytoscape© software, an open 
access platform for visualization of complex biological networks (i.e. genomic, proteomic, 
metabolomics), based on public databases. Specifically, we utilized KEGG metabolomics 
dataset  (Okuda et al., 2008) in order to integrate the specific proteins and metabolites revealed 
by our study. As mentioned, metabolic enzymes and metabolites of IDH1m glioma patients are 
most often upregulated when compared to IDHwt tumors. Although increased enzyme 
abundance suggest a higher pathway activity, higher metabolite levels could mean either 




















Figure 2. Proteomics analysis reveals altered metabolic processes in IDH1m gliomas 
Label-free quantitative (LFQ) LC-MS proteomic comparison on three different glioma models: patient 
samples (IDH1m n=16 IDHwt n=17), patient-derived cell lines (PDCs) (IDHwt: NCH644 (n=4), NCH601 
(n=4), NCH421k (n=4); IDH1m: NCH1681 (n=6), NCH551b (n=4), NCH612 (n=4)) and IDH1m knock-in 
(KI) cells (sgIDH1m NCH644 (n=4) and IDHwt NCH644 (n=4)) (A) Number of differentially expressed 
proteins detected in the different models (B) Venn diagram of the upregulated proteins among the three 
different settings. Four proteins were shared between all conditions: GSTM2, GSTM3, GNG7 and DTNA 
(C) Top 10 Enriched Gene Ontology Biological Processes (GOBP) from upregulated proteins in IDH1m 
samples in each model. Processes shared in >1 model are highlighted in red. 
 
 
levels, further functional validation should be applied, e.g. tracing flux studies. Yet, our 
integrative analysis aids to understand relevant metabolic pathways and specific reactions that 
might be decisive in IDH1m gliomas. 
Visualization of glycolysis pathway suggests that glucose derivatives may be used to generate 
precursors for nucleotides and lipids through glucose 6P and glycerol 3P respectively. Glucose 
6P is as well the precursor for the pentose phosphate pathway (PPP), one of the main sources 
of cytosolic NADPH besides IDHwt reaction. Amino acids, such as serine can as well be 
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In addition, several glucose-independent pyruvate synthesis enzymes were found increased, 
such as LDHB and MPST, suggesting alternative TCA cycle influx. Besides, ACSS1 (acetyl-
CoA synthase 1) catalyzes the synthesis of acetyl-CoA through other metabolites instead of 
pyruvate (e.g. ethanol, acetate) (Figure 3).  
We observed certain TCA cycle enzymes to be upregulated in IDH1m tumors, including IDH3, 
ACO2 (aconitase hydratase), SUCLA2 (succinate-CoA ligase) (Figure S4). However, our 
previously reported low glucose turnover into TCA intermediates (Fack et al., 2017) suggests 
this pathway may be fueled by anaplerotic input, such as the aforementioned glucose-
indepenedent pyruvate production. Moreover, our study showed glutamate metabolism may 
also play a crucial role in anaplerotic influx into the TCA cycle. Glutamate was in fact, one of 
the only metabolites significantly decreased in IDH1m tumors. The high levels of glutamate to 
α-ketoglutarate catabolic enzyme, GLUD1, suggests that IDH1m tumors may increase α-
ketoglutarate pool through glutamate in order to cope with its vast D-2HG production (Figure 
S4). Moreover, high levels of glutamine conversion via glutamate via GLUL higlights the limiting 
availability of glutamate in these cells.  In addition, we found BCAT1 to be downregulated as 
well as leucine, which participate in the production of glutamate (Figure S4). Finally, as 
previously mentioned glutamate transporter SLC1A2 or EAAT2 was found increased in IDH1 
mutants (Figure S4).  
The other major metabolic route found significantly increased in IDH1m gliomas was GSH de 
novo synthesis (Figure S5). The transsulfuration pathway is a multistep route, key for GSH 
synthesis, where methionine is metabolized to cysteine. We found central enzymes of 
transsulfuration pathway to be upregulated such as AHCYL1/2, CBS and GCLC (Figure S5). 
Different metabolites were also found increased here such as S-adenosymethionine (SAM) or 
α-ketobutyrate. SAM is the methyl donor in cytosine methylation, which is a key epigenetic 
regulatory process, thus higher SAM levels may be linked to the hypermethylated status 
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transsulfuration pathway may be also linked to lipid metabolism such as CRAT, but also 
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Figure 3. IDH1m metabolic regulation of glucose derivatives  
Cytoscape representation of glycolysis pathway regulation in IDH1m glioma patients (Source: KEGG 
database). Proteins and metabolites that were found differentially expressed from our analysis are 
colored. The coloring pattern determines the fold change (FC) of IDH1m/IDHwt ranging from red to blue. 
Each star next to a protein or metabolite indicates that it was also found significantly differential in other 
complementary model: PDCs and isogenic IDH1m models for proteins; PDCs and xenografts for 
metabolites.  
 
upregulated in IDH1m gliomas, not only in patients but in all models analyzed, highlighting the 
capital importance of GSH utilization in these tumors (Figure S5).  
Overall, we present a metabolic network visualization of IDH1m glioma displaying aberrant 
regulation in important intermediary pathways such as central carbon metabolism or GSH 
synthesis. Thus, our study highlights the importance of these pathways as potential targetable 
vulnerabilities against IDH1m gliomas.  
 
Central enzymes in intermediary metabolism as potential therapeutic 
targets for IDH1m gliomas 
After our integrative analysis we listed a number of different enzymes that could be promising 
therapeutic targets for IDH1m gliomas due to its central relevance in intermediary metabolism 
(Figure 4). We confirmed the upregulation of these sets of metabolic enzymes by consulting 
gene expression data from a different patient cohort (source: TCGA database, GlioVis 
(Bowman et al., 2017)). In concordance to the proteomics data from our patient samples, the 
genes encoding for those proteins were found to be upregulated in IDH1m patients in the 
TCGA dataset (Figure S6). 
Among glucose metabolism enzymes, we found the following to be upregulated in IDH1m 
gliomas: ALDOC, PDHA1, PC, LDHB and PHGDH (Figure 4A). Fructose-biphosphate 
aldolase (ALDOC) was the most significantly upregulated in IDH1 mutant samples. This 
enzyme mediates glycolytic flux through conversion of fructose 1,6-BP into glyceraldehyde 3-
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alternative processing of glucose for serine synthesis, and is upregulated in many cancers 
(Mattaini et al., 2016). PDHA1 belongs to the pyruvate dehydrogenase (PDH) enzymatic 
complex which mediates the conversion of pyruvate into acetyl-CoA thereby linking glycolysis 
to the TCA cycle. Pyruvate carboxylase (PC), on the other hand, catalyzes the synthesis of the 
TCA intermediate oxaloacetate from pyruvate, as anaplerotic influx into the TCA cycle. Lactate 
dehydrogenase B (LDHB) isoform, unlike LDHA, has higher affinity for lactate to pyruvate 
conversion, thus sustaining cells with alternative sources of pyruvate to the detriment of lactate. 
We previously reported a lower energetic yield in IDH1m gliomas (Fack et al., 2017). Then, the 
high abundance of glycolytic enzymes observed here suggests that IDH1m cells may redirect 
glucose derivatives for biosynthesis of different metabolites such as nucleotides, phospholipids 
or amino acids. The targeting of some of these enzymes might compromise the capacity of 
these cells to perform metabolic biosynthesis.  
With regard to glutamate metabolism, IDH1m patients showed high levels of different 
glutamate synthesis and catabolism enzymes including: SLC1A2, GLUD1, GOT1 and GLUL 
(Figure 4B). SLC1A2 gene encodes EAAT2 (excitatory amino acid transporter 2), which is the 
main transporter mediating the uptake of glutamate into the cell. GLUD1 (Glutamate 
dehydrogenase 1), catalyzes the conversion of glutamate into α-KG, an anaplerotic influx into 
the TCA cycle. This might act as α-KG source in IDH1m cells. GOT1, performs the reverse 
reaction, combining α-KG and aspartate to synthesize glutamate. Finally, glutamine synthase 
(GLUL), is the enzyme in charge of glutamate to glutamine conversion. The activity of these 
enzymes together with the low levels of glutamate highlights the importance of glutamate 
metabolism in IDH1m cells. Besides its role as source for α-KG, glutamate is a limiting 
metabolite for anaplerosis of the TCA cycle, synthesis of glutathione or synaptic signaling. This 
suggests that inhibition of glutamate synthesis or transport via some of these enzymes might 
accentuate the g of IDH1m cells to glutamate dependence.  
In addition, several enzymes upregulated in IDH1m patients are important mediators of GSH 
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β-synthase like protein), GCLC (Glutamate-cysteine ligase catalytic subunit) and AHCYL1 (S-
adenosylhomocysteine hydrolase 1 like protein) participate in de novo synthesis of GSH 
through transsulfuration pathway. We did not detect CSE (i.e. CTH) which is a key enzyme in 
transsulfuration pathway synthesizing cysteine de novo. However, according to parallel 
investigations currently under process of publication, we have observed that CSE is specifically 
upregulated in IDH1m astrocytomas and not in IDH1m oligodendrogliomas (Chapter IV-2). As 
aforementioned, GSTM enzymes were significantly upregulated as well in IDH1m patients, 
participating in GSH-dependent detoxification. NADPH is required as reducing agent for 
recycling of GSH. As we previously reported we did not observe differences in GSH levels in 
IDH1m cells although the mutation compromises their NADPH production. The higher activity 
of transsulfuration pathway enzymes suggests that IDH1m cells rely on de novo synthesis of 
GSH due to their lack of NADPH production derived from IDH mutation. Overall, this uncovers 
a redox vulnerability of IDH1m cells which could be harnessed by targeting transsulfuration 
pathway enzymes, or GSTM2 isoform.  
Finally, important enzymes involved in fatty acid metabolism were increased in IDH1m patients 
including PCCA, ACOT1 and CRAT (Figure 4D). PCCA (Propionyl-CoA carboxylase A) 
mediates catabolism of fatty acids, and ACTO1 (acyl-CoA thioesterase) converts acyl-CoA into 
free fatty acids. CRAT (Carnitine O-acetyltransferase) regulates the availability of acyl-CoA. 
Due to the defect in reductive carboxylation of IDH during the mutation, there is a restricted 
availability of isocitrate, a key substrate for fatty acids. This suggests, some of these enzymes 
compensate this deficiency in IDH1m cells, therefore its targeting could compromise their fatty 
acid availability.  
IDH1m glioma cells display a low energy metabolism 
 
Besides the observed increase in central carbon metabolism intermediaries, we have 
previously reported that IDH1m gliomas harbor a low ATP production when compared to IDHwt 
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Figure 4. IDH1m glioma patients upregulate central enzymes of the intermediary metabolism 
Significantly upregulated proteins in IDH1m glioma patients (IDH1m n=16, IDHwt n=17) revealed by the 
LC-MS-based untargeted proteomics comparison grouped in (A) glucose metabolism, (B) glutamate 
metabolism, (C) glutathione and (D) lipid metabolism.   
 
However, we hypothesize that IDH1m cells rewire their central carbon metabolism to perform 
alternative biosynthesis of metabolites. To confirm the low energetic capacity of IDHm cells 
from a functional perspective, we measured extracellular acidification rate (ECAR) and oxygen 
consumption rate (OCR) in the PDCs as a proxy of their glycolytic and respiratory capacity 
respectively. IDH1m cells showed stable levels of the mutant protein (Figure 5A). However, 
IDH1m allele frequency was especially high in astrocytomas, reaching ~100% (Figure 5B). 
This suggests a loss of the heterozygosity normally associated with IDH1m tumors. The 
tendency to develop an IDH1m homozygosity in vitro has been already reported by others 
(Luchman et al., 2013). Despite the observed loss of heterozygosity, these models yet present 
active production of D2HG, therefore are still used as correct models to study IDH1 mutation 
(Figure S1). However the mechanism by which the cells are able to produce D2HG despite 
their IDH1m homozygous status remains unclear. These PDCs grow as 3D spheres in serum-
free medium, and are not easily amenable to assays where cells need to be coated on the 
assay plate. NCH421k and NCH551b were especially reluctant to attach and tended to end up 
as big sphere clusters (Figure 5C). We observed both a significantly decreased basal 
respiratory capacity and a significantly decreased basal glycolytic capacity in IDH1m cells 
when compared to IDHwt (Figure 5D). This is in line with the reduction of ATP previously 





Mutations in genes encoding IDH1/2 enzymes, are commonly observed in different cancer 
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alterations have been well studied due to the advance of genomic profiling technologies 
(Ceccarelli et al., 2016, Turcan et al., 2012), the metabolic repercussions associated to this 
























Figure 5. IDH1m glioma cell lines display a low energetic metabolism 
(A) Western blot for IDH1m (R132H) and GAPDH in the six glioma patient derived cell (PDC) lines. 
NCH644, NCH601 and NCH421k correspond to patients with IDH1wt primary glioblastoma (GBM); 
NCH1681 and NCH551b correspond to patients with IDH1m astrocytoma; NCH612 correspond to a 
patient with IDH1m oligodendroglioma. (B) Percentage of IDH1 mutant allele frequency (MAF) observed 
by digital PCR in all IDH1m cell lines, including astrocytomas (AS) and oligodendroglioma (OD). MAF 
and 95% confidence interval (CI) for each cell line were: NCH612 MAF=64.85%, CI= 61.196% -- 
68.65%; NCH1681 MAF= 99.45%, CI= 93.223% -- 106%; NCH551b MAF= 99.98%, CI= 94.808% -- 
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confidence intervals (CI) of MAF estimation. One cell stock replicate for each line (n=1)..(C) Phase 
contrast microscope imaging of PDCs coated to assay plate. (D) Basal respiratory capacity and basal 
glycolytic capacity based on oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) 
respectively, in IHDwt and IDH1m cell lines. Each different symbol corresponds to a different cell line 
and each repeated symbol correspond to one biological replicate. The statistical analysis was performed 
between all the biological replicates of IDHwt and IDH1m cell lines (n=9). Data normalized to cell density 
and presented as means ± SEM.  
 
glutaminolysis, lipid biosynthesis and redox metabolism in IDH1m gliomas (Parker and Metallo, 
2015), however, the lack of a complete metabolics characterization of these tumors has 
hampered the deeper understanding. 
Some recent mass spectrometry (MS)-based metabolomics studies have attempted to 
characterize IDHm gliomas, however, data obtained in engineered IDHm GBM cell lines, has 
not been completely reproduced in PDCs and patient material (Garrett et al., 2018, Miyata et 
al., 2019). Here we present a comprehensive characterization of IDH1m glioma metabolism 
through the combination of proteomics, metabolomics and functional assays and making use 
of in vitro, in vivo and patient material harboring the mutation. We observed that IDH1m tumors 
dysregulate essential metabolic pathways such as glucose/glutamate central carbon 
metabolism and GSH synthesis and utilization. This study reveals new insights, to our 
knowledge not yet exploited, that may instruct future investigations within the field of IDHm 
glioma metabolism.  
Overall, we observed higher metabolite and metabolic enzyme abundance in IDH1m gliomas 
when compared to IDHwt. It is not clear whether the high metabolite levels means a high 
production or otherwise an accumulation due to low consumption, while increased enzyme 
levels suggest increased pathway activity. In order to confirm this, further tracing flux studies 
should be applied as functional validation.  
We previously reported that IDHm gliomas show decreased ATP levels and reduced energy 
charge index when compared to IDHwt tumors (Fack et al., 2017). This was confirmed here by 
our observation that IDH1m PDCs display a decreased basal respiratory and glycolytic 
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proteo-metabolomics analysis in patients and in vitro models, we found interestingly that 
glycolytic and TCA cycle mediators were upregulated in IDH1m gliomas. We previously shown 
by 13C glucose tracing experiments in vivo, that IDH1m gliomas have a decreased glucose 
turnover into TCA intermediates, especially α-KG (Fack et al., 2017). This suggests that the 
observed high levels of glycolytic mediators such as glucose, glucose 6P or fructose 1,6BP 
may be dedicated to fuel other intermediary metabolism routes, instead of the TCA cycle. 
Indeed, we observed high levels of enzymes mediating glucose derived amino acid production 
(i.e. PHGDH) or glucose derivatives important in nucleotide metabolism (i.e. GMP, adenosine) 
and phospholipid synthesis (i.e. glycerol 3P) (Figure 3). On the other hand we observe higher 
expression of LDHB in IDH1m tumors which may also contribute to a decreased glycolytic 
capacity. LDHB is considered to have higher affinity for lactate to pyruvate reaction (Dang, 
2013), what would mean that IDH1m tumors consume lactate in order to increase their 
pyruvate production, explaining the low ECAR levels we observe. High expression of LDHB 
has been already reported in IDH1m gliomas (Mustafa et al., 2014).  
We found upregulation of certain TCA cycle enzymes including IDH3, ACO2, SUCL2 and 
SUCLG1. High TCA cycle activity may be directed to increase α-KG availability. IDH1 mutant 
enzyme consists of a heterodimer formed by an IDH1wt monomer and an IDH1m one. Due to 
the vast production of D-2HG by the mutant enzyme (FC>40 IDH1m/IDHwt in patients; Figure 
1), IDH1wt monomer might not be a sufficient source of α-KG. This would specially match with 
the increased levels of IDH3 (Figure S4). However, our previously reported low glucose 
turnover into TCA intermediates (Fack et al., 2017) suggests an anaplerotic input into this 
pathway. We observed different enzymatic mediators that regulate pyruvate synthesis 
independent of glucose, such as PC, MPST, or enzymes that fuel the TCA cycle via other 
glucose-independent anaplerosis (e.g. via oxaloacetate, malate, acetyl-CoA), such as 
GOT1/2, MDH1, ACSS1 (Figure 3). We also observed high levels of PKM which synthesizes 
pyruvate from phosphoenolpyruvate, which can be generated from glycolysis but also from 
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production such as GOT1 and MDH1 (Figure 3). Yet, although through anaplerotic sources, 
TCA cycle would be highly active in IDH1m gliomas, which a priori may not explain the low 
OCR we observed by Seahorse analyzer. It has been reported that D-2HG inhibits complex IV 
of the electron transport chain (ETC) (Chan et al., 2015, da Silva et al., 2002, Latini et al., 
2005). This would explain low OCR levels, meaning that even bearing an active TCA cycle, 
cellular respiration is yet defective in IDH1m tumors. 
Other important anaplerotic sources are glutamate and glutamine (i.e. glutaminolysis). Our 
data suggests glutamate is limiting in IDH1m gliomas due to high conversion into α-KG via 
GLUD1 (Figure S4). In fact, GLUD1/2 (also known as GDH1/2) have already been shown to 
promote growth in IDH1m gliomas (Chen et al., 2014). Other sources may attempt to 
compensate the lack of glutamate, such as glutamate transporter SLC1A2 (i.e. EAAT2), yet 
glutamate levels are significantly lower in IDH1m gliomas. We also observed that branched-
chain amino acid aminotransferase 1 (BCAT1) is downregulated in IDH1m gliomas, as well as 
the branched-chain amino acid (BCAA) leucine (Figure S4). BCATs are enzymes in charge of 
the synthesis of glutamate through BCAAs. Indeed, it has been shown that D-2HG inhibits 
BCAT enzymes, further constraining glutamate availability in IDH1m gliomas (McBrayer et al., 
2018). Currently glutaminase inhibitors are being tested in clinical trials as potential treatment 
against IDH1m myeloid malignancies by preventing glutamate synthesis through glutamine 
(Waitkus et al., 2018a). 
Finally, we observed many mediators of GSH metabolism increased in IDH1m gliomas (Figure 
S5). In fact, redox homeostasis is one of the most important metabolic routes thought to be 
altered in these tumors because of the major role of IDHwt to generate the cytosolic reducing 
equivalent NADPH, crucial for GSH recycling (Parker and Metallo, 2015, Shi et al., 2015, Fan 
et al., 2014). Since the IDHm isoform consumes NADPH to produce the oncometabolite D-
2HG, it is expected that NADPH is reduced in IDHm gliomas. This is supported by preliminary 
reports (Bleeker et al., 2010), however due to the difficulty to accurately measure 
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certain transsulfuration pathway enzymes, including CBS and GCLC, are upregulated in 
IDH1m gliomas, suggesting a compensatory pathway to produce GSH independently of 
NADPH (Fack et al., 2017). Moreover, the consistent upregulation of GSTM enzymes suggests 
that IDH1m gliomas strictly depend on GSH utilization to be defended against xenobiotic 
agents. Overall this highlights the potential of targeting GSH synthesis as therapeutic strategy 
against IDH1m gliomas. On the other hand, NADPH can as well be produced through PPP. 
We observed that IDH1m gliomas have high levels of glucose 6P (Figure S5), which is a 
precursor for PPP. This could mean that this tumors upregulate the synthesis of NADPH 
through this pathway to compensate their imbalance generated by IDH mutation.  
To conclude, in this study we observed that IDH1 mutation in gliomas leads to a significant 
dysregulation in diverse enzymes and metabolites within central carbon and GSH metabolism. 
To fully elucidate the exact implications that upregulation of these pathways have in IDH1m 
gliomas, it would be interesting to perform additional functional and metabolic flux analyses. 
Yet, here we show an integrative metabolic characterization of IDH1m gliomas, to our 
knowledge not yet reported, linking the presence of IDH mutation to the dysregulation of 
intermediary, energetic and redox metabolism. Moreover we present different enzymatic 
targets to further investigate their therapeutic potential in IDH1m glioma models Therefore, we 
expect to provide here with the basis of future investigations that may be of help to comprehend 
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Figure S1. Metabole analysis in IDH1m patient-derived cell lines 
LC-MS-based detection of differentially regulated metabolites in IDHwt (NCH644 (n=3), NCH421k (n=3)) 
and IDH1m (NCH1681 (n=3), NCH551b (n=3)) cell lines corresponding to the specific metabolic 
pathways revealed by proteomic analysis, (A), (B), (C) and (D). Each dot of the bar charts corresponds 
to one independent experiment (n=3). Statistical comparison was applied against NCH644 IDHwt 


















































Figure S2. Metabolite analysis in IDH1m xenograft tumors compared to healthy brain tissue 
LC-MS-based detection of differentially regulated metabolites in healthy mouse brain and IDH1m glioma 
xenograft (orthotopic implantation of NCH1681 PDC), corresponding to the specific metabolic pathways 
revealed by proteomic analysis, (A), (B), (C) and (D). Each dot of the charts corresponds to one 
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Figure S3. Metabolic pathways dysregulated in IDH1m glioma models 
Each table represents the different pathways to which the dysregulated proteins in the proteomics 
analysis belong, in each of the three different models: Patient samples, patient derived cells (PDCs) and 
IDH+m knock-in (KI) cells. These are grouped in pathways of upregulated proteins (Up) and 
downregulated proteins (Down). Pathways are grouped within 3 major metabolic groups: Central carbon 
metabolism, GSH metabolism and lipid metabolism. “Other” refers to pathways not classified within 
these three groups. Detected/Total refers to the number of proteins found differential in our analysis 
over the total proteins listed in the pathway. The pathways were obtained from KEGG, Canonical 



















































 CHAPTER IV 
Figure S4. TCA cycle and glutamate regulation in IDH1m gliomas 
Cytoscape representation of TCA cycle and glutamate metabolism in IDH1m glioma patients 
(Source: KEGG database). All proteins and metabolites that were found differentially 
expressed from our analysis are colored. The coloring pattern determines the fold change (FC) 
of IDH1m/IDHwt ranging from red to blue being red the most upregulated in IDH1m gliomas 
and red the most downregulated. Each star next to a protein or metabolite indicates that it was 
also found significantly differential in other complementary model: PDCs and isogenic IDH1m 
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Figure S5. GSH and transulfuration pathway regulation of IDHm gliomas 
Cytoscape representation of GSH metabolism and transsulfuration pathway in IDH1m glioma 
patients (Source: KEGG database). All proteins and metabolites that were found differentially 
expressed from our analysis are colored. The coloring pattern determines the fold change (FC) 
of IDH1m/IDHwt ranging from red to blue being red the most upregulated in IDH1m gliomas 
and red the most downregulated. Each star next to a protein or metabolite indicates that it was 
also found significantly differential in other complementary model: PDCs and isogenic IDH1m 
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Figure S6. TCGA patient dataset confirms upregulation of specific metabolic genes 
IDH1m vs IDHwt glioma significantly differential genes corresponding to the dysregulated metabolic 
proteins from our proteomic comparison, according to The Cancer Genome Atlas (TCGA), which 
displays patient gene expression data. TCGA_GBMLGG adult glioma dataset. Pairwise t tests. Pairwise 
comparisons between group levels with corrections for multiple testing (p-values with Bonferroni 
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ABSTRACT 
Background. Mutations in isocitrate dehydrogenase 1 or 2 (IDH1/2) define glioma subtypes 
and are considered primary events in gliomagenesis, impacting tumor epigenetics and 
metabolism. IDH enzyme activity is crucial for the generation of reducing potential in normal 
cells, yet the impact of the mutation on the cellular antioxidant system in glioma is not 
understood. The aim of this study was to determine how glutathione (GSH), the main 
antioxidant in the brain, is maintained in IDH1 mutant gliomas, despite an altered 
NADPH/NADP balance.  
Methods. Proteomics, metabolomics, metabolic tracer studies, genetic silencing and drug 
targeting approaches in vitro and in vivo were applied. Analyses were done in clinical specimen 
of different glioma subtypes, in glioma patient-derived cell lines carrying the endogenous IDH1 
mutation and corresponding orthotopic xenografts in mice.   
Results. We find that cystathionine-γ-lyase (CSE), the enzyme responsible for cysteine 
production upstream of GSH biosynthesis, is specifically upregulated in IDH1 mutant 
astrocytomas. CSE inhibition sensitized these cells to cysteine depletion, an effect not 
observed in IDH1 wild-type gliomas. This correlated with an increase in reactive oxygen 
species and reduced GSH synthesis. Propargylglycine (PAG), a brain-penetrant drug 
specifically targeting CSE, led to delayed tumor growth in mice.  
Conclusions. We show that IDH1 mutant astrocytic gliomas critically rely on NADPH-
independent de novo GSH synthesis via CSE to maintain the antioxidant defense, which 
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2.1. Introduction 
 
The identification of a point mutation in the enzymes isocitrate dehydrogenase 1 or 2 (IDH1, 
IDH2) has dramatically improved our understanding of glioma genesis (Parsons et al., 2008) 
and led to a better delineation of glioma subtypes. Whereas primary glioblastomas (GBM) 
harbour the wild-type enzyme (IDHwt), mutated IDH (IDHm) defines lower grade gliomas, 
which are further subdivided based on codeletion of chromosomal arms 1p and 19q (1p19q 
codel) for oligodendrogliomas (OD) and mutations in TP53 and ATRX for astrocytomas (AS) 
(Louis et al., 2016b). While both IDH1 and IDH2 can be mutated in cancer, gliomas most often 
display the R132H mutation in IDH1. IDH1 is a cytoplasmic enzyme that β-decarboxylates 
isocitrate to α-ketoglutarate (αKG) thereby generating NADPH and CO2, while the mutant 
enzyme converts αKG into D-2-hydroxyglutarate (D2HG) and oxidizing NADPH (Dang et al., 
2009b). D2HG competitively inhibits αKG-dependent TET dioxygenases and JmjC histone 
demethylases (Xu et al., 2011a, Losman and Kaelin, 2013) leading to hypermethylation of CpG 
islands and histones H3 and H4 respectively (Turcan et al., 2012, Duncan et al., 2012).  Wild-
type IDH1 is one of the main contributors of cytosolic NADPH, which is crucial for anabolic 
processes and redox homeostasis via GSH recycling (Jiang et al., 2016). It has been shown 
that up to 65% of total NADPH comes from this reaction in IDH1wt GBM, whereas this 
contribution is decreased in IDH1m gliomas (Bleeker et al., 2010). Moreover, several reports 
suggest that the IDH1 mutation enhances chemo-radiosensitivity through GSH depletion and 
ROS generation (Shi et al., 2015, Juratli et al., 2015, Li et al., 2017, Reitman et al., 2011). 
We previously reported metabolic aberrations in phospholipids, energy and oxidative stress 
regulation in IDH1m glioma patients and derived orthotopic xenografts (Fack et al., 2017). 
Notably, despite a drop in the NADPH/NADP ratio, we detected high levels of GSH in IDH1m 
tumors, while enzymes related to cysteine metabolism and de novo GSH production such as 
cystathionine-β-synthase (CBS) and Glutamate-cysteine ligase catalytic subunit (GCLC) 
showed increased gene expression in IDH1m gliomas, suggesting that de novo GSH synthesis 
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A major limitation in the study of metabolic adaptations of IDH1m gliomas is the lack of 
appropriate cell culture and animal models. The notorious difficulty of growing glioma cells 
carrying the endogenous IDH mutation has led various research groups to use GBM cell lines 
engineered to overexpress the mutant enzyme (Zhu et al., 2017, Li et al., 2017, Reitman et al., 
2011, McBrayer et al., 2018). Although a practical cellular set up, such models lack the 
phenotype and genetic background of astrocytoma or oligodendroglioma subtypes. Here we 
were able to use clinical material of different glioma types as well as unique patient-derived 
cell lines with and without the endogenous IDH1 mutation and corresponding orthotopic 
xenografts to interrogate GSH and cysteine metabolism in IDH1m gliomas. Using proteomics, 
metabolomics, tracer studies and genetic silencing approaches, we report that IDH1m 
astrocytomas specifically rely on cystathionine-γ-lyase (CSE, also known as cystathionase 
encoded by the CTH gene) to increase their cysteine pool for de novo GSH synthesis. 
Furthermore, we show that the CSE inhibitor propargylglycine (PAG) leads to increased 
reactive oxygen species (ROS) and cytotoxicity at low cysteine levels in vitro, and decreases 
tumor growth in vivo. Our data provide a rationale for therapeutically targeting CSE in IDH1m 




IDH1m astrocytomas upregulate cystathionine-γ-lyase (CSE) 
 
We previously reported the upregulation of CBS and GCLC in IDHm gliomas, suggesting an 
activation of the transsulfuration pathway (Figure 1a) in these tumors(Fack et al., 2017), an 
important source of cysteine for GSH synthesis in astrocytes(McBean, 2012, McBean, 2017). 
To corroborate this at the metabolite level, we analyzed specimen from 22 glioma patients 
including IDHwt GBM (n=10), IDH1m OD (n=4) and IDH1m AS (n=8) (Supplementary Table 
1). As expected, IDHm gliomas showed high D2HG and reduced αKG levels compared to 
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in glutamate and an increase in glucose and cystathionine in IDHm gliomas, supporting 
activation of the transsulfuration pathway (Figure 1b).  
To address this in a model amenable to experimental manipulation, we turned to patient-
derived glioma stem-like cells (GSCs) carrying the endogenous IDH1 mutation (NCH1681, 
NCH551b, NCH612) and control cells of IDHwt GBM (NCH644,  NCH601, NCH421k) (Figure 
S1a). IDH1m GSCs exhibited D2HG levels comparable to patients and display low proliferation 
rates(Trong et al., 2020, Dao Trong et al., 2018, Dettling et al., 2018). We confirmed the 
presence of the mutation at the genetic (Figure S1b) and protein level (Figure 1c) and a more 
than 20 fold increase in D2HG (Figure S1c). IDH1m allele frequency reached almost 100% in 
astrocytic cell lines (Figure S1b), suggesting a loss of heterozygosity over time. The tendency 
to develop an IDH1m homozygosity in vitro has already been reported by others(Luchman et 
al., 2013). Next we investigated the expression of the main mediators of GSH production, CBS 
and cystathionine-γ-lyase (CSE) at the protein level. CSE is central to this pathway and the 
only known enzyme capable to synthesize cysteine, the limiting metabolite for GSH 
production(Berg et al., 2012). CSE generates cysteine, α-ketobutyrate and ammonia through 
the breakdown of cystathionine which is provided by CBS in the transsulfuration pathway 
(Figure 1a). While CBS showed similar expression in all tumor types, we found that CSE was 
upregulated in IDH1m cells both at the protein and mRNA level, (Figure 1c-e). Among glioma 
subtypes, the upregulation of CSE was mainly seen in the IDH1m AS cell lines (NCH1681, 
NCH551b) (Figure 1c-e). This was confirmed in vivo in a panel of patient-derived orthotopic 
xenografts, while there was variable expression in IDHwt xenografts (Figure S1d-f). We further 
validated these data interrogating our clinical material, which showed increased CSE protein 
in IDH1m tumors compared to IDHwt, with highest expression in AS (Figure S1g,h). Gene 
expression data from public databases using the GlioVis portal, further confirmed these 
observations (Bowman et al., 2017) (Figure S1i).  
To obtain a more comprehensive view of protein deregulation in IDH1m gliomas, we performed 
label-free quantitative (LFQ) MS-based proteomics and identified a total of 6.265 proteins 




 CHAPTER IV 
based on IDH1 status (Figure S1j). From the identified proteins, 575 were differentially 
expressed between IDH1wt and IDH1m cell lines (FDR<0.05) (Figure 1f and Supplementary 
table 3), with 127 proteins upregulated and 258 downregulated in IDH1m cells (FDR <0.05, 
fold change (FC) >2) (Figure 1g). Further analysis between AS and OD was not possible 
because only 1 OD sample was available. Of note, CSE was the most upregulated protein in 
IDH1m cells (FC=37). In concordance with the above, this increase in CSE was mainly seen 
in AS cells (FC=71). By gene ontology interrogation, we found that the top 10 processes of 
IDH1m upregulated proteins were linked to metabolism (Figure S1k), while ribosome and RNA 
related processes were downregulated in IDH1m cells (Figure S1k), in line with the low 
proliferative phenotype of these tumors. Among the metabolic processes upregulated is the 
oxidation-reduction process including several proteins involved in redox regulation: glutathione 
S-transferase Mu 2 (GSTM2) in charge of GSH conjugation and dehydrogenase/reductase 
SDR family member 4 (DHRS4) an important NADPH producer (Figure 1g). In summary, we 
found that cystathionine accumulates in IDHm gliomas and identify its converting enzyme CSE 
and related partners to be specifically upregulated in IDH1m AS, suggesting an increased 
activity of the transsulfuration pathway in this glioma type.  
 
Loss of CSE reduces viability in IDH1m astrocytoma cells under 
cysteine depletion 
 
To investigate the role of CSE in IDH1m AS, we established stable CSE knockdown (KD) lines 
in NCH1681 cells (IDH1m AS) using two different shRNAs. Both KD clones (shCSE1 and 
shCSE2) showed a strong drop in CSE protein (Figure 2a,b), yet we did not observe a 
significant difference in sphere size over time (Figure 2c) compared to control (shCTR), 
indicating that the proliferation capacity of these cells was unaltered under standard culture 
conditions. We argued that CSE may not be required if sufficient cysteine is provided from 
extracellular sources.  In standard culture medium the concentration of cysteine (360 µM 
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Figure 1. CSE is specifically upregulated in IDH1m astrocytomas  
(a) Schematic of GSH de novo synthesis through the transsulfuration pathway. (b) Total levels of 
metabolites in 22 clinical samples, presented as peak area relative to mg of tissue. IDHwt (n=10), IDH1m 
OD (n=4) and IDH1m AS patients (n=8). (c) Western blot for CBS, IDH1m, CSE and GAPDH in IDH1wt 
and IDH1m cell lines. MW (Da) indicates specific molecular weight of each protein. (d) Quantification 
relative to GAPDH (n=3). (e) CSE gene expression relative to EF1α determined by qPCR (n=3). (f) 
Untargeted proteomic analysis of 3 IDH1wt and 3 IDH1m cell lines. Heat map representation of 575 
differentially expressed proteins (false discovery rate (FDR) <0.05). 127 proteins upregulated and 258 
downregulated in IDH1m glioma cells (n=2 /cell line, except for NCH612 where n=1). (g) Volcano plot of 
all 6,265 detected proteins (in red differential proteins with FDR<0.05, FC>2). CSE, GSTM2 and DHRS4 
are highlighted. For complete protein list see Supplementary Data 1.  
D2HG: D2-hydroxyglutarate; αKG: α-ketoglutarate; GSH: glutathione; CSE: cystathionine-γ-lyase; CBS: 
cystathionine-β-synthase; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase. IDH1wt: isocitrate 
dehydrogenase wild type; IDH1m: IDH1 mutant, AS: Astrocytoma; OD: Oligodendroglioma. Each 
independent dot of the bar charts corresponds to one biological replicate (n). Data presented as means 
± SEM. * p<0.05; ** p<0.01; *** p<0.001. 
 
than in human blood (80-180 µM)(Psychogios et al., 2011) (source: HMDB). In contrast, in 
cerebrospinal fluid (CSF), a reference for nutrient values in the brain, cysteine is one of the 
lowest amino acids with values below 1 µM(Engelborghs et al., 2003) (source: HMDB). To 
reach a concentration more relevant to neural tissue, cysteine was serially diluted in cysteine-
free DMEM. This led to a gradual loss of sphere viability (based on GFP fluorescence) in CSE 
KD cells (Figure 2d, e). Control cells only were affected upon complete cysteine withdrawal. 
The selective impact on CSE KD cells was most prominent at 30 µM cysteine, where the 
decrease in viability was already observed after 2 days of culture further increasing over time 
(Figure 2f). Taken together, these data provide evidence that under physiological cysteine 
concentrations, CSE is required to maintain viability of IDH1m AS cells. 
 
CSE directs GSH biosynthesis upon cysteine starvation 
 
We next asked whether CSE was required to maintain the cysteine pool for GSH production 
and whether the observed loss of viability was caused by a decrease in GSH levels. We 
determined the contribution of CSE to the overall GSH pool, by quantifying metabolites in 
cultures with 30 µM cysteine at different time points. After a 3 day incubation, no effects of 
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Figure 2. CSE is required to maintain viability of IDH1m astrocytoma cells under cysteine 
depletion. 
(a) CSE western blot analysis and (b) quantification relative to LaminB1 in IDH1m AS cells (NCH1681) 
with two CSE KD clones (shCSE1, shCSE2) compared to the parental and scramble control (shCTR) 
(n=3). (c) Relative sphere size under standard culture conditions (360 µM cysteine). Data presented as 
fold change of phase object confluence (POC) of each cell line relative to day 0. (n=3 with 5 spheres 
per experiment). (d) Representative fluorescent images of spheres after 6 days. (e) Relative GFP signal 
in CSE KD cells at decreasing cysteine concentrations (day 6). Measurements expressed as fold change 
of mean green fluorescence (MGF) of each cell line relative to starting point (360 µM cysteine at day 0.5 
once the sphere was formed). (n=3 with 5 spheres per experiment). (f) Time course of GFP signal of 
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However, at 4 days, we found a decrease of total GSH level in the CSE KD cells (Figure 3a). 
Presumably all remaining cysteine had been used up which was also reflected in cell viability. 
This was confirmed in a 2nd experiment (Figure S2b). Unfortunately because of the gradual 
exhaustion of cysteine, many cells were vulnerable at day 4 and not all datapoints could be 
recovered in these experiments. Interestingly, there was a tendency for decreased serine, 
glycine, glutamate and glucose in CSE KD cells, along with a slight accumulation in 
cystathionine (Figure 3a, S2b), suggesting an attempt of the cells to compensate for the loss 
of GSH. Taken together, these data support the premise that GSH biosynthesis depends at 
least in part on CSE activity upon cysteine depletion.  
To confirm that the drop in GSH in CSE knockdown cells was due to a decrease of de novo 
GSH synthesis, we traced 13C3-serine in cells cultured with 30 µM cysteine for 4 days (ratio 
13C3-serine/natural serine = 1:1) (Figure 3b). As aforementioned, the limiting culture conditions 
prevented to recover sufficient biological replicates to perform statistical analysis (Figure 3c 
and Figure S2c respectively). Comparable levels of 13C3-serine were observed in all cells 
(Figure 3c, S2c), whereas the natural serine isotopologue was reduced in the KDs (Figure 
S2d). This drop in natural serine together with the decrease in total glucose (Figure 3a) 
suggests a preference for glucose-derived serine when there is a high demand for this 
metabolite. In fact, the enrichment of heavy carbon labelled serine did not exceed 10% of the 
total pool (Figure S2e). Despite the low serine tracer incorporation, there was a tendency for 
lower 13C2-glycine in CSE KD cells (Figure 3c, S2c) suggesting reduced serine-to-glycine 
conversion. In addition, shCSE cells tended towards increased levels of 13C3-cystathionine and 
a consistent decrease in 13C3-GSH (Figure 3c, S2c). The ratios GSH m+3/Serine m+3 (Figure 
S2f) was significantly lower in the CSE KDs. These data support the notion that under cysteine 
deprivation CSE is essential to generate cysteine, preferentially via the transsulfuration 




















































































































































































































































































































 CHAPTER IV 
Figure 3. CSE directs GSH biosynthesis upon cysteine starvation 
(a) Total metabolite level represented as normalized peak areas at 4 days in 30 µM cysteine. (b) 
Schematic of 13C3-serine metabolite flux towards GSH synthesis. (c) Isotopologues (normalized peak 
area) after 13C3-serine tracing at 4 days in 30µM cysteine. (n=1 with 3 technical replicates in (a) and (c), 
no statistical analysis). CBS: cystathionine β-synthase; SHMT: Serine hydroxymethyltransferase; CSE: 
cystathionine-γ-lyase; GCLC: Glutamate-cysteine ligase catalytic subunit; GSS: glutathione synthetase. 
 
 
IDH1m astrocytoma cells are selectively sensitive to CSE 
inhibition  
 
Next we wished to evaluate the therapeutic potential of CSE inhibition in glioma using available 
chemical inhibitors of CSE. Propargylglycine (PAG) (Figure S3a) is a non-proteinogenic amino 
acid that irreversibly blocks CSE through the double interaction with CSE and its cofactor 
pyridoxal 5-phosphate, which confers strong specificity to the PAG-CSE bond (Sun et al., 2009, 
Szabo and Papapetropoulos, 2017). We first performed a time course experiment in two 
IDH1m AS cell lines (NCH1681, NCH551b) with different concentrations of the inhibitor (10, 4, 
2, 1, 0 mM) and of cysteine (360, 60, 30 µM) (Figure S3b). At 360 µM cysteine, glioma cells 
were insensitive to PAG even at the highest concentration tested (10 mM), excluding significant 
off-target effects of the compound. Toxicity increased over time under cysteine-low conditions 
(60-30 µM) in line with the CSE KD experiments (Figure S3b). Interestingly, the cytotoxic effect 
of PAG was specific to IDHm AS cells, and no significant toxicity was observed in PAG-treated 
IDHwt GBM cells (NCH644 and NCH421k) (Figure 4a). Again the effect was limited to low 
cysteine (≤ 60 µM) (Figure 4b).  
To test if the dependency of IDH1m AS cells on CSE activity was related to their antioxidant 
capacity, we measured ROS levels in IDH1m and IDHwt cells. In line with the cytotoxicity, ROS 
increased in one of the PAG treated IDH1m AS cells, although this was not robust in the 2nd 
cell line (Figure S3d). Taken together these data provide evidence that CSE inhibition under 
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Figure 4. CSE inhibition selectively targets IDH1m astrocytoma cells under cysteine depletion 
(a) Toxicity over time in IDH1m AS (NCH1681, NCH551b, in red, n=6). and IDH1wt GBM (NCH644, 
NCH421k, in blue, n=3) cells following PAG (10mM) at 30µM cysteine. Data presented as fold change 
of celltox (Promega®) probe fluorescence intensity (FI) relative to normal medium untreated (360 µM 
cysteine) at day 0. (b) Toxicity of PAG (10mM) upon decreasing cysteine. Data presented as fold change 
relative to normal medium (360µM cysteine) at day 0. IDH1m AS (n=6). IDH1wt GBM (n=3).  Data 
presented as means ± SEM. * p<0.05; ** p<0.01 
 
CSE inhibition delays tumor growth in vivo 
 
To evaluate the efficacy of CSE inhibition on tumor growth in vivo, we implanted IDH1m AS 
cells (NCH1681) into the brain of mice. After two months, tumors were detectable by MRI 
(around 5 mm3), mice were randomized into saline and PAG (35mg/kg, 5 times/ week) treated 
groups (Figure 5a). Treatment continued for 3 months and tumor size was monitored by bi-
weekly MRIs. Within the first two months of treatment we found a significant decrease in tumor 
growth rate in PAG treated mice (n=8) (Figure 5b). A relative difference in tumor size was 
observed between both groups over time, which became pronounced, though not significant 
at the end of the 3rd month (Figure 5c d). The experiment was stopped when two mice of the 
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To determine the effect of PAG at the metabolite level, labelled 13C3-serine (130 mg/kg) was 
terminally infused in the tail vein (n=2/group) (Figure 5a), reaching steady state at 4-6 hours 
in the circulation and in the brain (Figure S4b). Consistent with the CSE KD experiment, PAG 
treated brain tumors showed a slight decrease in serine and glycine when compared to the 
control group (Figure 5e). Moreover the total level of cystathionine was considerably increased 
in PAG-treated tumors (Figure 5e), demonstrating target engagement in vivo. This was 
accompanied by some decrease of methionine and a significant decrease of homocysteine 
(Figure 5e), both precursors of cystathionine. In line with the KD results, GSH and glucose 
levels were reduced in PAG-treated tumors (Figure 5e). A clear accumulation of cystathionine 
in PAG treated mice was also observed in the liver, where de novo GSH biosynthesis normally 
occurs (Mosharov et al., 2000), while most other metabolic differences appeared to be tumor-
specific (Figure S4c). The isotopologue distribution revealed that unlabeled serine decreased 
in treated tumors, whereas 13C3-serine (M+3) showed a significant increase (Figure S4d). 
Again, labeled serine only accounted for ~10% of the total pool, reflected in the small amount 
of labeled cystathionine (M+3) in contrast to the strong accumulation of unlabeled one (M+0) 
(Figure S4d), suggesting preferential use of compensatory glucose-derived serine of IDH1m 
AS tumors also in vivo. In summary, we show that PAG inhibits CSE activity in IDH1m AS brain 
tumors which causes a significant delay in tumor growth, providing a rationale for a therapeutic 




Due to the central role of IDH1 in NADPH recycling (Fan et al., 2014, Jiang et al., 2016), several 
research groups including ours, have suggested that IDH1m tumors may display specific 
vulnerabilities in redox metabolism and GSH production that might be therapeutically 
harnessed (Fack et al., 2017, Shi et al., 2015, Bleeker et al., 2010). Nevertheless, to date there 
Due to the central role of IDH1 in NADPH recycling (Fan et al., 2014, Jiang et al., 2016), several 































Figure 5. CSE inhibition delays tumor growth in vivo 
(a) Setup of in vivo experiment. (b) Tumor growth rate of CTR and PAG treated mice during the first 8 
weeks of treatment (n=8). (c) Tumor volume over time during the 3 months treatment period as 
determined by MRI (n=8; except for CTR where n=7 at weeks 8/10 and n=6 at week 12). Tendency to 
reduced volume at week 12 (not significant). Note that 2 CTR mice died after week 8. (d) Representative 
MRI pictures at week 12. (e) Total metabolite levels represented as normalized peak area in CTR and 
PAG treated tumors after 12 weeks of treatment (n=5). Each dot in charts B and F correspond to different 

































































































































































































 CHAPTER IV 
vulnerabilities in redox metabolism and GSH production that might be therapeutically 
harnessed (Fack et al., 2017, Shi et al., 2015, Bleeker et al., 2010). Nevertheless, to date there 
is still limited understanding of this pathway in IDHm gliomas in part due to the difficulties of 
establishing IDHm cellular and animal models relevant to the human disease. The results 
presented in this study were generated in patient-derived astrocytic and oligodendroglial cells 
and tumors that carry the endogenous IDH mutation. We show that CSE, the only known 
enzyme capable of synthesizing cysteine, is specifically upregulated in IDH1m astrocytomas 
and it is essential to maintain GSH production under limited cysteine availability in vitro and in 
vivo in this specific glioma subtype (Figure 6). To our knowledge, we show for the first time 
that inhibition of CSE reduces astrocytoma tumor growth in the brain of mice, thus uncovering 
a novel metabolic vulnerability in this aggressive glioma subtype.   
A key finding of our study is the upregulation of CSE in IDH1m astrocytomas compared to 
IDH1m oligodendrogliomas and IDHwt GBM. The importance of CSE as a source of cysteine 
for GSH production is well established in astrocytes (McBean, 2012, McBean, 2017). An early 
study in C6 glioma cells showed that CSE expression increases when GSH is experimentally 
depleted (Kandil et al., 2010). While the upregulation of CSE in astrocytomas over 
oligodendrogliomas was clear in all samples analyzed, the expression in GBM was more 
variable, suggesting that GBM are more adaptable to cysteine shortage. This was consistent 
with the specific vulnerability to CSE inhibition observed in IDHm AS cells compared to IDHwt 
GBM. The loss of the chromosomal arm 1p, where CTH is located, in IDH1m ODs, likely 
explains the drop in CSE expression in this glioma subtype. In line with this, a recent study 
reported that cystathionine, the substrate of CSE, accumulates in IDH1m ODs (Branzoli et al., 
2019).  
In addition, our proteomics analysis uncovered a list of 575 novel proteins dysregulated in 
IDH1m tumors involved in a number of different biochemical pathways. Among the total of 127 
upregulated proteins, one interesting target in the context of redox metabolism is DHRS4. This 
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power in IDH1m gliomas. The detailed evaluation of all dysregulated proteins and pathways 
revealed by our proteomics study could open different promising future investigations. On the 
other hand, this untargeted proteomics analysis confirmed the importance of CSE in IDH1m 
astrocytomas as the most significantly upregulated protein of all. A possible mechanism by 
which astrocytomas upregulate CSE could be through mTOR signaling, which was recently 
described to control the transsulfuration pathway in yeast (Lyu et al., 2019). The amino-acid 
sensing GCN2-ATF4 pathway has also been implicated in regulating the expression of CBS 
and CTH in various cancer cell lines (Zhu et al., 2019). However, the exact mechanism behind 
the CSE regulation in IDHm AS remains to be elucidated.  
We found that in addition to the IDH mutational status, the availability of extracellular cysteine 
determines the susceptibility to CSE inhibition. This is in agreement with recent data obtained 
in established cell lines, where the expression of CBS was shown to support cell growth during 
cysteine depletion (Zhu et al., 2019). In the microenvironment of gliomas, where the uptake of 
amino acids is regulated by the blood brain barrier (BBB), the cysteine concentration is 
reportedly very low (Engelborghs et al., 2003). Interestingly, the neuroprotective role of 
astrocytes depends on their capacity to exchange cysteine and GSH precursors with neurons 
(Belanger et al., 2011), highlighting the importance of the transsulfuration pathway for 
astrocytic function (Paul et al., 2018, McBean, 2017, Cakir et al., 2007, Wang and Cynader, 
2000, Banos et al., 1975).  
Mammalian cells have two ways to acquire cysteine: via CSE-dependent synthesis or by 
uptake from the extracellular environment. A key player in the supply of cysteine is the xCT 
antiporter, which exchanges glutamate for cystine, the oxidized form of cysteine. We previously 
showed that in glioma patients, the expression of SLC7A11, the gene encoding for xCT, does 
not differ between IDHwt and IDHm tumors, nor between IDHm AS and ODs (Fack et al., 
2017). Nevertheless, several studies suggested a role for xCT to counteract ROS in IDHwt 
GBM (Singer et al., 2015, Chen et al., 2015, Polewski et al., 2016) and xCT inhibition has been 
explored in clinical trials against GBM (Takeuchi et al., 2014, Robe et al., 2006). In IDHm 
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precursor for glutamate synthesis. Consistently, we have shown (and confirmed here Fig. 1B) 
that glutamate levels are lower in IDHm than in IDHwt gliomas (Fack et al., 2017). Importantly, 
xCT selectively transports cystine but not cysteine and the conversion of cystine to cysteine 
requires reducing equivalents (Paul et al., 2018). Hence the antioxidant power of xCT is 
expected to be blunted in NADPH-scarce tumors, such as IDHm gliomas (Figure 6). 
CSE inhibition in vitro and in vivo, led to a significant decrease in natural serine (m+0) with no 
differences in the heavy carbon labelled isotopologues (Figure 3C, S3B, S5C). In parallel, the 
observed reduction in total glucose after CSE blockade, indicates that during CSE inhibition 
tumor cells deplete glucose-derived serine rather than the labeled one in their attempt to 
generate GSH (Figure 6). Indeed, in the brain serine may rather be synthesized from glucose 
which readily enters the brain rather than being taken up from the circulation (Belanger et al., 
2011). Moreover, we observed in our clinical samples how IDH1m gliomas have higher levels 
of glucose, which may thus result in the preference for glucose-derived serine in this tumor 
type. To further investigate the role of glucose in the redox defense of IDH1m gliomas it would 
be interesting to perform a glucose flux analysis.  
IDHm astrocytoma patients are known to benefit from radiotherapy (Juratli et al., 2015), 
suggesting a vulnerability to the oxidative damage caused by radiation. Therefore, it is tempting 
to speculate that the addition of PAG might increase the anticancer effects of radiation therapy. 
This is in line with a recent study, where the combination of radiotherapy with a glutaminase 
inhibitor (CB-839) led to increased mouse survival (McBrayer et al., 2018). It would be 
interesting to probe the anti-tumor effects of CSE inhibition in combination with a dietary 
restriction of cysteine. Indeed, this combinatorial approach was shown to be tolerated and even 
more effective in depleting GSH in the brain of healthy rats compared to PAG alone (Cho et 
al., 1991). Furthermore a study in prostate and breast cancer models elegantly showed how 
the enzyme cyst(e)inase efficiently degrades cysteine in the circulation, thereby significantly 
increasing oxidative damage and decreasing tumor cell proliferation (Cramer et al., 2017). On 
























Figure 6. IDH1 mutant astrocytoma critically depend on CSE for GSH synthesis to counteract 
ROS 
Schematic summary showing how IDH1 mutant astrocytomas increase de novo GSH synthesis through 
CSE upregulation leading to increased cysteine from cystathionine. This pathway compensates the lack 
of NADPH for GSH recycling due to the IDH1 mutation. Cysteine input from xCT may not be efficient in 
astrocytomas because of limited cysteine availability in the brain and/or limited intracellular glutamate 
which is consumed for 2HG production. CSE knockdown or chemical inhibition through PAG hampers 
the cysteine availability for GSH synthesis thus increasing ROS and subsequent cell death. 
 
 
the combination of cyst(e)inase and PAG, aiming to block exogenous and endogenous 
cysteine supply to the tumor. 
In conclusion, here we identified a specific metabolic vulnerability of IDH1m astrocytomas that 
in a cysteine-restricted microenvironment depend on CSE activity to maintain their antioxidant 
homeostasis, and are selectively susceptible to pharmacological inhibition of CSE in vivo. 
 
LIMITATIONS OF STUDY 
(1) Patient-derived glioma cells with the endogenous IDH mutation are slow growing cells and 
poorly adapted to culture conditions. This restricts the experimental procedures possible (e.g. 
high sensitivity to transfection/infection protocols and depletion of extracellular cysteine) and 
the amount of material recoverable e.g. for metabolite analysis. Despite this limitation, we were 
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models under low cysteine supply. Similarly the slow in vivo growth required extended 
treatment periods (3 months) and an even longer time would probably have been required to 
observe a significant difference in tumor volume. Nevertheless cystathionine accumulation was 
observed in tumors in the brain, supporting a role for CSE in GSH production also in vivo.  
(2) Our serine tracing studies in vitro clearly show that CSE knockdown led to an accumulation 
of cystathionine concomitant with GSH depletion, both in total levels as well as the m+3 
isotopologues (Figure 3A-B). The percentage of 13C3-serine detected in cells was low (<10% 
of the total) (Figure S3B) which may explain the subsequent low level of GSH isotopologue 
m+3 (<1%) and the lack of detectable GSH m+5 (m+3 from cysteine and m+2 from glycine) 
(Figure S3B). Yet a significant decrease in GSH m+3 percentage was observed (Figure S3C). 
A complementary approach would be to trace methionine as an alternative substrate for the 
transsulfuration pathway.  
(3) Similarly after CSE inhibition in vivo, there was a significant decrease in natural serine 
isotope (m+0), followed by a drastic accumulation of cystathionine m+0 and a subsequent 
decrease of GSH m+0 (Figure S5C). Moreover the observed reduction in glucose after PAG 
treatment, indicates that during CSE inhibition tumor cells consume glucose-derived serine 
rather than the labeled one in their attempt to generate GSH. A possible explanation to this 
effect could be a limited transport of serine through the BBB and/or a time delay in available 
labeled serine passing the extracellular matrix to the tumor cells. Indeed the MID percentage 
of labeled serine detected in the brain was much lower than in the liver and other organs 
(Figure S5A, S5D), where some cystathionine m+3, GSH m+3 and GSH m+5 were detectable 
after PAG treatment (Figure S5C). Thus in the brain serine may rather be synthesized from 
glucose which readily enters the brain rather than being taken up from the circulation (Belanger 
et al., 2011), suggesting that a glucose tracing might be more efficient to follow GSH production 
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 CHAPTER IV 
Figure S1. Relative to Figure 1 
(a) Phase contrast microscope imaging of the six patient derived glioma cell lines. NCH644, NCH601 
and NCH421k correspond to patients with IDH1wt primary glioblastoma (GBM); NCH1681 and 
NCH551b correspond to patients with IDH1m astrocytoma; NCH612 correspond to a patient with IDH1m 
oligodendroglioma. 
(b) Percentage of IDH1 mutant allele frequency (MAF) observed by digital PCR in all IDH1m cell lines, 
including astrocytomas (AS) (NCH551b, NCH1681) and oligodendroglioma (OD) (NCH612) and one of 
the IDHwt cell lines (NCH644). MAF and 95% confidence interval (CI) for each cell line were: NCH644 
MAF= 0.00032%, CI= 8.59E-3% -- 0.117%; NCH612 MAF= 64.85%, CI= 61.196% -- 68.65%; NCH1681 
MAF= 99.45%, CI= 93.223% -- 106%; NCH551b MAF= 99.98%, CI= 94.808% -- 105.33%. Digital PCR 
procedure was performed as described in(Golebiewska et al., 2020). Error bars correspond to 95% 
confidence intervals (CI) of MAF estimation. One cell stock replicate for each line (n=1). 
(c) D2HG and GSH levels in patient-derived IDH1wt glioblastoma and IDH1m astrocytoma cell lines as 
determined by LC-MS. Each biological replicate (n) correspond to an independent cell culture stock of 
each cell line (n=3). 
(d) Western blot of CSE in patient-derived orthotopic xenografts: IDH1wt GBM (P3, T434, P8), IDH1m 
OD (E478) and IDHm AS (T394, T186). MW (Da) represents the specific molecular weights of each 
protein. (e) Quantification thereof relative to GAPDH. Each biological replicate (n) correspond to an 
indepenedent xenograft tumor (n=2). Original blots are shown in Figure 1SC.  
(f) CSE gene expression in patient-derived orthotopic xenografts relative to EZRIN determined by qPCR. 
Each biological replicate (n) correspond to an independent xenograft tumor (n=3, except for T434 and 
T394 where n=2). 
(g) Western blot of clinical samples for CSE. IDHwt (blue; P1-P10), IDH1m AS (red; P11-P18) and 
IDH1m OD (pink; P19-P22). (h) Quantification thereof relative to total protein amount. Each biological 
replicate (n) correspond to an independent patient tumor, IDHwt (n=10), IDH1m AS (n=6) and IDH1m 
OD (n=4).   
(i) CSE gene expression in glioma patients (source: Gliovis (Bowman et al., 2017)). IDH1m OD (169; 
25.76%), IDH1m AS (258; 39.33%), IDH1wt (229; 34.91%). TCGA_GBMLGG adult glioma dataset. 
Pairwise t tests. Pairwise comparisons between group levels with corrections for multiple testing (p-
values with Bonferroni correction). 
(j) Principal Component Analysis (PCA) of the untargeted proteomics comparison between IDH1m AS 
(red) IDH1m OD (pink) and IDHwt GBM (blue) cell lines 
GBM: Glioblastoma; OD: Oligodendroglioma; AS: Astrocytoma 
(k) Gene Ontology Biological Process (GOBP) terms representation of the top 10 terms (IDHwt) and top 
15 (IDH1m) terms, based on STRING database analysis (Szklarczyk et al., 2019).  
















































































































































































































3 days culture at 30 µM cysteine 







































































































































































































































































































































































































































 CHAPTER IV 
Figure S2. Relative to Figure 3 
(a) Total GSH, serine, glycine and cystathionine levels in parental, shCTR, shCSE1 and shCSE2. Cells 
were incubated during 3 days at 30 µM cysteine. Each dot of the bar charts correspond to an 
independent experiment (n=4). 
(b) Total GSH, serine, glycine, glutamate cystathionine and glucose levels in parental, shCSE1 and 
shCSE2. Cells were incubated during 4 days at 30 µM cysteine.  
(c) Isotopologue levels of GSH, serine, glycine and cystathionine after 13C3-serine tracing (ratio 1:1 
natural L-Serine and L-Serine13C3) in parental, shCSE1 and shCSE2. One independent experiment 
represented in (b) and (c) (n=1). Each dot corresponds to a technical replicate. Three technical replicates 
in each group. No statistical analysis was applied due to the lack of biological replicates 
(d) Natural serine (m+0) levels of parental, shCTR, shCSE1 and shCSE2 cells incubated during 4 days 
with 30 µM cysteine and 13C3-serine tracing. Each dot of the bar charts correspond to an independent 
experiment (n). Parental (n=3), shCTR (n=1), shCSE1 (n=2) and shCSE2 (n=2).   
(e) Mass Isotopologue Distribution (MID) percentages of serine m+3, glycine m+2, cystathionine m+3 
and GSH m+3in CSE knockdown and control cells. Cells were incubated during 4 days at 30 µM 
cysteine. Each dot of the bar charts correspond to an independent experiment (n). Parental (n=3), 
shCTR (n=1), shCSE1 (n=2) and shCSE2 (n=2). (f) GSH m+3/Ser m+3 ratio of same cells as in (d).  
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 CHAPTER IV 
Figure S3. Relative to Figure 4 
(a) Chemical structure of PAG.  
(b) Toxicity of IDH1m astrocytoma cell lines (NCH1681 and NCH551b) incubated with different cysteine 
concentrations (360, 60 and 30 µM respectively) and with different PAG concentrations (0, 1, 2, 4 and 
10 mM) over time. Data of toxicity presented as fold change relative to 360 µM cysteine medium, day 0 
untreated (n=3). 
(c) Validation of in vitro cysteine titration via BSA Insulin Transferring (BIT) supplement dilution (Detailed 
explanation in methods section “Cysteine titration mediums”). Toxicity of IDH1m astrocytoma cell lines 
(NCH1681 and NCH551b) incubated with 20% and 5%BIT expecting to obtain 120 µM and 30 µM 
cysteine respectively. The toxicity of CSE inhibitor PAG at 5%BIT is rescued by addition of extra cysteine 
up to 120 µM, which matches with the lack of toxicity at 20%BIT and the expected 120 µM cysteine. 
Data presented as fold change relative to 20% BIT (120µM) at day 0 untreated (n=3). 
(d) ROS production upon PAG (10mM) and at different cysteine concentrations, presented as fold 
change of DCFDA fluorescence intensity (FI) relative to control cells (untreated, 360µM cysteine) (n=3).   
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 CHAPTER IV 
Figure S4. Relative to Figure 5 
(a) Mass Isotopologue Distribution (MID) percentage of heavy labelled 13C3-serine (serine m+3) 
incorporated in different tissues after tracer infusion over time (n=1). 
(b) Total serine, glycine, cystathionine, GSH, glucose, methionine and homocysteine levels in tumor and 
liver with and without PAG treatment (tumor CTR (n=5), tumor PAG (n=5), liver CTR (n=2), liver PAG 
(n=3)). Data presented as means ± SEM. 
(c) Total isotopologue levels of serine, glycine, cystathionine and GSH in tumor and in liver with and 
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Supplementary Table 1. Clinical sample characteristics and glioma classification.  
NA: not available. * IDH status of samples which methylation diagnosis was not available, were 
determined by ddPCR 
       











P1 38 Male GBM  NA IDHwt* 
  
P2 65 Male GBM GBM, mesenchymal  IDHwt 
  
P3 56 Male GBM NA  IDHwt* 
IDH wt 
P4 71 Female GBM GBM, RTK II IDHwt 
  
P5 51 Male GBM GBM, RTK I  IDHwt 
  
P6 69 Male GBM GBM, mesenchymal  IDHwt 
  
P7 73 Male GBM  NA IDHwt* 
  
P8 72 Male GBM GBM, mesenchymal  IDHwt 
  




Oligodendroglioma NA  IDHwt* 
  















P14 23 Male Astrocytic glioma Astrocytoma IDH1m 
  
P15 34 Male Astrocytic glioma Astrocytoma IDH1m 
  














Oligodendroglioma  NA IDH1m* 
IDHm OD 
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Supplementary Table 2. Cell culture media with different cysteine concentrations 
* Cys concentrations refer to the combination of both cysteine (oxidized) and cystine (reduced). 
DMEMF12: 300 µM cys = 100 µM oxidized and 100 µM reduced. BIT100: 600 µM cys = 300 µM reduced. 









(600 µM cys) * 
Extra 30mM 
cys 
Final [cys]  
Normal 
NCH cells 





- 80% 20% 1% 360 µM 
- 80% 20% - 120 µM 
- 90% 10% - 60 µM 













































 CHAPTER V 
As stated in the dissertation’s title, this PhD project aimed to “identify and target metabolic 
vulnerabilities in IDH mutant gliomas”. To explore this objective we analyzed in vitro and in 
vivo glioma models as well as clinical material carrying wild type IDH and IDH mutation. Via 
proteomics, metabolomics and genetic editing approaches we identified the dysregulation of 
central metabolic pathways derived from IDH1 mutation, highlighting potential strategies that 
could interrupt tumor progression. Specifically, our data reveal alterations in glucose 
metabolism, glutamate/glutamine metabolism, lipid processing and glutathione (GSH) 
regulation. Additionally, we specifically targeted one of these vulnerabilties, evidencing the 
dependence of IDH1m astrocytomas on cystathionine γ-lyase (CSE) for de novo cysteine 
synthesis and GSH production, and disclosing a novel oxidative stress vulnerability for these 
tumors.  
 
In chapter IV-1 we showed the impact of the IDH1 mutation in the dysregulation of central 
carbon metabolism and GSH metabolism, and we proposed potential therapeutic targets that 
could be further investigated. We observed that IDH1m gliomas have a particularly high 
storage of glucose. Being the most abundant metabolite in the brain (Allaman et al., 2011), 
glucose plays a pivotal role in energy production but also as source of intermediates for 
biosynthesis of amino acids, nucleotides, reducing power or phospholipids (Metallo and 
Vander Heiden, 2013). We previously reported a tendency towards low glucose turnover to 
TCA cycle intermediates as well as a reduced ATP production in IDHm tumors (Fack et al., 
2017). However, here we observed that IDH1m tumors upregulate glycolytic and TCA 
metabolite and enzymatic mediators. Yet we also report high expression of glucose-
independent pyruvate synthesis enzymes, and enzymes in charge of anaplerotic entry into 
TCA cycle, suggesting that IDH1m tumors upregulate glycolysis to fuel alternative biosynthetic 
pathways, and activate TCA cycle through secondary inputs. In fact, our observed high 
pyruvate carboxylase (PC) level, matches with previous observations that this enzyme is 
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been shown that D-2HG readily inhibits the complex IV of electron transport chain (ETC) which 
may explain the especially low energetic capacity of IDH1m cells (da Silva et al., 2002, Latini 
et al., 2005). This deficient ATP production in IDH1m gliomas may be an explanation for the 
decreased aggressiveness of these tumors when compared to IDHwt glioblastomas (Brat et 
al., 2015). Based on the critical energy constraints that IDH1m cells have, as a future 
perspective it would be interesting to observe the sensitivity of IDH1m cells against respiration 
inhibitors such as rotenone or phenformin, an approach previously addressed (Grassian et al., 
2014), in combination with inhibitors of some of the upregulated enzymes fueling TCA 
observed in our study, such as PKM, PC, LDHB or ACSS1.  
We found that glutamate is a limiting metabolite in IDH1m tumors, likely due to its increased 
consumption to satisfy high D-2HG production, via GLUD1, and due to the inhibition in these 
tumors of glutamate synthesis through branched-chain amino acids (BCAAs), as previously 
reported (McBrayer et al., 2018). Indeed, it has been shown that GLUD1/2 knockdowns in in 
vivo IDH1m gliomas develop a decreased tumor growth (Chen et al., 2014).  Moreover, there 
seems to be upregulation of alternative production of glutamate as an attempt to compensate 
this deficiency, through increased extracellular glutamate uptake. Glutaminolysis has been 
reported to be especially important in cancer cell growth (Cheng et al., 2011), thus representing 
a potential IDH1m metabolic vulnerability. Indeed glutaminase inhibitors have been already 
extensively tested against IDHm glioma cells, showing promising results (Seltzer et al., 2010, 
McBrayer et al., 2018). It would be interesting to address the effect of combining GLS inhibitors 
with inhibitors of transporters of glutamate (SLC1A2) or glutamine synthase, since these were 
proteins revealed upregulated in IDH1m tumors in our study. 
Glutathione (GSH) is thought to be the most important antioxidant in the human body due to 
its evolutionary conserved enzymatic organization which enables it not only to counteract the 
effect of reactive oxygen species (ROS) but also to neutralize xenobiotic agents (Forman et 
al., 2009). Our study served us to confirm the hypothesis stating that IDHm gliomas bear an 
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2017). In line with this, the efficacy of blocking GSH through glutaminase inhibition in IDH1m 
gliomas has been reported (McBrayer et al., 2018). Here we observed several intermediates 
of the transsulfuration pathway and de novo GSH synthesis to be upregulated in IDH1m 
models, as well as enzymes directly in charge of GSH mediated detoxification such as 
glutathione S-transferases (GSTMs). Indeed, to our knowledge there are no reports testing the 
effect of GSTM inhibition in IDH1m gliomas, which could be an interesting study to approach. 
The antioxidant machinery of these tumors is an attractive area of study due to the specific 
vulnerability of IDHm gliomas to oxidative stress induced by radio-chemotherapy (Juratli et al., 
2015). Thus, here we consistently show that IDH1m tumors display an altered biosynthesis 
and regulation of GSH, what served us as preliminary data for the next experimental strategy 
conducted in this PhD project, based on targeting GSH-dependent specific vulnerability of 
IDH1m gliomas. 
 
In chapter IV-2, we further analyzed via functional approaches the relevance of GSH 
biosynthesis in IDH1m glioma cells, and proposed a potential therapeutic strategy that would 
combine the depletion of this antioxidant with conventional therapeutic agents which inflict 
oxidative damage in the tumor.  
Here we observed that cystathionine γ-lyase (CSE), a central mediator of the TP and the only 
enzyme in charge of cysteine de novo synthesis, was significantly increased in IDH1m 
astrocytomas, an effect to our knowledge undiscovered as of today. In fact, CSE is located in 
the chromosome arm 1p, what explains our observed low expression of this enzyme in IDH1m 
1p/19q co-deleted oligodendrogliomas. Indeed, a recent study observed an increased 
accumulation of cystathionine, the direct substrate of the CSE reaction, in oligodendroglioma 
patients when compared to IDHm astrocytomas or IDHwt GBM (Branzoli et al., 2019). CSE 
upregulation may be an astrocytoma-specific compensatory mechanism to cope with the 
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explain the better patient prognosis of these tumors with respect to astrocytomas and GBM 
(Brat et al., 2015), as aspect that would be interesting to further study. 
We found CSE activity to be critical upon cysteine restriction in culture, a metabolic state that 
resembles the physiological scenario in the brain (Engelborghs et al., 2003). Indeed, we 
observed that CSE was the main source of cysteine which was at the same time the limiting 
factor for GSH de novo synthesis in IDH1m AS cells. Thus, inhibition of CSE under limiting 
cysteine conditions promoted an oxidative stress-dependent cell toxicity. This toxic effect 
showed to be exclusive in IDH1m AS, since the same conditions were harmless in IDHwt 
glioblastoma cells. Yet, the specific transcriptional signal that mediates overexpression of CSE 
in IDH1m AS is still unknown, and would be an interesting mechanism to determine in future 
investigations. According to recent evidence, it is possible that GSH biosynthesis via TP is 
activated through NRF2 and mTOR signaling pathways (Tang et al., 2020, Zhu et al., 2019, 
Gureev et al., 2020). 
Interestingly, we observed that CSE inhibition via propargylglycine (PAG) effectively delayed 
IDH1m AS tumor growth in vivo, via relative decrease of GSH. These data suggest a potential 
therapeutic strategy to combine conventional oxidative stress agents with CSE inhibition. 
Although there was a clear tendency towards an increasing difference in tumor growth and 
survival over time in PAG treated vs control xenografts, the slow growth of IDH1m AS would 
have required longer treatment and follow up times. In fact, the slow-growing nature of these 
tumors considerably hampered the in vitro experimentation as well, e.g. metabolomics. Thus 
it would be very interesting to follow the effect of PAG treatment in vivo during longer time 
points. Moreover, the use of oxidative stress inducing agents in combination of CSE inhibition 
could be a strategy to consider in the future in order to increase the toxic effect of the treatment. 
In addition, it has been already shown that the combination of the CSE inhibitor PAG with 
cysteine-free diets increased the GSH blocking effect, without presenting side effects in 
healthy rats (Cho et al., 1991). Thus, dietary restriction in combination with CSE blockade 
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Although the serine tracing experiments demonstrated the importance of TP in vitro, the 
incorporation and processing rate of heavy label serine in the brain was lower than expected, 
harnessing the TP flux analysis in vivo. Indeed, according to our data, we believe that IDHm 
AS, instead of incorporating extracellular serine may rather synthesize it de novo via glucose, 
which is highly abundant in the brain. For this reason, it will be worthwhile to trace in the future 
the fate of glucose towards serine, cysteine and GSH synthesis. 
Generally, the use of inhibitors of transsulfuration pathway enzymes such as PAG focused on 
the regulation of hydrogen sulfide (H2S), a gasotransmitter that has been suggested as an 
important modulator of tumor cell proliferation, with roles in oxidative stress, VEGF induction 
and HIF-1α stabilization, among others (Szabo and Papapetropoulos, 2017). Depending on 
the amino acid availability, CSE can also be in charge of cysteine degradation producing H2S. 
In fact CSE, CBS and 3-mercaptopyruvate sulfurtransferase (3-MST) are the only enzymes in 
charge of H2S production. Here we show that CSE inhibitor PAG is selectively toxic in IDHm 
AS cells inducing tumor growth delay in vivo, although its role in ROS is not yet conclusive. 
Whether H2S modulation via CSE inhibition has an additive toxic impact in IDH1m AS would 
be an interesting future topic to study. 
 
In conclusion, in this PhD project we characterized IDH1m gliomas from an integrative 
approach, generating a comprehensive perspective of the exclusive metabolic regulation that 
uncovers a specific vulnerability in these tumors. In addition, we identified CSE inhibition as a 
novel therapeutic strategy that affects tumor cell viability via GSH depletion and oxidative 
damage, an approach that could serve as the basis for clinical investigations to improve IDH1m 
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